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ABSTRACT 
Psychiatric symptoms are more prevalent in Huntington’s disease (HD) than the general 
population, but reasons for this are unknown. The primary aim of this research was to 
investigate possible familial influences on the psychiatric phenotype in HD. 
96 gene positive and 5 gene negative siblings were recruited from 50 HD families throughout 
the UK and underwent a lifetime psychiatric history assessment using semi-structured 
interview and case-note review.  
Gene positive index individuals had high lifetime rates of depressive (56%) and anxiety (38%) 
disorders.  Their depressive episodes were less severe and more frequent with an older age 
of onset and fewer biological symptoms than individuals with depression without HD. Within 
gene positive sibling-pairs (n=53), there was significant familial aggregation of the presence 
(κ=0.46, p=0.004) and course (ICC=0.47, p=0.002) of depressive disorders and the presence 
of irritability (κ=0.357, p=0.024) and aggression (κ=0.384, p=0.016). Two gene negative 
siblings had lifetime psychiatric diagnoses. 
The high prevalence of psychiatric co-morbidity in HD cannot be entirely explained by the HD 
gene. Familial factors, most likely other genetic factors, are likely to play a role.  Further 
research into the contribution of biological and environmental factors to the psychiatric 
phenotype in large samples of individuals with HD is warranted.  
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CHAPTER 1: HUNTINGTON’S DISEASE 
 
This chapter will provide an introduction to Huntington’s disease (HD). It will outline the 
history of HD, epidemiology of HD, genetics of HD as well as a clinical description of the 
disease, the neuropathology and management of HD. 
 
1.1 History of Huntington’s Disease 
George Huntington’s seminal paper in 1872 titled “On Chorea” described an unusual 
hereditary disease that has subsequently borne his name. His striking description 
emphasising three distinctive features of the disease, including: i) its hereditary nature, ii) a 
tendency to insanity and suicide, and iii) its manifesting itself as a grave disease only in adult 
life, remains highly relevant today. Although recognised and described before 1872, 
Huntington’s account of HD was widely accepted from publication and knowledge of 
hereditary chorea spread rapidly. This was perhaps due to an increasing interest in heredity 
at this time but also due to the detailed clinical description of George Huntington’s paper 
that comprised not only his observations but also those of his father and grandfather, all 
family doctors on Long Island, New York (Harper, 2014).  
 
This publication by Huntington provided the foundation for all successive work on HD (see 
Table 1.1). Several papers on the genetics of HD were published in the early twentieth 
century but the true major advances came in the 1980s with the development of molecular 
genetic techniques (Petersen et al., 1999). The most exciting and perhaps most important of 
these advances being the identification of the causal HD gene in 1993 (Huntington’s Disease 
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Collaborative Research Group, 1993), which has opened the door to more extensive 
approaches to better understand this highly complex disorder. 
Table 1.1: The main landmarks in the study of HD (adapted from Walker, 2007 and Harper, 
2014, p. 19).  
Year Event 
1686 Thomas Sydenham describes post-infectious chorea 
1832 John Elliston identifies inherited form of chorea 
1841 First definite description of HD (Charles Waters) 
1872 George Huntington characterises HD 
1888 Hoffman clearly describes Juvenile HD 
1908 Mendelian dominant inheritance is recognised 
1953 DNA structure is elucidated 
1955 HD is described in Lake Maracaibo region of Venezuela 
1967 World Federation of Neurology research group formed 
1976 First animal model (kainic acid) of HD described 
1983 Localisation of HD gene on chromosome 4 
1993 Identification of HD gene and of mutation as expanded cytosine-adenine-
guanine (CAG) trinucleotide repeat 
1996 Transgenic mouse with expanded HD repeat developed 
1997 Neuronal inclusions recognised in transgenic mouse and human HD brain 
2000 Drugs screened for effectiveness in transgenic animal models 
2001 PREDICT-HD: to study healthy individuals at risk for HD 
2003 REGISTRY study: European observational study of HD >10 000 participants 
2006 COHORT-HD: large-scale observational study of HD in United States and 
Australia, 3500 participants. 
2009 TRACK-HD: observational biomarker study of pre-manifest and early-stage HD 
2012 ENROLL study: worldwide observational study of HD, foundation for clinical 
trials in HD 
 
1.2 Epidemiology of HD 
HD is a rare neuropsychiatric disorder with a similar prevalence for men and women. 
Although the estimated worldwide prevalence of HD is 2.71 per 100 000 (Pringsheim et al., 
2012), it’s prevalence between and even within countries is variable due to population 
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differences in the normal distribution of predisposing alleles (Squitieri et al., 1994). The 
prevalence rate is highest in people of Western European descent (where it is thought the 
HD gene originated) with estimates of 5-10 cases per 100 000 (Roos, 2010; Pringsheim et al., 
2012) and lower in the rest of the world with Japan for example, having a much lower 
prevalence of approximately one-tenth that of most populations of European descent 
(Nakashima et al., 1996). However, it is thought that the actual prevalence rates are much 
higher than those reported. One recent UK study using patients’ electronic medical records 
found that the estimated prevalence rate rose from 5.4 per 100 000 in 1990 to 12.3 per 100 
000 in 2010 (Evans et al., 2013). 
 
Unusually high local concentrations of HD are also known to exist in particular populations, 
owing to large individual kindreds (Harper, 2014). Examples of these local foci of HD include: 
Gwent, South Wales (Walker et al., 1981); Moray Firth, Scotland (Lyon, 1962); and, 
Tasmania, Australia (Pridmore, 1990). The most well known of such kindreds is the 
Venezuelan isolate by the shores of Lake Maracaibo. This unique community consisting of 
over 100 affected individuals with the occurrence of probable homozygotes became a focus 
of study for the Hereditary Disease Foundation (Wexler et al., 1987). Annual visits from 1981 
led to the creation of the pedigree of this kindred and blood samples taken for analysis 
culminated in the major breakthrough of locating and then isolating the HD gene in 1993.  
 
1.3 Genetics of HD 
Since George Huntington’s initial description in 1872, it has been known that HD is 
hereditary in nature. More specifically, HD shows a form of autosomal dominant inheritance 
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characterised by: (1) an equal incidence in both sexes; (2) equal transmission by both sexes; 
(3) 50% of offspring of an affected parent also being affected by the time they reach old age, 
and; (4) no transmission of the disorder by an unaffected offspring (Cazeneuve and Durr, 
2014). 
  
After an arduous search for the genetic basis of HD, in 1983 the HD gene was mapped to 
chromosome 4p16.3 using haplotype linkage analysis (molecular genetic testing to identify a 
set of closely linked segments of DNA) and by linkage disequilibrium (the non-random 
association of two genes on the same chromosome) (Gusella et al., 1983). However, it was 
still not until a decade later that it was discovered the HD causing mutation is an expanded 
CAG repeat in the first exon of the interesting transcript gene 15, IT-15 (Huntington’s Disease 
Collaborative Research Group, 1993). The gene contains 67 exons and encodes the 
cytoplasmic protein, huntingtin (Huntington’s Disease Collaborative Research Group, 1993).    
 
 
Figure 1.1 The distribution of normal and expanded HD repeat sizes (Myers et al., 2004, 
p.256). 
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At this site, normal alleles contain CAG repeat sizes between 9 and 35 (Snell et al., 1993). 
However, when this trinucleotide repeat length expands to 40 or more CAGs, the disease 
becomes fully penetrant (Rubinsztein et al., 1996). The HD and normal range have quite 
distinct peaks with the tails of both curves very close to each other and no gap between the 
normal and disease ranges (see Figure 1.1) (Myers, 2004).  
 
CAG repeat lengths of 36-39 are not always associated with an HD phenotype, suggesting 
incomplete penetrance of the gene in this range. A repeat size of 35 CAGs or less has not 
been associated with manifest HD (Goldberg et al., 1995). However, an intermediate repeat 
size of between 27 and 35 has been shown to demonstrate instability on replication and 
expansion of the repeat length into the pathological range (Maat-Kievit et al., 2001). This 
instability could account for new onset cases of HD where there appears to be a negative 
family history. Expansion of the repeat length occurs much more frequently than contraction 
(73% versus 23%) and is also greater in spermatogenesis than oogenesis (Ranen et al., 1995). 
These findings can explain the known phenomenon of anticipation in HD, whereby the age 
of onset of the disease decreases with successive generations. Large expansions of the allele 
size (i.e. an expansion of more than 7 CAG repeats) happen almost exclusively in males and 
consequently paternal transmission accounts for the majority of cases of juvenile-onset 
disease (Ranen et al., 1995). 
 
Identification of the HD gene has fuelled a wealth of research into the genotype-phenotype 
correlation in HD. Numerous studies have confirmed the existence of a significant inverse 
relationship between the number of CAG repeats and the age of onset of the disease (see 
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Figure 1.2) (Snell et al., 1993; Duyao et al., 1993; Andrew et al., 1993; Langbehn et al., 2010). 
This correlation is particularly strong for juvenile-onset cases, where individuals often have 
an allele size greater than 60 CAG repeats (Quarrell et al., 2013). It is important to recognise 
that although there is a clear inverse correlation (with the repeat length determining about 
70% of the variance in age at onset), for each repeat number, there is a considerable range 
in the age at onset (Brinkman et al., 1997; Langbehn et al., 2010). 
 
Figure 1.2 Inverse correlation of age at neurologic onset and HD CAG repeat length for 
1,200 HD subjects of known age at neurologic onset (Gusella and McDonald, 2009, p. 80.2) 
 
 
The CAG repeat length does not provide any indication as to the presenting symptom, the 
course or the duration of illness (Roos, 2010). However, a longer CAG repeat has been 
associated with faster weight loss (Aziz et al., 2008). Additionally, a positive correlation has 
been found between CAG repeat number and severity of brain pathology including degree of 
atrophy (Penney et al., 1997), loss of striatal dopamine 2 receptors (Antonini et al., 1998) 
and density of intranuclear inclusions (Becher et al., 1998). 
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1.4 Clinical description of HD 
HD is a progressive disorder characterised by motor, cognitive and psychiatric disturbances. 
Other prevalent but less well-known features of HD include autonomic nervous system 
dysfunction, sleep- and circadian rhythm disturbances and unintended weight loss (Roos, 
2010). The mean age of onset is 35 to 44 years; however the disease may manifest itself 
from the age of 2 years up to the mid-80s (Huntington Disease Collaborative Research 
Group, 1993). Juvenile HD, whereby onset of symptoms is at or before the age of 20 years, 
accounts for approximately 5-10% of all HD cases (Quarrell, 2012). The duration of the illness 
also varies considerably but is typically about 15 to 20 years from motor onset to death with 
no difference between the sexes (Foroud et al., 1999). As the disease progresses, symptoms 
vary considerably and disability increases to the point where patients are no longer able to 
live independently. Common causes of death in HD patients are pneumonia, choking, heart 
disease, nutritional deficiencies and suicide (Lanska et al., 1988; Sørensen and Fenger, 1992). 
Although HD is caused by a single gene mutation, it gives rise to a wide array of phenotypic 
symptoms that vary from one individual to the next. Although it is the motor abnormalities 
that are most evident, it is the non-motor symptoms that are often most distressing to the 
patient and family (Craufurd and Snowden, 2014). 
 
1.4.1. Motor abnormalities 
Disturbances of both involuntary and voluntary motor functions occur in individuals with HD. 
Chorea, from the Greek word meaning ‘dance’, is the classical feature of the disease, hence 
the former name, Huntington’s chorea. The World Federation of Neurology defines chorea 
as, “a state of excessive, spontaneous movements, irregularly timed, randomly distributed 
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and abrupt. Severity may vary from restlessness with mild, intermittent exaggeration of 
gesture and expression, fidgeting movements of the hands and unstable dance-like gait to a 
continuous flow of disabling, violent movements” (Barbeau et al., 1981). Initially the 
choreatic movements are in the distal extremities such as the fingers and toes, spreading to 
all other muscles from distal to more proximal and axial (Roos, 2010). These movements 
cannot be suppressed voluntarily, are continuously present during waking hours and 
typically worsen with stress.  
 
As the disease progresses, other abnormalities of movement appear gradually including 
bradykinesia, rigidity and dystonia (abnormal postures with increased muscle tone) and tend 
to dominate the latter stages of the disease (Kremer, 2002). Disturbances in voluntary motor 
function are early indicators of disease presence. Clumsiness is commonly reported by 
patients with motor speed, fine motor control and gait all affected. Oculomotor 
abnormalities are also frequent and manifest early in the disease and worsen with disease 
progression (Lasker and Zee, 1997). Specific difficulties include the initiation of saccadic 
movements, which are slower and unco-ordinated, an inability to suppress blinking or head 
movements and smooth pursuits are often interrupted by saccadic intrusions (Lasker and 
Zee, 1997).  
 
Impairments of speech (dysarthria) typically occur early in the illness and swallowing 
difficulties (dysphagia) tend to present later in the course of disease and can significantly 
impact both intake of fluids and solids. As the motor disorder progresses, it interferes 
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increasingly with walking and standing as well as daily activities such as getting out of bed, 
showering, dressing and toileting. 
 
1.4.2 Cognitive abnormalities 
Cognitive decline is characteristic of HD but the rate of progression as well as the severity of 
these cognitive changes can vary considerably between individuals. Cognitive deficits have 
been demonstrated at least 15 years prior to a motor diagnosis of HD (Paulsen et al., 2006a; 
Paulsen et al., 2008; Stout et al., 2011) and are highly associated with disease-specific 
volume loss on MRI (Aylward et al., 2011).  
 
The earliest cognitive deficits to be detected in pre-manifest individuals who are up to 15 
years from their predicted motor onset are emotional recognition (Stout et al., 2011), 
deficits to the speed of cognitive and motor skills (Bechtel et al., 2010; Stout et al., 2011), 
difficulties with estimating time (Rowe et al., 2010; Tabrizi et al., 2011), and learning and 
memory problems (notably the implicit learning and memory system) (Montoya et al., 2006; 
Say et al., 2011). Cognitive abnormalities that can be detected in individuals with less than 
ten years to motor diagnosis include: smell identification (Stout et al., 2011; Tabrizi et al., 
2011), attentional deficits (Nehl et al., 2001) and impairment of executive functions such as 
planning, the organisation of sequential events and mental flexibility (Duff et al., 2010; Stout 
et al., 2011). In contrast to cortical degenerative disorders such as Alzheimer’s Disease, 
language skills, localisation skills, spatial orientation and semantic memory are generally well 
preserved in HD patients (Craufurd and Snowden, 2014). 
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1.4.3 Psychiatric symptoms 
Psychiatric symptoms have been recognised as common features of Huntington’s Disease 
since George Huntington’s original description of the disease in 1872 when he wrote “The 
tendency to insanity, and sometimes that form of insanity which leads to suicide, is marked.” 
Indeed, a wide range of psychopathology and behavioural abnormalities are seen in HD and 
include depression, anxiety, apathy, irritability, obsessive-compulsive disorders, aggression, 
sexual dysfunction and psychotic symptoms (Chatterjee et al., 2005).  
 
Psychiatric disorders/symptoms are evident throughout the disease course with prevalence 
rates of between 33% and 76% being reported (van Duijn et al., 2007). Psychopathology may 
also present in the prodromal phase of HD (the phase prior to motor diagnosis) in many 
patients (Folstein et al., 1983; Duff et al., 2007; Julien et al., 2007). However, the psychiatric 
symptoms do not seem to follow the same progressive course as the motor and cognitive 
changes. Of all the commonly observed neuropsychiatric symptoms in HD, only apathy 
appears intrinsic to disease progression (Craufurd et al., 2001; Thompson et al., 2012).  
 
Factor analyses of scales designed to assess the severity and frequency of behavioural 
problems in the HD population reveal similar factor structures. Craufurd et al (2001) and 
Kingma et al (2008) who both used the Problem Behaviours Assessment for Huntington’s 
Disease (PBA-HD) found three factor solutions reflecting apathy, depression and irritability. 
Rickards et al (2011) using the Unified Huntington’s Disease Rating Scale – Behaviour Section 
(UHDRS-BS) found four factors for depression, executive function, irritability/aggression and 
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psychosis. These results suggest that specific clusters of psychiatric symptoms exist in HD. 
The psychopathology of HD will be discussed in further detail in Chapter 2.  
 
1.5 Neuropathology of HD 
It has been long recognised that the pathology of HD is distinctly brain specific (although, 
pathology is also seen in peripheral tissues, Björkvist et al., 2008) and primarily a disease of 
the basal ganglia. The basal ganglia are subcortical structures located beneath the anterior 
portion of the lateral ventricles in the forebrain and classically refers to the caudate-
putamen (or striatum) and the globus pallidus (one of the striatum’s main projection areas) 
(Vonsattel et al., 2011). Other structures considered an integral part of the basal ganglia core 
are the subthalamic nucleus and the substantia nigra.  
 
Although post-mortem studies indicate that the pattern of pathological change in the brains 
of HD patients can vary, overall, the neuropathologic hallmark of HD is atrophy of the 
caudate nucleus, putamen and external segment of the globus pallidus (Vonsattel et al., 
2011). Additionally, there is atrophy of the cerebral cortex, subcortical white matter, 
thalamus, specific hypothalamic nuceli and other brain regions (Ross and Tabrizi, 2011). 
Neuroimaging techniques have demonstrated structural brain changes in individuals who are 
over 15 years from predicted age of motor onset (Tabrizi et al., 2009). The earliest changes 
appear to be reductions in caudate and putamen volumes, however, progressive 
abnormailities in both grey and white matter, involving both cortical and subcortical regions 
have been evidenced (Tabrizi et al., 2009).  By the later stages of the disease, the weight of 
the brain is often reduced by as much as 25-30% (see Figure 1.3) (Vonsattel et al., 1985). 
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Figure 1.3 Macroscopic image in which a slice of Huntington's brain (left) is put next to a 
slice from a normal control (right). Harvard Brain Tissue Resource Center (2014)  
 
The preferential loss of up to 95% of the GABAergic medium-spiny projection neurons of the 
indirect pathway concerned with motor control in the basal ganglia results in a reduced 
basal ganglia inhibitory output to the thalamus (Ross and Tabrizi, 2011). This in turn causes 
overactivation of thalamocortical projection systems, which manifests itself as chorea 
(Hedreen and Folstein, 1995).   
 
Aside from the basal ganglia’s involvement in motor function (namely skeletomotor and 
oculomotor), they are also involved in three other cortical-thalamic circuits that are 
concerned with non-motor aspects of behaviour (Cummings, 1993). These include the 
dorsolateral pre-frontal circuit, the lateral orbitofrontal circuit and the anterior cingulate 
circuit. The dorsolateral pre-frontal circuit appears to be involved in executive functions and 
damage to this circuit produces various behavioural abnormalities related to these cognitive 
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functions such as planning, organising and problem solving (Bonelli and Cummings, 2007). 
The lateral orbitofrontal circuit has been implicated in mediating empathetic and socially 
appropriate responses (Bonelli and Cummings, 2007). Damage to this circuit is associated 
with irritability, lack of empathy, emotional lability and is also thought to be involved in the 
neuropsychiatric disturbance, obsessive-compulsive disorder. The anterior cingulate circuit is 
believed to be involved in motivated behaviour and damage to this circuit may result in 
akinetic mutism, a significant impairment of movement initiation (Bonelli and Cummings, 
2007).   
 
The pathogenic mechanism(s) whereby mutant huntingtin induces neuronal dysfunction and 
death has yet to be satisfactorily elucidated. However, with the creation of accurate 
transgenic models of HD has come much greater understanding of the pathogenic process at 
molecular and cellular levels. Some of the most consistently described mechanisms that 
have been implicated in mediating HD pathogenesis include: abnormal protein aggregation 
and degradation (Davies et al., 1997; Young, 2003; Ravikumar et al., 2004); proteolytic 
cleavage (Goldberg et al., 1996; Wellington et al., 2002) transcriptional dysregulation (Li et 
al., 2002; Sugars and Rubenzstein, 2003); synaptic dysfunction (van Dellen and Hannan, 
2004); excitotoxicity (Tabrizi et al., 1999; Li et al., 2003); neurotrophins (Zuccato and 
Cattaneo, 1997; Ferrer et al., 2000); cytoskeletal defects and axonal transport (Gunawardena 
and Goldstein, 2005); microglia activation (Sapp et al., 2001); apoptosis (Portera-Cailliau et 
al., 1995) and, mitochondrial abnormalities and impaired energy metabolism (Beal et al., 
1993; Turner and Schapira, 2010). As the pathogenic pathways of HD are increasingly 
understood, some of these mechanisms may provide suitable targets for treatments. 
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1.6 Management of HD 
Currently, there is no preventive or curative treatment for HD. Due to the very nature of HD, 
as a progressive disorder of long duration, the management of the disease to maximise 
patients’ quality of life and functional capabilities is of upmost importance. The great 
variation in clinical presentation between individuals also necessitates management and 
care that is specific to each patient’s personal needs. A multi-disciplinary approach using 
non-pharmacologic as well as pharmacologic treatments is particularly beneficial to HD 
families due to the wide range of presenting symptoms and social problems.  
 
Specialist input is required from neurologists, psychiatrists, neuropsychologists, genetic 
counsellors, occupational therapists, speech therapists, dieticians, physiotherapists, social 
services and HD support teams. It is important that symptoms are treated as and when they 
arise, whilst weighing up the many side effects associated with available pharmacologic 
treatments, for which there is little evidence available about which drug or dosage to 
prescribe. In order to address this, three recent international surveys of clinicians regarded 
as experts in the treatment of HD have led to the publication of algorithms to help inform 
clinical decision-making in the pharamacologic treatment of chorea (Burgunder et al., 2011), 
irritability (Groves et al., 2011) and obsessive –compulsive behaviours (Anderson et al., 
2011). An example of the algorithm for the pharmacologic treatment of irritability in HD is 
outlined in figure 1.4. 
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Figure 1.4 Algorithm for the treatment of irritability in Huntington’s disease (Groves et al., 
2011).   
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Whereas chorea and psychiatric disturbances can be relatively well addressed by 
pharmacologic intervention, there are currently no medications available to either reduce or 
halt the progression of dementia in HD. However, attention must also focus on the general 
health of the patients, including diet and nutrition and sleep. Marked weight loss is 
commonly observed in HD, even when the calorie intake is adequate (Trejo et al., 2004; 
Robbins et al., 2006). Given that a higher premorbid body mass index has been associated 
with slower progression of disease (Myers et al., 1991), it is particularly important that 
dysphagia and appropriate changes in food texture as well as nutritional requirements 
receive continued attention. Sleep disturbances in HD are common and have been 
associated with reduced quality of life and depression as well as lower cognitive and 
functional performance (Aziz et al., 2010). Although there have been no efficacy studies of 
pharmaceuticals used to treat sleep deficits (Morton, 2013), hypnotics are considered useful 
at treating insomnia as well as subclinical cases of sleep disturbance (Morton et al., 2005).  
 
The high diagnostic precision in HD, the ability to track individuals in the prodrome to detect 
the earliest biological changes in HD, the development of transgenic mouse models and an 
increasing understanding of the pathogenic mechanisms involved, provides a great 
opportunity for developing therapeutic interventions. Many of the possible lines of 
treatment that are in development are aimed at interfering with the pathological process 
with the hope of slowing down, delaying or even preventing the onset of HD (Roos, 2010). 
Some examples include: gene silencing drugs that prevent cells from making the huntingtin 
protein e.g. anti-sense oligonucleotides (ASOs) (Southwell et al., 2014) and RNA interference 
(RNAi)(Yu et al., 2012); interventions to increase the amount of neurotrophic support 
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(Gharami et al., 2008); compounds that enhance mitochondrial function such as coenzyme 
Q10 and creatine (Galpern and Cudkowicz, 2007; Rosas et al., 2014); and, agents that 
promote autophagy and lysosomal clearance e.g. rapamycin (Renna et al., 2010). 
 
Research and clinical emphases are often biased towards the motor and cognitive changes in 
HD. However, psychiatric symptoms deserve increased attention, owing to the fact that in 
HD, behavioural abnormalities have been associated with functional decline (Marder et al., 
2000; Hamilton et al., 2003) and reduced quality of life (Ho et al., 2009). Moreover, they 
place the greatest burden on families (Paulsen, 2011) and can be predicitive of 
institutionalisation (Wheelock et al., 2003). The psychiatric phenotype in HD will be the focus 
of this thesis and an overview of the psychopathology of HD will be discussed in the 
following chapter (Chapter 2). 
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CHAPTER 2: THE PSYCHOPATHOLOGY OF HUNTINGTON’S 
DISEASE 
 
This chapter will provide an overview of existing research on the psychopathology of 
Huntington’s disease (HD). For both formal psychiatric disorders (mood disorders, anxiety 
disorders, obsessive-compulsive disorder, alcohol abuse and psychotic disorders) and 
frequently observed neuropsychiatric symptoms in HD (irritability, aggression and apathy), 
the reported prevalence rates and their relationship to the disease course of HD will be 
discussed. Finally, the possible aetiology of the psychiatric disorders/symptoms will be 
reviewed.   
 
2.1 Introduction 
In addition to the motor and cognitive deterioration observed in individuals with HD, 
neuropsychiatric symptoms comprise a significant component of the HD phenotype. 
Estimated prevalence rates of psychiatric disorders and symptoms in HD vary greatly, largely 
due to methodological differences including the assessment measures used, where the 
study sample was ascertained from and varying definitions of the neuropsychiatric 
phenomena. However, prevalence rates are undoubtedly high with one study finding that 
98% of a sample of 52 individuals with HD reported experiencing at least one 
neuropsychiatric symptom in the last month (Paulsen et al., 2001). A literature review of the 
psychopathology in verified Huntington’s disease gene carriers found that the most 
frequently reported neuropsychiatric symptoms were depressed mood, anxiety, irritability 
and apathy (each with prevalence rates of between 33% and 76%), followed by obsessive 
and compulsive symptoms (reported prevalence rates of 10% to 52%) and that psychotic 
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symptoms occurred least frequently (prevalence rates of between 3% and 11%) (van Duijn et 
al., 2007).  
 
The neuropsychiatric symptoms of HD often cause considerably more distress to both the 
patients and their caregivers than the motor and cognitive aspects of the disease (Craufurd 
and Snowden, 2014). Such behavioural symptoms are also more likely to impact on daily 
functioning (Hamilton et al., 2003) and result in nursing home placement (Wheelock et al., 
2003). Additionally, evidence suggests that psychopathology may predate motor symptom 
onset in many individuals with HD (Folstein et al., 1983; Di Maio et al., 1993; Duff et al., 
2007). Together, these findings suggest that further understanding of the psychopathology 
of HD is warranted. 
 
2.2 Depression in Huntington’s Disease 
Neurological diseases have long been associated with higher than expected rates of 
depression (Rickards, 2005) and HD is no exception. Indeed, George Huntington noted the 
high prevalence of depression in HD in his seminal 19th Century paper on the disease 
(Huntington, 1872). Depression has been associated with reduced cognitive performance in 
HD gene carriers (Nehl et al., 2001; Smith et al., 2012), functional decline (Hamilton et al., 
2003) and has been rated by HD patients as having the greatest impact on perceived quality 
of life (Ho et al., 2009). Depression has been described in HD both in terms of a formal 
psychiatric disorder and as the symptom “depressed mood” and consequently the 
prevalence rates reported vary greatly. 
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2.2.1 Prevalence of depression in HD 
Lifetime Diagnostic and Statistical Manual of Mental Disorders (DSM) (American Psychiatric 
Association, 2000) prevalence rates for depressive disorders in the motor manifest HD 
population have been reported at around 30% to 40% (Folstein et al., 1983,1987; Leroi et al., 
2002; Rosenblatt, 2007). In a study of 89 pre-motor manifest individuals, 20% of the sample 
had a lifetime DSM-III diagnosis of major depression (Julien et al., 2007). Other studies using 
DSM criteria have looked at point or period prevalence rates only, which are likely to 
underestimate the lifetime prevalence of depression in HD. Van Duijn and colleagues (2008) 
found 12-month prevalence rates of DSM-IV depressive disorders of 17.9% in a sample of 
140 mutation carriers. Caine and Shoulson (1983) used DSM-III classification to determine 
point-prevalence of depression or dysthymia and reported 5 (20.8%) and 6 (25%) affected 
individuals respectively out of 24. 
 
Studies using scales that assess the symptom of depressed mood have found high 
prevalence rates. Studies using the behavioural section of the Unified Huntington’s Disease 
Rating Scale (UHDRS-b; Huntington Study Group, 1996) and the Problem Behaviour 
Assessment Scale for Huntington’s Disease (PBA-HD; Craufurd  et al., 2001), which rate the 
frequency and severity of the symptom in question over the previous month have reported 
prevalence rates of 33% (Craufurd et al., 2001) and 40.5% (Paulsen et al., 2005a). Studies 
using the Neuropsychiatric Inventory (NPI) have reported prevelance rates of dysphoria of 
41% (Kulisevsky et al., 2001) and 69% (Paulsen et al., 2001). However, these studies could be 
underestimating the lifetime prevalence of depressive symptoms given that they only report 
its presence or absence over the previous month. Indeed, a study that assessed the 
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prevalence of neuropsychiatric symptoms in HD at baseline and longitudinally clearly 
demonstrated that the prevalence of symptoms was considerably higher when the 
longitudinal assessments were taken into account (Thompson et al., 2012). For example, at 
baseline, the percentage of HD patients endorsing the symptom of depressed mood was 
33% but this figure rose to 60% over the follow-up period, which was on average 5.2 years 
(based on a mean of 5 assessments with a mean inter-assessment duration of 1.3 years) 
(Thompson et al., 2012). 
 
2.2.2 Age at onset of depression in HD 
There has been little research into the age at onset of depression in HD, although it has been 
recognised for many years that onset of depression may precede motor symptom onset by 
up to 20 years (Folstein et al., 1983). A retrospective study by Folstein and colleagues found 
that for 23 HD patients for whom accurate onset data was available, depressive symptoms 
preceded motor onset by an average of 5.1 years (Folstein et al., 1983). Leroi et al. 2002 
reported an average age at onset of first psychiatric symptom of 42.3 years in their HD 
sample (N=21), which was significantly higher than the average age at first psychiatric 
symptom onset reported by the neurologically healthy comparison participants (33.8 years). 
A significant negative correlation has also been reported between the age of onset of 
psychiatric disorders and the length of the CAG repeat in HD (Vassos et al., 2008). This 
finding suggests that the age of onset of psychiatric disorders is related to the age at clinical 
diagnosis of HD given that the CAG repeat length is also strongly associated with the age at 
onset of diagnostic motor symptoms (Lee et al., 2012). The development of the 
presymptomatic genetic test for HD in 1993 has enabled the study of individuals during the 
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illness prodrome (the period before manifestation of motor symptoms). Results from such 
studies strongly suggest that behavioural problems including depression are among the first 
disease symptoms in HD (Julien et al., 2007; Kingma et al., 2008; van Duijn et al., 2008; 
Epping and Paulsen, 2011). 
 
2.2.3 Depression and the HD disease process 
Depressive symptoms do not have a clear relationship with the progression of HD 
(Thompson et al., 2002; Kingma et al., 2008; Thompson et al., 2012). Evidence to date 
suggests they are most common in the mild-moderate stages of the illness (Paulsen et al., 
2005a, Thompson et al., 2012) with a study using a sample of 2835 individuals finding that 
depressive symptoms were most frequently reported in stage 2 of the disease (see Section 
3.4.4.2.3)(Paulsen et al., 2005a). It is also thought that the prevalence of depressive 
symptoms may then decline during the latter stages of the disease (Paulsen et al., 2005a; 
Thompson et al., 2012). This finding could be due to impaired insight, which means patients 
are less aware of their disability (Paulsen et al., 2005a), blunted affect, which increases with 
disease progression (Thompson et al., 2012) and/or better adaptation over time to their 
illness and prognosis. Alternatively (or additionally), patients in the latter stages of the 
disease are less likely to be assessed for depression and included in studies due to cognitive 
and communicative deficits making it more difficult for self-report of such depressive 
symptoms (Craufurd et al., 2001; Paulsen et al., 2005a).  
 
It has also been reported that prevalence rates of depression in the illness prodrome may 
differ based on proximity to motor onset of HD (Julien et al., 2007). After an initial 
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psychiatric assessment where both interviewers and participants were blinded to genetic 
status, 51 gene carriers (for whom HD motor onset dates were subsequently available) were 
followed up for a number of years. The results showed that prevalence rates for current 
DSM-III affective disorder were significantly higher in those individuals who were closer to 
motor onset at the time of the psychiatric interview (Julien et al., 2007). Together, this 
evidence suggests that critical periods for depression in HD are close to the onset of motor 
symptoms and in the mild-moderate stage of the disease. 
 
2.2.4 Suicide in HD 
Individuals with HD have a marked increased risk for suicide or attempted suicide (Paulsen et 
al., 2005b). Reported prevalence rates of completed suicide among HD patients range from 
4% (Schoenfeld et al., 1984) to 13% (Cummings, 1995), which are much higher than the 
completed suicide rate of 1.16% observed in the UK general population (Office for National 
Statistics, 2012). Additionally, one study reported that 27.6% of HD affected individuals had 
attempted suicide at least once previously (Farrer, 1986). In a study of 1941 motor manifest 
individuals, 26.5% had a history of suicidal ideation (current suicidality rate was 19%) and 
9.5% of the sample had a history of at least one suicide attempt (Wetzel et al., 2011).  
 
Studies have demonstrated an increased incidence of suicide and heightened suicide risk 
shortly prior to receiving a clinical diagnosis of HD (Schoenfeld et al., 1984; Paulsen et al., 
2005b) and in Stage 2 of the disease (see Section 3.4.4.2.3) when functional loss is apparent 
such as termination of employment and driving (Lam et al., 1988; Paulsen et al., 2005). Other 
risk factors that have been associated with increased rates of suicidal ideation and suicide in 
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HD include: male gender (Schoenfeld et al., 1984; Di Maio et al.,1993), having no offspring 
(Lipe et al., 1993), being unemployed (Almqvist et al., 1999), the presence of a depressed 
mood (Wetzel et al., 2011; Hubers et al., 2012, 2013), taking anti-depressants (Hubers et al., 
2012) and the presence of other neuropsychiatric symptoms such as anxiety, aggression and 
alcohol abuse (Wetzel et al., 2012; Hubers et al., 2013).  
 
Like in other populations (Epping and Paulsen, 2011), the most consistent predictor for 
suicidality in HD is depressed mood (Hubers et al., 2012, 2013). Therefore, given the high 
prevalence of depression in HD (see section 2.2.1), it is perhaps not surprising that suicidality 
in HD is also high. Although published studies suggest that individuals with HD are more 
likely to commit suicide than the general population, this is in keeping with the well-
established association between suicidality and general medical illness (Harris and 
Barraclough, 1997; Druss and Pincuss, 2000). However, the presence of the neuropsychiatric 
symptoms impulsivity and emotional lability, which are commonly observed in HD, may 
increase an individual’s risk for suicide by reducing their ability to inhibit emotionally-driven 
behaviour (Wetzel et al., 2011).  
 
2.3 Bipolar Disorder 
The prevalence of bipolar disorder in HD is controversial. Older reports suggest that 
hypomania and/or bipolar disorder is more prevalent in the HD population than expected by 
chance, with estimated prevalence rates of 5% to 10% (Heathfield, 1967; Folstein et al, 
1987). However, although many individuals with HD experience manic symptoms such as 
prolonged periods of irritable mood, emotional lability and disinhibition, elevated mood and 
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other core symptoms of mania are rarely observed suggesting that operationally defined 
episodes of mania/hypomania are uncommon in the HD population (Julien et al., 2007; 
Rosenblatt, 2007; Craufurd and Snowden, 2014). Previous authors may have been describing 
symptoms that are more likely the result of the organic brain changes and cognitive 
impairment associated with HD than mania (Craufurd and Snowden, 2014). More recent 
research using DSM criteria have reported bipolar disorder prevalence rates of 2.1% (van 
Duijn et al., 2008), 4.8% (Leroi et al., 2002) and in a sample of 89 pre-motor symptomatic HD 
patients, no individuals had sufficient manic symptoms that fulfilled DSM-III diagnostic 
criteria for bipolar disorder (Julien et al, 2007). 
 
 2.4 Anxiety Disorders 
Anxiety in HD is thought to often be concerned with worries about the disease itself (Planz et 
al., 1991), which has maybe led to anxiety disorders in HD being dismissed as an 
understandable reaction to having a terminal, degenerative illness. Indeed, there is little 
literature on anxiety disorders in HD even though estimated prevalence rates of anxiety 
symptoms and “worrying” have been reported between 34% (Kulisevsky et al., 2001) and 
61% (Murgod et al., 2001).  
 
A study which determined 12-month prevalence rates of DSM-IV psychiatric disorders found 
a prevalence rate for all anxiety disorders of 14.5% in the presymptomatic mutation carriers 
and 16.5% in the symptomatic mutation carriers (van Duijn et al., 2008). The most common 
of the anxiety disorders reported for all the gene carriers was social phobia (5.7%) then 
generalised anxiety disorder (5.0%), panic disorder (4.3%) and obsessive compulsive disorder 
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(4.3%) (van Duijn et al., 2008). A further study investigating lifetime prevalence of DSM-III 
psychiatric disorders in pre-symptomatic gene carriers who were unaware of their genetic 
status found a lifetime prevalence of 17% for any anxiety disorder,  with the most common 
diagnoses being generalised anxiety disorder (11%), agoraphobia (9%), panic disorder (8%) 
and simple phobia (8%) (Julien et al., 2007). A lifetime prevalence of 23.8% for any anxiety 
disorder (including generalized anxiety disorder, panic disorder, obsessive-compulsive 
disorder, phobia and posttraumatic stress disorder) has been reported in a sample of 21 
early to mid-stage Huntington’s patients (Leroi et al., 2002).  
 
2.4.1 Obsessive Compulsive Disorder, Obsessive Compulsive Symptoms and 
Perseverative thinking/behaviours 
 
The prevalence of obsessive-compulsive disorder (OCD) in HD, like mania, is a contentious 
issue. Individuals with HD commonly experience cognitive inflexibility, which can manifest as 
repetitive thoughts and behaviours where individuals are unable to shift to a different topic 
of conversation or action (Craufurd and Snowden, 2014). However, unlike obsessive and 
compulsive symptoms, these perseverative thoughts and/or behaviours do not typically 
cause any distress to the patient, are not perceived as abnormal and the individual does not 
try to resist them. Nevertheless, some studies have reported that obsessive and compulsive 
symptoms (O/Cs) are commonly observed in HD. For example, Anderson et al. (2010) 
reported in their sample of 1642 individuals with a clinical diagnosis of HD that 27.2% 
endorsed current O/Cs on the UHDRS-b. Also using the UHDRS-b, Marder and colleagues 
(2000) found that 22.3% of HD patients reported O/Cs at their first clinic visit and a further 
study in a smaller sample of 27 HD patients found that 14 (52%) of the individuals endorsed 
at least one obsessive symptom on the Yale-Brown Obsessive Compulsive Scale 
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(YBOCS)(Anderson et al., 2001). However, the UHDRS-b measures perseverative thinking and 
obsessional thinking as the same item and in the study using the YBOCS, only the checklist 
part of the scale was used, which does not assess severity. Therefore, it is difficult to 
interpret exactly what phenomena these studies are measuring. 
 
Prevalence rates of OCD according to DSM criteria in HD patients appear less common than 
the reported rates of O/Cs. A lifetime prevalence of 5% for OCD according to DSM-III criteria 
was found in a sample of 89 presymptomatic mutation carriers (Julien et al., 2007). Van 
Duijn and colleagues (2008) found an increased 12 month prevalence of OCD in HD mutation 
carriers relative to the general population (4.3% versus 0.5%). Case reports have also 
detailed HD patients with OCD (Cummings and Cunningham, 1992; Molano-Eslava et al., 
2008), including a 72-year old man with late-onset HD and OCD (Scicutella et al., 2000).  
 
Although O/Cs may predate motor onset (Duff et al., 2010), age at onset of OCD according to 
DSM is thought to be later in HD patients (Cummings and Cunningham, 1992; Scicutella, 
2000) than in non-HD individuals with OCD (Kessler et al., 2005). 
 
2.5 Alcohol Abuse 
Alcohol has well-known short term effects on cognition and behaviour including:  impaired 
memory and concentration, slowed reaction times, difficulties with balance, slurred speech 
and a decrease in inhibition. In symptomatic HD individuals, alcohol can exacerbate these 
already present difficulties (Mattoo and Khurana, 1999) and possibly accounts for the finding 
that consumption of alcohol decreases after the motor onset of HD (Di Maio et al., 1993). A 
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small study of 42 HD patients in Baltimore, USA found a DSM-III prevalence rate for current 
or past alcohol abuse of 16.7% (24% for males and 5.9% for females) (King, 1985). This rate 
was comparable to that of the local Baltimore community (King, 1985). Another study using 
DSM-III criteria found a lifetime prevalence rate for alcohol dependence of 3% (Julien et al., 
2007). A more recent study of 136 individuals with motor symptomatic HD used DSM-IV 
criteria to determine a lifetime alcohol abuse prevalence rate of 30.9% (43% for males and 
19% for females) (Byars et al., 2012).  
 
One study found the average age at onset of alcohol abuse in HD to be 16.9 years (standard 
deviation 4.6) (Byars et al., 2012) and alcohol abuse has been associated with an earlier age 
at HD onset (Ehret et al., 2007; Byars et al., 2012), notably in women (Byars et al., 2012). 
Alcohol abuse in Huntington’s disease has been linked to increased rates of criminal 
convictions (Jensen et al., 1998) as well as more psychiatric symptoms (Ehret et al., 2007) 
and more severe suicidal ideation (Wetzel et al., 2013). 
 
2.6 Psychotic disorders 
Early reports suggested that schizophrenia was a predominant feature of the psychiatric 
presentation of Huntington’s disease. In a sample of 80 patients with HD, Dewhurst and 
colleagues (1967) reported that six of the individuals had paranoid schizophrenia and three 
had a diagnosis of schizophrenia simplex. Assessment of the clinical features of a sample of 
334 HD patients living in the West of Scotland revealed that paranoid ideas, often poorly 
systematised, were found in 109 of the patients (32.6%), visual or auditory hallucinations 
were found in 12 individuals (3.6%), grandiose ideas in 11 (3.3%) and religiosity in 4 
29 
 
individuals (1.2%) (Bolt, 1970). However, well-defined delusional and schizophrenia-like 
disorders are less common than these older research reports would suggest.  More accurate 
and earlier diagnoses of HD as well as a shift in the focus of research from in-patient to out-
patient populations likely account for these changes in prevalence rates (van Duijn et al., 
2007).  
 
Recent research using  DSM criteria found a lifetime prevalence of 1% for schizophrenia 
(Julien et al., 2007) and a 12-month prevalence rate of 1.4% for non-affective psychosis (van 
Duijn et al., 2007) in individuals gene positive for HD. However, the prevalence of 
schizophrenia-like symptoms (delusions and hallucinations) in HD may be higher and studies 
using dimensional rating scales such as the NPI and PBA-HD have found cross-sectional 
prevalence rates of between 3% (Craufurd et al., 2001) and 11% (Paulsen et al., 2001).  
 
2.7 Irritability and Aggression 
Irritability, in the context of psychopathology, is defined as a mood state characterised by a 
reduction in control over temper, which may result in verbal or behavioural outbursts 
(Snaith and Taylor, 1985). In individuals with HD, irritability often presents as poor temper 
control, verbal outbursts and behavioural inflexibility (Thompson et al., 2012). It is a 
common neuropsychiatric symptom in HD and can be the cause of great distress to the HD 
patients and their families and may determine admittance to a nursing home (Wheelock, 
2003). Various instruments have been used to assess the current prevalence of irritability in 
HD such as the PBA-HD (Craufurd et al., 2001; Kingma et al., 2008; Thompson et al., 2012), 
the UHDRS-b (Murgod et al., 2001); the NPI (Paulsen et al., 2001; Kulisevsky et al., 2010) and 
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the Irritability Scale (IS) (Chaterjee et al., 2005; Klöppel et al., 2010; Reedeker et al., 2012). 
The reported prevalence rates from these studies have ranged from 35% (Reedeker et al., 
2012) to 73% (Murgod et al., 2001).  
 
Increased levels of irritability have been found in pre-motor symptomatic gene carriers 
(Kirkwood et al., 2002) who were unaware of their genetic status and were up to 10 years 
from their estimated motor onset  (Julien et al., 2007). The use of psychiatric medication 
may hide the true prevalence of irritability throughout the disease course but there is 
evidence that it may increase through the early stages of the illness, peaking (or reaching a 
plateau) by Stage 3 (see Section 3.4.4.2.3) and then decreasing again (perhaps when apathy 
and abulia become more apparent) (Craufurd et al., 2001; Thompson et al., 2012).  
 
Alternatively, given that irritability/aggression may result in an individual no longer being 
able to be cared for in the community (Wheelock et al., 2003), it is possible that the previous 
studies using out-patient populations have under-reported the prevalence of 
irritability/aggression in the later stages of the disease. A study of 27 HD patients in a nursing 
home reported a significant relationship between aggression and functional impairment 
(Shiwach and Patel, 1993). One third of the sample was reported to be at least mildly 
aggressive during the 3-day observation period (Shiwach and Patel, 1993). 
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2.8 Apathy 
Apathy in HD, although difficult to conceptualise and therefore define, is often thought of as 
a disorder of motivation characterised by diminished goal-oriented behaviour, cognition and 
emotion (Starkstein and Leentjens, 2008). Apathy can of course be a symptom of a mood 
disorder but often manifests as a syndrome distinct from depression (Levy et al., 1998; 
Naarding et al., 2009). A factor analysis of the PBA-HD revealed an “apathy” factor consisting 
of the following seven symptoms: reduced energy and activity, self-neglect, blunting of 
affect, loss of initiative, lack of perseverance, impaired work performance, and poor 
judgment (Craufurd et al., 2001).  
 
Apathy is one of the most frequently observed neuropsychiatric features of HD with most 
patients succumbing to some degree of apathy by the latter stages of the illness (Thompson 
et al., 2012). Estimated prevalence rates from cross-sectional studies have varied from 34% 
(Kulisevsky et al., 2001) to 76% (Craufurd et al., 2001), with a longitudinal study showing that 
99% of a sample of 111 individuals with a genetic and clinical diagnosis of HD endorsed 
symptoms of reduced activity/energy at some point during the follow-up period (Thompson 
et al., 2012). Independent correlates of apathy (after the exclusion of HD mutation carriers 
with depression) have been found to be male sex, worse total functioning, higher use of 
neuroleptics and higher use of benzodiazapines (van Duijn et al., 2010). Apathy appears to 
correlate with duration of illness as well as motor, cognitive and functional measures of 
disease severity (Craufurd et al., 2001; Thompson et al., 2002; Reedeker et al., 2011; 
Thompson et al., 2012).  
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2.9 Aetiology of psychiatric disorders/symptoms in HD 
The aetiology of psychiatric disorders/symptoms in HD is most likely complex and 
multifactorial. As summarised in Table 2.1, although there are great differences in the 
reported prevalence rates of psychiatric disorders/symptoms in HD, in general, these 
prevalence rates are higher than those observed in the general population (van Duijn et al., 
2007). Reasons for this overrepresentation in HD are unknown, however, a number of 
possibilities have been proposed, including: pleiotropic effects of the HD gene (HTT gene), 
genetic linkage disequlibrium, overlapping biological pathways, organic brain changes as a 
result of HD and psychosocial effects.  
 
2.9.1 The HTT gene 
The HTT gene may itself increase the risk of individuals developing psychiatric symptoms 
through pleiotropic effects in the brain. The HTT gene codes for the protein huntingtin and 
although the exact function of this protein is unknown, it plays an important role in nerve 
cells and is thought to be involved in cell signalling, transporting materials, binding to 
proteins and other structures and protecting cells from apoptosis. Given the likely multiple 
roles of the huntingtin protein, it is possible that the HD mutation has wide-ranging effects 
(particularly in the brain where it is mainly expressed) and may predispose individuals to the 
development of psychiatric symptoms. However, studies to date have found no correlation 
between the length of the CAG repeat and the presence or severity of psychiatric symptoms 
(Zappacosta et al., 1996; Weigell-Weber et al., 1996; Berrios et al., 2001; Vassos et al., 2008). 
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Table 2.1 Summary of the estimated prevalence rates of the most common psychiatric syndromes/symptoms in HD compared to the 
general population 
Syndrome/Symptom Lifetime DSM prevalence rates in 
the HD population (%)* 
Current prevalence rates in the HD 
population using standardised 
instruments (%)* 
 
General population lifetime 
prevalence rates (%) (NCS-R) 
 
Major depression 20a-32b 33c-69d 16.9 
Completed suicide 4e-13f N/A 0.012** 
Suicidal ideation 26.5g 19g 13.7† 
Bipolar Disorder 0a-9b N/A 4.4 
Irritability/Aggression N/A 35h-73i N/A 
Anxiety Disorders 17a-23.8j 34k-61i 31.2 
Obsessive Compulsive 
Disorder 
5a 5c-52l 2.3 
Alcohol Abuse 3a-30.9m N/A 13.2 
Psychotic disorders 1a-11.3n 3c-11d N/A 
Apathy N/A 34j-76c N/A 
a
Julien et al., 2007; 
b
Folstein et al., 1983; 
c
Craufurd et al., 2001; 
d
Paulsen et al., 2001; 
e
Schoenfeld et al., 1884; 
f
Cummings, 1995; 
g
Wetzel et al., 2011; 
h
Reedeker 
et al., 2012; 
i
Murgod et al., 2001; 
j 
Leroi et al., 2002; 
k
Kulisevsky et al., 2001; 
l
Anderson et al., 2001; 
m
Byars et al., 2012; 
n
Dewhurst et al., 1967. 
NCS-R; National Comorbidity Survey-Replication (updated data as of July 19, 2007) (Kessler et al., 2005). 
*The range is stated where applicable, otherwise, single prevalence rates are reported. 
** Completed suicide data taken from the Office of National Statistics, UK, 2012 
†Suicidal ideation data taken from the APMS; The Adult Psychiatric Morbidity Survey, 2007 
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2.9.2 Linkage disequilibrium 
An alternative hypothesis is that a gene predisposing for psychiatric disorders/symptoms is 
in linkage disequilibrium with the HD gene and therefore inherited together during meiosis. 
As yet, there are no known genes that are thought to increase the risk for psychiatric 
disorders/symptoms in close proximity to the HTT gene on chromosome 4p16.3 (Lohoff et 
al., 2010). 
 
2.9.3 Overlapping biological pathways 
Dysfunction of specific molecular and cellular mechanisms that have been evidenced in HD 
pathogenesis and in individuals with psychiatric disorders/symptoms without HD may 
provide common biological pathways to explain the high prevalence of psychiatric 
disorders/symptoms in HD. For example, possible overlapping pathways associated with 
major depression include; dysregulation of the serotonin (5-HT) signalling system; 
hyperactivity of the hypothalamic pituitary adrenal (HPA) axis; reduced expression of brain 
derived neurotrophic factor (BDNF), and activation of the immune system (Du et al., 2013).  
Alterations in the dopamine system have been implicated in cognitive inflexibility, which has 
been associated with irritability and perseverative thinking/behaviour (Chen et al., 2013). A 
role for the serotonergic system in irritability and aggression has also been suggested given 
that selective serotonin reuptake inhibitors may be useful for treating irritability in HD 
(Ranen et al., 1996). 
 
2.9.4 Organic brain changes 
The high prevalence of psychiatric disorders/symptoms may be secondary to the organic 
brain changes that occur as a result of the HD gene.  
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2.9.4.1 Depression 
HD is associated with gross atrophy of the caudate nucleus (see Chapter 1.5) and major 
depression has been correlated with a decrease in caudate nucleus volume (Krishnan et al., 
1992). Cummings (1995) postulated that neuronal loss in the ventral striatum as seen in 
individuals with HD may reduce the effectiveness of reward-mediated pathways thus 
increasing vulnerability to anhedonia and depression. However, even in the pre-motor 
manifest HD population, atrophy is not confined to the striatum (Tabrizi et al., 2009) and 
other important structural changes that occur in the brain as a result of HD are worth 
consideration as possibly aetiologically relevant in the psychopathology associated with HD.  
 
Dysfunction of the frontal-subcortical circuits (more specifically the limbic-thalamic-cortical 
(LTC) circuit and the limbic-cortical-striatal-pallidal-thalamic (LCSPT) circuit) have been 
identified as being of critical importance in mood disorders (Carlson et al., 2006) and lesions 
in these areas are also common to HD pathology (Bonelli and Cummings, 2007). Dysfunction 
of the frontal lobes has also been hypothesised as contributing to depression in HD and has 
been shown to occur in the early stages of the disease even before the onset of motor 
symptoms (Jason et al., 1988). Hypometabolism in the orbital inferior prefrontal cortex has 
been evidenced in depressed HD patients (Mayberg et al., 1992) and reduced activity in the 
dorsal and ventral sectors of the prefrontal lobes were found in individuals with HD 
compared to healthy controls when dysphoric mood was induced in the participants using 
pictorial stimuli (Paradiso et al., 2008). 
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2.9.4.2 Obsessive Compulsive Disorder/Obsessive Compulsive symptoms 
Huntington’s patients may be more prone to obsessive and compulsive symptoms than the 
general population due to shared frontostriatal pathology between HD and OCD (Anderson 
et al., 2001). Abnormal metabolic activity in the orbitofrontal cortex , the anterior 
cingulate/caudal medial prefrontal cortex, the basal ganglia and thalamus has been reported 
in functional imaging studies of individuals with OCD (Baxter et al., 1987; Nordahl et al., 
1989; Saxena et al., 2001), which can then be normalised following successful treatment 
(Graybiel and Rauch, 2000). Intuitively, these results suggest that the striatal pathology and 
disruption of frontostriatal circuitry (in particular the orbitofrontal circuit) seen in HD gene 
carriers is related to the increased frequency of obsessive/compulsive symptoms seen in this 
population. 
 
2.9.4.3 Alcohol abuse 
Alcohol abuse in HD could arise due to common cortical-striatal circuit involvement in both 
HD and substance use disorders (Ehret et al., 2007). Dysfunction of these circuits in HD, 
which have been implicated in reward mediated pathways (Cummings, 1993) may increase 
vulnerability to alcohol abuse. 
 
2.9.4.4 Psychotic symptoms 
Psychotic symptoms in HD are thought to mainly occur in those patients who already have 
dementia (Shiwach and Norbury, 1994) and therefore, the underlying neuropathology of HD 
may contribute given that organic brain disorders have long been associated with symptoms 
including auditory hallucinations and delusions (Lyketsos, 2006). Deficits in neurocircuitry 
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that are common to both HD and schizophrenia may account for the increased prevalence of 
psychotic symptoms in the HD population (Bonelli and Cummings, 2007). The psychotic 
presentation in HD has been described as most often consisting of poorly systematised 
paranoia and overvalued ideas, often accompanied by irritability, aggression and poor 
impulse control (Guttman et al., 2003), which may result from disturbance of the 
dorsolateral prefrontal circuit, which contributes to the executive dysfunction seen in both 
HD and schizophrenia (Bonelli and Cummings, 2007).   
 
2.9.4.5 Irritability and Aggression 
Irritability in HD is thought to be associated with HD pathology (Bonelli and Cummings, 2007; 
van Duijn et al., 2007; Reedeker et al., 2012; Thompson et al., 2012). Dysfunction of the 
orbitofrontal-subcortical circuit, as observed in HD patients, is thought to disconnect frontal 
monitoring systems from limbic input, resulting in inappropriate behavioural responses 
(Bonelli and Cummings, 2007). This can manifest as emotional lability (including irritability 
and aggression), disinhibition and a loss of socially appropriate behaviour (Bonelli and 
Cunnings, 2007). Disrupted emotional circuitry including the medial orbitofrontal cortex and 
amygdala has also been identifed using functional magnetic imaging (fMRI), in pre-
symptomatic HD gene carriers completing tasks that induced irritation (Klöppel et al., 2010).  
 
2.9.4.6 Apathy 
The correlation between apathy and measures of the HD disease course suggest that it is 
associated with the underlying neuropathology of HD (Craufurd et al., 2001; Thompson et 
al., 2002; Reedeker et al., 2011; Thompson et al., 2012). Apathy, in general, has been 
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associated with dysfunction of the anterior cingulate circuit given its role in motivated 
behaviour (Mega and Cummings, 1994; Bonelli and Cummings, 2007).   
 
More specifically, Levy and Dubois (2006) refer to three subtypes of disrupted processing 
when describing the underlying mechanisms of apathy, including: emotional-affective, 
cognitive and auto-activation. Emotional-affective apathy is displayed as emotional blunting 
and a loss of interest in daily activities previously considered as motivating and is thought to 
be associated with dysfunction of the orbital and medial prefrontal cortex. Apathy due to 
disrupted cognitive processing is expressed as impaired executive functioning, including 
difficulties with: rule generation, set-shifting, planning and maintaining information in 
working memory. It is associated with damage to the lateral prefrontal cortex and the dorsal 
territories of the basal ganglia (notably the dorsal part of the head of the caudate nucleus). 
Deficits in auto-activation processing leads to the most severe form of apathy characterised 
by difficulties in self-generated thoughts and actions and are associated with damage to the 
dorsal-medial prefrontal cortex and the internal segment of the globus pallidus. 
 
2.9.4.7 Cognitive impairment 
Cognitive deficits (including impairments in memory, attention and executive skills) in HD 
may also account for the high prevalence of particular neuropsychiatric symptoms in HD. 
Apathy (not in the context of depression) in particular has been associated with cognitive 
dysfunction (Thompson et al., 2002; Baudic et al., 2006). Difficulties in planning and 
organising, as evidenced by poor performance on cognitive tasks that require individuals to 
plan a sequence of actions such as the Tower of London task (Lange et al., 1995; Lawrence et 
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al., 1996; Watkins et al., 2000) and picture-ordering tasks (Snowden et al., 2001), likely 
contribute to the passive, amotivational states frequently seen in HD patients. 
 
Impaired performance on specific cognitive tasks, including the Wisconsin Card Sorting Test 
and attentional set-shifting tasks, demonstrates reduced cognitive flexibility in HD patients 
(Owen et al., 1993; Paulsen et al., 1995; Lawrence et al., 1996). In the real world, a lack of 
cognitive flexibility is likely to impair an individual’s ability to adapt to new situations or 
altered circumstances, which could lead to feelings of agitation and irritability when faced 
with unexpected changes. However, the direction of this relationship is unknown given that 
it is also possible that the presence of psychiatric symptoms leads to cognitive impairment. 
 
2.9.5 Psychosocial factors 
Psychosocial factors are likely to play a role in the development of psychiatric 
disorders/symptoms in HD. Specific stressors associated with HD including: growing up in a 
dysfunctional family, undergoing genetic testing; having to adjust to living with a hereditary, 
terminal illness and increasing disability are likely to contribute to the development of 
psychiatric disorders/symptoms. For example, a positive correlation has been found 
between stressful life events (measured using the Perceived Stress Scale) and depression in 
a pre-motor manifest HD sample (Downing et al., 2012). Anxiety is a feasible result of a gene 
positive individual wondering whether they are showing symptoms of HD yet or a 
symptomatic individual no longer coping at work and worrying about financial issues. Some 
individuals with HD may choose to self-medicate with alcohol as a way of coping with 
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stressful life events, especially if they are experiencing other psychiatric symptoms such as 
depressed mood and anxiety.  
 
Environmental factors, including frustration and particular socio-demographic 
characteristics, may contribute to the increased irritability observed in HD gene carriers. 
Frustration is thought to augment aggression in certain situations (Buss and Arnold, 1963) 
and it is highly likely that individuals with HD can become frustrated with having a disabling 
illness and the loss of independence that comes with it as well as through experiencing 
reduced mental flexibility. Irritable behaviour exhibited by HD gene carriers can often be 
targeted at a specific household member closely involved in the individual’s care (Craufurd 
and Snowden, 2014). Indeed, to date, being married/living together has been the only socio-
demographic characteristic found to correlate with self-reported levels of irritability in HD 
(Reedeker et al., 2012). The authors of the study suggested that this could be due to the fact 
that intimate relationships may comprise more potential triggers of irritability (Reedeker et 
al., 2012).  
 
2.9.6 Familiality studies in HD 
Studies investigating the genotype-phenotype correlation in HD have focused on the CAG 
repeat length in the huntingtin gene. However, evidence to date strongly suggests that the 
presence and severity of psychiatric symptoms in HD is independent of the length of the 
trinucleotide expansion (Weigell-Weber et al., 1996; Naarding et al., 2001; Vassos et al., 
2007). Although research on familial factors has received little attention, the few studies 
that have been carried out suggest that familial factors may play a role in the psychiatric 
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presentation of HD i.e. some psychiatric symptoms/syndromes may occur with higher 
frequency within some HD families than can be accounted for by chance.  
 
2.9.6.1 Familiality of affective disorders in HD 
HD and affective disorder (including bipolar disorder and major depressive disorder) have 
been demonstrated to cosegregate in certain families (Folstein et al., 1983). In this study, 
Folstein and colleagues found a significant difference in the prevalence of major affective 
disorder in HD families where the HD proband had affective disorder (20 of 23 HD affected 
relatives had affective disorder) compared to those HD families where the HD proband did 
not have affective disorder (only 5 of the 23 HD affected relatives had affective disorder). 
This is the only study to date investigating the familiality of affective disorder in HD but 
suggests that familial factors (whether genetic or shared environmental factors) are 
important in the aetiology of mood disorders in HD. 
 
2.9.6.2 Familiality of suicide in HD 
A study has demonstrated a possible predisposition to suicide in some HD families, with 40 
out of 143 (28%) families included in the study having 99 out of the 205 (48%) cases of 
suicide (Di Maio et al., 1993).  
 
2.9.6.3 Familiality of OCD in HD 
A pedigree has also been described where three cases of OCD and two cases of pathological 
gambling were identified in the family members who carried the HD gene mutation only (De 
Marchi et al., 1998).  
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2.9.6.4 Familiality of psychotic symptoms in HD 
There have been reports of a possible association between HD and schizophrenia-like 
psychotic symptoms due to findings that a subset of HD families have a predisposition to 
developing psychosis (Heathfield, 1967; Lovestone et al., 1996; Tsuang et al., 1998; Tsuang 
et al., 2000; Corrêa et al., 2006). Heathfield (1967) described a family where a brother and 
sister with HD also both had a diagnosis of paranoid schizophrenia as did another brother, 
although he did not develop motor symptoms of HD. Another family has been described 
where four family members presented with a severe psychiatric disorder (three were 
diagnosed with a schizophrenia-like syndrome and the other family member with 
depression) before the onset of motor symptoms (Lovestone et al., 1996). Additionally, two 
other family members at 50% risk for HD, who were displaying no signs of chorea or 
dementia, had received psychiatric treatment for schizoaffective disorder and major 
depression respectively (Lovestone et al., 1996).  
 
Tsuang et al., (1998) compared two juvenile-onset HD families, one where the proband had 
schizophrenia-like symptoms and one where the proband had no psychotic presentation. HD 
co-occurring with schizophrenia-like symptoms was only found in the family members (the 
father and paternal grandmother) of the proband who also exhibited psychotic symptoms. A 
further study by Tsuang and colleagues (2000) on a larger group of Huntington’s disease 
patients produced similar results where the HD probands who had psychotic symptoms were 
significantly more likely to have a first degree relative with psychosis than the probands who 
did not have psychosis. Finally, a family pedigree has been described where a three-
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generation-long family history of HD and schizophrenia-like psychosis occurred, with the 
psychosis preceding motor onset by at least 5 years (Corrêa et al., 2006).  
 
2.10 Summary and Aims of Study 
Prevalence of psychiatric symptoms/syndromes in HD: 
Psychiatric syndromes and symptoms are undoubtedly common in HD as summarised in 
Table 2.1. It is apparent, however, that the use of a variety of instruments and differing 
definitions to measure prevalence rates, over different time courses and different disease 
stages has resulted in a wide range of prevalence rates being reported. In addition, the great 
deal of overlap between symptoms of various psychiatric disorders (major depression, 
bipolar disorder, OCD, psychotic disorders) and symptoms of HD itself, make the process of 
reaching a psychiatric diagnosis in the setting of HD very difficult. The fact that an exclusion 
clause of DSM criteria is that the psychiatric episodes are not attributable to an organic 
mental disorder adds to the difficulty of accurately assessing and diagnosing psychiatric 
syndromes in HD.  However, it has been argued that the DSM criteria should be used as the 
gold standard measure for psychiatric diagnoses and that additional standardised 
instruments should be used to assess the presence/absence of other neuropsychiatric 
symptoms such as irritability, perseverative thinking and apathy in HD (van Duijn et al., 
2007). 
 
Aetiology of psychiatric syndromes/symptoms in HD 
The basis of psychiatric disorders and symptoms in HD is complex, with genetic factors 
(including the HD gene) and non-genetic factors (including psychosocial factors) 
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hypothesised to play a role. Family studies provide a useful means to investigate the relative 
roles the shared genetic and/or shared environmental factors play in the aetiology of 
psychiatric disorders/symptoms. 
 
However, the majority of these studies in HD families (Heathfield, 1967; Lovestone et al., 
1996; De Marchi et al., 1998; Tsuang et al., 1998; Corrêa et al., 2006) have described one or 
two family pedigrees only, which are not generalisable to the HD population. Additionally, 
face-to-face interviews have not always been administered, instead relying on retrospective 
case notes and/or family informants to draw conclusions about psychiatric diagnoses and HD 
symptomatology.  Two of the studies (Heathfield, 1967; Folstein et al., 1983) were 
conducted before the HD gene was identified, rendering the diagnostic criteria for HD less 
reliable than post-1993 studies. These family studies have also mainly focused on the 
association between HD and psychosis, rather than the more frequently observed psychiatric 
syndromes/symptoms in HD.  
 
Therefore, there is a great need to build on this previous research by using gold-standard 
methodology to investigate a wide range of psychopathology in a large sample of HD 
families to better understand the role shared genetic and/or environmental factors may play 
in the aetiology of psychiatric syndromes/symptoms in HD . This research has implications 
not only for improving the clinical management of HD patients but also for enabling the 
development of more effective treatments and maybe even for preventing the onset of 
psychiatric symptoms. Research of this type in HD may also provide important insight 
regarding the aetiology of psychiatric disorders in the general population. 
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Aims of Study: 
The main aims of this thesis are to: 
1. Determine whether a broad range of psychiatric syndromes and symptoms aggregate 
in families affected with HD by conducting a systematic, standardised psychiatric 
assessment on a large sample of sibling pairs with HD. 
2. Further improve current understanding of the relative role the HD gene, other 
genetic factors and psychosocial factors may play in explaining the increased 
prevalence of psychiatric symptoms in HD. This will be achieved by administering the 
psychiatric assessment to unaffected siblings who have had a negative HD genetic 
test. 
Secondary aims include: 
1. To assess and determine the lifetime prevalence rates of a broad range of psychiatric 
symptoms and syndromes defined using DSM-IV criteria in a large sample of 
unrelated individuals with HD.  
2. To compare the depression phenotype in this HD sample with that in a large sample 
of individuals with unipolar depression without HD. 
3. To validate the use of self-report depression rating scales in HD so that depression 
can be more accurately assessed in this population. 
 
The following chapter (Chapter 3) describes the recruitment, assessment and clinical 
description of 50 unrelated individuals with HD and 40 of their siblings. 
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  CHAPTER 3: METHODS AND CLINICAL DESCRIPTION OF THE HD 
FAMILY SAMPLE 
 
This chapter will outline the methods and clinical description of the sample relevant to 
Chapters 4 and 5. It will describe the recruitment, clinical and neuropsychiatric assessments 
of 50 unrelated individuals with HD, 40 of their siblings with HD and five gene negative 
siblings. The demographic characteristics and HD clinical features of the index and sibling 
samples will then be discussed. 
 
3.1 Ethical Approval 
Multi-centre NHS ethical approval was granted by Cornwall and Plymouth Research Ethics 
Committee, reference: 08/H0203/157. Local Trust Research and Development (R&D) 
approval was then sought for the sites throughout the U.K. that had agreed to act as 
participant identification centres. These initially were: Birmingham and Solihull Mental 
Health Foundation Trust; University Hospital Wales, Cardiff; NHS Fife; Leicestershire 
Partnership NHS Trust; Central Manchester and Manchester Children’s University Hospitals 
NHS Trust.  
 
Local R&D approval was obtained from the following four extra sites half way through the 
study to increase potential recruitment: North Bristol NHS Trust; Newcastle Upon Tyne 
Hospitals NHS Foundation Trust; Oxford Radcliffe Hospitals NHS Trust, and; Sheffield 
Children’s NHS Foundation Trust. Recruitment began from the sites once the relevant R&D 
approvals had been awarded. 
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3.2 Recruitment of Participants 
The recruitment of participants took place between February 2009 and March 2011. Families 
where at least two siblings were known to have the HD gene were recruited to the study.  
 
3.2.1 Sibling sample ascertainment 
3.2.1.1 Consultant approach 
The main recruitment of families to the study was achieved with the help of the Consultants, 
HD specialists and HD researchers at the HD centres where local R&D approval had been 
obtained: Dr Hugh Rickards, Consultant Neuropsychiatrist, Birmingham; Dr David Craufurd, 
Consultant Neuropsychiatrist, Manchester; Professor Anne Rosser, Consultant Neurologist, 
Cardiff; Carole Clayton, HD Nurse Specialist, Leicester; Jillian Foster, HD Team Leader, Fife; Dr 
Oliver Quarrell, Consultant in Clinical Genetics, Sheffield; Dr Baldev Singh, Consultant 
Neuropsychiatrist, Newcastle; Dr Andrea Nemeth, Consultant in Clinical Genetics, Oxford 
and; Dr Kasia Sierazdan, Consultant Neurologist, Bristol. Whether an HD patient is seen by a 
Neuropsychiatrist, Neurologist or Clinical Geneticist is dependent on the location of HD 
services within each local Trust only rather than whether the patient has any psychiatric 
symptoms. The Consultants at all of the sites were responsible for systematically screening 
their caseloads and making the initial contact with suitable participants. The recruitment 
process via the Consultants is outlined in Figure 3.1. 
 
Potential participants were identified by their local Consultant during their routine HD clinic 
appointments.   Participants were approached about the study on the basis that they were 
thought to meet the inclusion/exclusion criteria outlined in Table 3.1. 
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Table 3.1 Inclusion and exclusion criteria for the HD gene positive sibling pairs. 
Inclusion criteria Exclusion criteria 
A genetic diagnosis of HD Any individual who was adopted away from 
their biological sibling 
Over 18 years of age Any individual who was a monozygotic twin 
of their sibling 
Cognitively able to give informed consent 
 
 
Fluent in English 
 
 
Have at least one full, biological sibling that 
met the above criteria 
 
 
 The Consultant outlined the purpose of the study and what taking part involved. After this 
initial contact, if a patient was interested in taking part then the Consultant gave the patient 
a copy of the patient information sheet (Appendix Ai pg. 217) together with a reply slip 
(Appendix Ai pg. 222) and stamped addressed envelope to take home. If after reading the 
information sheet individuals were still interested in taking part, then they were asked to 
complete the reply slip with their contact details and return in the stamped addressed 
envelope to JDS.  
  
Once the reply slip had been returned, the patient was contacted within two weeks to 
discuss the study further and clarify any questions he/she had and if still interested to 
arrange a suitable time to conduct the interview. Patients were interviewed at a location of 
their choice for example, at their home, at a sibling’s home or at hospital. 
 
Gene positive siblings were approached via one of two possible methods. Firstly, if the 
sibling was registered with the same participating HD service as their sibling, then the 
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relevant Consultants contacted the sibling(s) directly about the study. Contact was made 
either in clinic (if the sibling was due to attend the clinic in the next couple of months) or by 
a phone call. If the sibling was interested in receiving further information then they were 
either given or sent in the post the information sheet, reply slip and stamped addressed 
envelope and were asked to complete and return their contact details to JDS. Secondly, for 
those siblings not in the same participating HD service, the sibling already recruited to the 
study was asked to forward the patient information sheet onto their sibling(s) together with 
the reply slip and stamped addressed envelope for them to return to JDS with their contact 
details. Once the reply slip had been received by JDS, then the same recruitment procedure 
as described in the paragraph above was followed. As a result of this recruitment process, 47 
families were recruited to the study. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Recruitment process of HD gene positive siblings via Consultants  
Consultant approaches potential 
participant who meets inclusion criteria 
Consultant approaches sibling of 
recruited participant 
Individual provided with information 
sheet, reply slip and stamped 
addressed envelope 
Sibling provided with information 
sheet, reply slip and stamped 
addressed envelope 
 
55 unrelated individuals 
initially agreed to take 
part 
5 individuals 
subsequently 
declined 
56 siblings initially 
agreed to take part 
 
9 siblings subsequently 
declined 
 
1 sibling was a half sibling 
and therefore excluded 
50 unrelated 
individuals with 
HD take part 
46 gene positive 
siblings take part 
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3.2.1.2 Huntington’s Disease Association 
To facilitate recruitment to the study, other means of promoting the study were employed. 
The study was advertised on the charity Huntington’s Disease Association (HDA) website 
where many patients and carers regularly log on for details about the latest HDA meetings, 
news and research. The advertisement (Appendix Ai, pg. 223) briefly outlined the purpose of 
the study, who would be suitable to participate and what taking part involved. Anyone 
interested was asked to contact JDS directly and it was then possible to answer any 
questions and if they were suitable and still interested then they were sent the patient 
information sheets. One sibling pair was recruited via this method. 
 
JDS also attended support group meetings run by the HDA in Bristol, Stoke-on-Trent and 
Northampton to present the study to patients and carers. Two families returned their reply 
slips to JDS following these meetings and were subsequently recruited to the study. 
 
Table 3.2 Frequencies of families recruited to the study from the different sites and HDA.  
Centre Number of families 
Birmingham 16 
Bristol 3 
Cardiff 6 
Leicester 3 
Manchester 6 
Newcastle 4 
Oxford 2 
Sheffield 4  
Fife 3 
HDA meeting 2 
HDA website 1 
Total 50 
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A summary of the number of families recruited to the study and the site or means of how 
they were recruited is displayed in Table 3.2. Of the 50 families that took part in the study, 
the siblings that were the first family member to be recruited to the study were all 
interviewed. For 40 of these 50 families, at least one HD gene positive sibling was also 
interviewed. However for 9 families, although the sibling had initially agreed to take part, 
they subsequently decided not to participate, the reasons for which are outlined in Table 
3.3. Two individuals were having a difficult family time (one was going through a divorce and 
the other had not told her family about having the HD gene) and decided that it was not a 
good time for them to take part in research. Similarly, two individuals were in the process of 
moving to a nursing home so decided they no longer wanted to take part. Two individuals 
were unable to be contacted despite numerous attempts. One individual cancelled 
appointments continuously and then subsequently stated that he did not want to take part 
in the study after all. One individual decided not to sign the consent form and a further 
individual was hospitalised in the time between my initial contact and then arranging an 
interview date and so it was not possible for them to take part in the study. In addition, one 
sibling was discounted from the study after it became apparent during the interview that 
they were only half-siblings. 
Table 3.3 Frequencies of families that took part in the research and reasons for siblings not 
participating. 
 Frequency 
Families that were recruited to the study 50 
Families where at least 2 gene positive siblings were interviewed 40 
Families where sibling was having a difficult family time 2 
Families where sibling was moving to a nursing home 2 
Families where sibling was unable to be contacted 2 
Families where sibling decided not to participate 2 
Families where sibling was hospitalised 1 
Families where siblings were half-siblings 1 
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3.2.2 Gene negative sibling sample ascertainment 
For those families where in addition to the HD gene positive sibling pair there was a sibling 
who had received a negative predictive test result, a sibling already recruited to the study 
was again asked to contact the gene negative sibling about taking part in the study. The 
inclusion and exclusion criteria for the gene negative sibling are shown in Table 3.4.  
Table 3.4 Inclusion and exclusion criteria for the HD gene positive sibling pairs. 
Inclusion criteria Exclusion criteria 
A negative genetic test for HD Any individual who was adopted away 
from their biological sibling 
Over 18 years of age  
Cognitively able to give informed consent  
Fluent in English  
Have two gene positive full siblings who meet all of 
the inclusion criteria for the HD gene positive  sample  
 
 
The gene positive sibling was given a participant information sheet (Appendix Ai, pg. 220), 
reply slip and stamped addressed envelope to forward to the gene negative sibling. If the 
gene negative sibling was interested in taking part then they were asked to return their 
contact details to JDS. They were then contacted by telephone to confirm that they had 
indeed received a gene negative test result, to answer any questions they had about the 
study and to arrange a suitable time to visit them if they were still interested in taking part. 
This was a particularly difficult means of recruiting individuals as it relied on HD patients 
(who typically have difficulties with their memory, apathy and executive functions and are 
generally difficult to get hold of anyway) contacting their siblings. Any siblings who were 
unsure of their genetic status but were currently symptom free were not included in the 
study. Five gene negative siblings from 5 different families were recruited to the study.  
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A summary of the families and number of siblings that took part for each site/recruitment 
method is displayed in Table 3.5. Thirty one families had two gene positive siblings take part, 
four families had two gene positive and one gene negative sibling take part, three families 
had three gene positive siblings take part, one family had three gene positive and one gene 
negative sibling take part, one family had four gene positive siblings take part and there 
were ten families where only the initial gene positive sibling recruited to the study took part. 
Therefore, in total, 96 patients with HD and 5 unaffected siblings were recruited to the 
study. 
Table 3.5 Frequencies of families recruited to the study and the number of siblings for each 
family that took part from each site. 
 
Centre Number of families 
Total 1 gene 
positive  
sibling 
2 gene 
positive 
siblings 
2 gene positive 
siblings + 1 gene 
negative 
3 gene 
positive 
siblings 
3 gene positive 
siblings + 1 gene 
negative 
4 gene 
positive 
siblings 
Birmingham 16 6 7 2 0 1 0 
Bristol 3 1 2 0 0 0 0 
Cardiff 6 1 3 1 1 0 0 
Leicester 3 0 2 0 1 0 0 
Manchester 6 1 4 0 0 0 1 
Newcastle 4 0 3 1 0 0 0 
Oxford 2 1 1 0 0 0 0 
Sheffield 4 0 4 0 0 0 0 
Fife 3 0 2 0 1 0 0 
HDA meeting 2 0 2 0 0 0 0 
HDA website 1 0 1 0 0 0 0 
Total 50 10 31 4 3 1 1 
 
3.3 Informed Consent 
All participants had received prior to the interview the patient information sheet detailing 
the background to the study, what taking part involved as well as relevant contact numbers. 
In addition, they were all telephoned so that any concerns or questions they had 
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surrounding the study could be clarified before a suitable date and time to conduct the 
interview was arranged. 
 
Informed consent was taken by JDS at the start of each patient interview. The consent sheet 
(gene positive participant - Appendix Ai, pg. 224, gene negative participant – Appendix Ai, 
pg. 225) was read through with the participant and any points were explained if necessary. 
Subsequently, if the patient was still happy to take part then the form was signed and dated 
by both the participant and JDS. All participants were then sent a copy of their consent form 
for them to keep and additional copies were sent to their GP (Appendix Ai, pg. 226) and kept 
by JDS in a locked filing cabinet. 
 
3.4 Clinical and Neuropsychiatric Assessment of Participants 
The following section describes the clinical and neuropsychiatric assessment of the 96 HD 
gene positive and five gene negative individuals. The only differences in the assessment of 
the gene positive and gene negative individuals were that the gene negative individuals were 
not administered assessments of the clinical features of HD (section 3.4.4) or the Problem 
Behaviours Assessment (section 3.4.7.1), as this is a scale designed for use in the HD 
population. All participants (apart from one who was interviewed in a hospital and one 
individual for whom a telephone interview was only feasible) were assessed at their homes 
in one session lasting approximately 2-3 hours. After obtaining written informed consent, a 
single, clinical neuropsychiatric assessment was administered and is summarised in Figure 
3.2 and Figure 3.3. The data were entered into a relational Microsoft Windows Access 
Database designed by JDS. 
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Figure 3.2 Clinical and Neuropsychiatric Assessment of 96 HD gene positive individuals 
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Figure 3.3 Clinical and Neuropsychiatric Assessment of 5 HD gene negative individuals 
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3.4.1 Demographic Information 
Information was obtained on a variety of demographic variables (see Appendix Aii, pg. 227) 
including: date of birth, place of birth, sex, ethnicity, education, occupation, co-morbid 
conditions, current medication(s), height, weight and name of GP and GP’s address. 
 
3.4.2 Lifetime Physical Medical History 
A lifetime history of physical illnesses including age at onset of symptoms and duration of 
symptoms was recorded using self-report as well as the participants’ medical notes. Other 
important lifetime events such as age at the time of receiving a predictive test result, having 
to give up work due to HD symptoms or age of getting divorced were also recorded here 
using the same sources of information. 
 
3.4.3 Family History 
A family pedigree was drawn using as much information as possible from the information 
provided by all the siblings. The family history of HD as well as lifetime psychiatric diagnoses 
experienced by family members was also noted. 
 
3.4.4 Assessment of Clinical Features of HD  
3.4.4.1 HD History 
All participants were asked their age at the time of their genetic test. If applicable, 
participants were subsequently asked the age at onset of symptoms and what their initial 
presenting symptom(s) was (were). 
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3.4.4.2 HD severity assessments 
As a measure of HD severity, participants who were positive for the HD gene were also 
administered the Unified Huntington’s Disease Rating Scale (UHDRS, Huntington Study 
Group, 1996) motor, cognitive and total functional capacity (TFC) sections. The UHDRS is a 
research tool which has been developed by the Huntington Study Group to provide a 
uniform measure of clinical performance and course of HD. The UHDRS has undergone 
extensive reliability and validity testing and has been used in many HD research studies as a 
primary outcome measure (UHDRS, Huntington Study Group, 1996). 
 
3.4.4.2.1 UHDRS Motor assessment: 
The UHDRS motor section comprises standardised ratings of oculomotor function, 
dysarthria, chorea, dystonia, gait and postural stability (Appendix Aiii, pg. 229). Higher scores 
(range 0-124) indicate greater impairment. Training and certification in administering the 
UHDRS motor assessment has been undertaken annually by JDS by means of an online video 
assessment. 
 
3.4.4.2.2 UHDRS Cognitive assessment:  
The UHDRS cognitive assessment consists of a phonetic letter fluency test, the symbol digit 
modalities test and the stroop test, which tap into the neuropsychological deficits typically 
observed in HD. These tests have been found to differentiate pre-motor manifest HD 
individuals from controls with medium to large effect sizes (Paulsen et al., 2011). 
1) The letter fluency test (Appendix Aiii, pg. 233): this test measures the speed and 
flexibility of verbal thought processes. Participants were asked to generate in one 
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minute as many words as possible beginning with the letters F, A and S. The score 
was the total sum of correct responses across the three trials. Proper nouns and 
derivatives of the same word stem were not admissible. 
2) The symbol digit modalities test, SDMT (Appendix Aiii, pg. 235): the SDMT involves a 
simple substitution task and assesses attention, psychomotor speed and working 
memory. Using a reference key, the participants had to pair specific numbers with 
given geometric figures. An initial practice test consisting of 10 responses was 
performed to allow the participants to understand the task. The number of correct 
written responses in 90 seconds was recorded.  
3) The Stroop test: this test examines attention, mental speed and mental control and 
consists of the following procedure, which includes 3 conditions: 
i) Naming blocks of colour (Appendix Aiii, pg. 236) 
ii) Reading colour words printed in black ink (Appendix Aiii, pg. 237) 
iii) Naming ink colour of incongruous colour words : the ‘interference’ condition 
(Appendix Aiii, pg. 238) 
The score for this test consisted of the number of correct answers given in a 45 second 
period for each condition. 
 
3.4.4.2.3 Functional assessment: 
The Total Functional Capacity (TFC, range 0-13) is a measure of a person’s ability to work, 
look after their finances, perform the household chores and activities of daily living as well as 
whether they can be looked after at home or in a nursing home (Appendix Aiii, pg. 239). The 
lower the score, the greater the functional impairment. For clinical and research purposes, 
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the progression of HD is often divided into five stages according to scores obtained on the 
TFC, summarised in Table 3.6 (Shoulson and Fahn, 1979). 
Table 3.6 The TFC stages (Shoulson and Fahn, 1979) 
TFC Stage Score range Brief Description 
Stage 1: Early 
Stage  
11-13 The person is diagnosed as having HD and can function fully both at 
home and work. 
Stage 2: Early 
Intermediate Stage 
7-10 The person remains employable but at a lower capacity. They are 
still able to manage their daily affairs despite some difficulties. 
Stage 3: Late 
Intermediate Stage 
3-6 The person can no longer work and/or manage household 
responsibilities. They need considerable help or supervision to 
handle daily financial affairs. Other daily activities may be slightly 
difficult but usually only require minor help. 
Stage 4: Early 
Advanced Stage 
1-2 The person is no longer independent in daily activities but is still able 
to live at home supported by their family or professional carers. 
Stage 5: Advanced 
Stage 
0 The person with HD requires complete support in daily activities and 
professional nursing care is usually needed. 
 
3.4.5 Assessment of Lifetime Psychiatric Features – Interview 
3.4.5.1 Brief screen of psychiatric history 
In order to determine at the beginning of the interview whether the participant had a history 
of any particular psychiatric symptoms, a brief screen based on the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN, see section 3.4.5.2) was administered (Appendix Aiv, 
pg. 240). This consisted of questions referring to panic and anxiety disorders, depressive 
disorders, manic symptoms, psychotic symptoms, obsessive and compulsive disorders, 
eating disorders and other problems such as alcohol abuse/dependence. In order to get an 
idea of the severity of the symptoms, if participants answered affirmatively to any of the 
screen questions, they were then asked whether they had sought help from their GP, been 
prescribed medication, received counselling, been referred to and seen a psychiatrist, 
and/or been admitted to hospital. A positive brief screen resulted in the relevant sections of 
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the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) Interview (Wing et al., 
1990) being administered to assess the presence of these features in further detail. 
 
3.4.5.2 Schedules for Clinical Assessment in Neuropsychiatry (SCAN) Interview 
The SCAN is a widely used semi-structured interview aimed at assessing, measuring and 
classifying the psychopathology associated with major psychiatric disorders. The SCAN 
consists of prompted questions that assess the presence or absence of a symptom as well as 
the severity of that symptom in the time frame being measured, which was lifetime ever 
occurrence for the purpose of this study. If a participant responds positively to probe 
questions about core psychiatric symptoms, then the presence of associated symptoms are 
investigated further. 
 
 For this study, a modified version of the SCAN was administered to reduce the length of the 
interview. Items were selected that assess for the presence of clinical symptoms that are 
required to make a lifetime diagnosis of a psychiatric disorder according to standardised 
diagnostic criteria. Consequently, the following sections of the SCAN were administered 
where relevant: 4 – panic/anxiety and phobias; 5 – obsessional symptoms; 6 – depressed 
mood and ideation; 7 – thinking, concentration, energy, interests; 8 – bodily functions; 9 – 
eating disorders; 10 – expansive mood and ideation; 11 – use of alcohol; 12 – substance use; 
17 – hallucinations; 18 – experiences of thought disorder and replacement of will, and; 19 – 
delusions.  
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Careful questioning was required in administering the SCAN to individuals with HD, owing to 
the fact that many core symptoms of HD overlap with core symptoms of psychiatric 
disorders (e.g. perseverative thinking due to cognitive impairment or obsessive thinking as 
seen in OCD, poor concentration due to cognitive changes in HD or as part of an episode of 
depression). Psychiatric symptoms were only rated as present if it was clear that the 
symptom was associated with psychiatric illness rather than the gradual changes typical of 
HD. Training in administering the SCAN was undertaken at the WHO approved centre of 
Nottingham University. The course consisted of 5 days training including seminars, small 
group tutorials and clinical interviews. Further familiarisation with the SCAN, ICD-10 and 
DSM-IV was carried out following the training and some practice interviews were carried out 
in attendance with a research psychologist with 9 years experience in using the SCAN. In 
addition, the same psychologist attended the first two interviews conducted for the study to 
ensure that the SCAN was being administered thoroughly and correctly.  
 
In order to supplement (and verify) the information obtained from the interview, GP case 
notes were requested. If a patient case note summary was provided rather than a copy of 
their full notes, additional medical notes were obtained by JDS visiting the HD services and 
viewing the patient medical records stored there. 
 
3.4.6 Assessment of Lifetime Psychiatric Features – Consensus Ratings 
Information obtained from the psychiatric interview together with available medical notes 
were reviewed and structured vignettes then written for each patient summarising all the 
psychiatric data. The vignettes were then used to make numerous psychiatric lifetime ratings 
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as outlined in the following sections. All ratings were made independently by JDS and KGS (a 
research psychologist with 9 years experience of making psychiatric diagnoses and using the 
rating tools) and after meeting regularly to discuss the psychiatric lifetime ratings, consensus 
was reached (with the input of a third independent rater, LAJ, research supervisor, when 
necessary). The consensus ratings were used in all data analyses and a copy of the consensus 
rating sheet is provided in Appendix v, pg. 241. 
 
3.4.6.1 Best-Estimate Main Lifetime Psychiatric Diagnoses 
Best-estimate main lifetime psychiatric diagnoses were made according to the standardised 
operational diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association, 2000) and the 
International Classification of Mental and Behavioural Disorders: Diagnostic Criteria for 
Research, 10th Edition (ICD-10, World Health Organisation, 1993). The diagnoses reported in 
the subsequent chapters are those according to DSM-IV to allow comparisons with previous 
literature. In the instances where an individual had more than one lifetime psychiatric 
disorder, the degree of impairment caused by the disorder was used to determine which 
diagnosis was considered the main, second or third lifetime psychiatric diagnosis, with most 
impairment indicating a main diagnosis.  
 
3.4.6.2 History of suicidal thoughts and suicide attempts 
Ratings of lifetime history of suicidal thoughts and attempts were made according to the 
rating scale displayed in Table 3.7. Scores ranged from 0 (the absence of any suicidal 
thoughts or attempts) through to 5 (multiple suicide attempts likely to result in death). 
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Table 3.7 Rating of Lifetime History of Suicidal Thoughts and Attempts 
 Rating 
Absent 0 
Tedium vitae 1 
Suicidal ideation 2 
Suicide attempt unlikely to result in death 3 
Suicide attempt likely to result in death 4 
Multiple suicide attempts likely to result in death 5 
 
3.4.6.3 Key psychiatric clinical variables 
Ratings of other key psychiatric clinical variables were also made where relevant, including: 
age of onset of any psychiatric illness, age of onset of specific psychiatric illnesses, which 
caused clinically significant impairment and number of admissions to hospital as a result of 
psychiatric illness. In addition, the number of episodes and longest duration of affective 
illness were recorded. 
 
3.4.6.4 The OPerational CRITeria checklist (OPCRIT) 
The OPCRIT checklist (McGuffin et al., 1991) consists of a 90 item symptom checklist that can 
be used to generate diagnoses for the main affective and psychotic disorders according to a 
number of operationalized diagnostic systems. For this study, a modified 63-item version of 
the checklist was used that incorporated items referring to depressive, manic, psychotic and 
psychotic affective symptoms. This modified version of OPCRIT has been shown to be valid 
for use in studies of mood disorders (Craddock et al., 1996) and has been used extensively by 
the Mood Disorders Research group. Using interview data and information obtained from 
case notes, it was possible to record the lifetime ever presence and absence of affective and 
psychotic symptoms. Symptoms were coded as absent 0, present 1 and unsure 9. A copy of 
the OPCRIT rating sheet is provided in Appendix vi, pg. 243. 
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3.4.6.5 The Bipolar Affective Disorder Dimension Scale (BADDS) 
The BADDS (Craddock et al., 2004) is a dimensional rating scale that can be used alongside 
best estimate lifetime diagnostic procedures to provide useful information, particularly 
about subclinical cases of psychopathology. The four domains measured by the scale 
include: mania (M); depression (D); psychosis (P), and; incongruence (I). Each dimension is 
measured on a 0-100 scale, which represents the severity and frequency of clinical features. 
Ratings were made for each individual based on information obtained from the SCAN and 
case note review. A copy of the BADDS ratings guidelines is provided in Appendix vii, pg. 245. 
 
3.4.6.6 The Global Assessment Scale (GAS) 
The GAS (Endicott et al., 1976) rates the function of a person according to their psychological 
well-being and functional capacity during a specified time frame. A score of 100 indicates 
functioning at the highest level with no psychological problems and a score of 0 represents 
the need for constant supervision for several days to prevent self-harm. For this study, GAS 
ratings were made for the lowest level of functioning in the worst depressive episode. A 
copy of the GAS ratings guidelines is provided in Appendix viii, pg. 251. 
 
3.4.7 Assessment of other psychiatric symptoms  
3.4.7.1 Problem Behaviours Assessment Scale for Huntington’s disease (PBA-HD) 
For the neuropsychiatric symptoms of irritability, aggression, apathy and perseverative 
thinking/behaviours, which are commonly observed in HD patients but not well-covered by 
the SCAN, the relevant items of the PBA-HD (Craufurd et al., 2001) were administered (see 
Appendix ix, pg. 253). The PBA-HD is a semi-structured interview specifically designed to 
66 
 
provide a reliable assessment of behavioural problems in HD. It measures the frequency and 
severity of symptoms (score range 0-4) over the past month and the values obtained are 
multiplied to give a total score for each item (score range 0-16). For this study, lifetime ever 
ratings of the neuropsychiatric symptoms were made, which measured their frequency and 
severity during the worst episode and the age of onset was also recorded where relevant for 
these neuropsychiatric symptoms. Informants were also interviewed whenever possible and 
any additional information provided by the GP case notes were taken into account when 
ratings were made. 
 
3.5 Analysis of the Demographics and HD Clinical Features of 50 unrelated 
individuals with HD and 40 of their siblings with HD 
 
This study was designed to address questions about the familiality of psychiatric 
syndromes/symptoms in HD and therefore, sibling pairs were recruited to the study. In order 
to ensure that only independent observations were reported, the total sample of 96 gene 
positive individuals was divided into an index and sibling sample for analysis. The advantage 
of this is that data are presented for two separate (although, not independent) samples.  
 
The index sample consisted of one individual per family so that no members of this sample 
were related. The sibling sample consisted of one sibling for each family where two or more 
siblings positive for the HD gene took part in the study. For the ten families where only one 
individual took part in the study, this individual automatically became part of the index 
sample. For the other 40 families, the random number generator in Microsoft Windows 
Excel was used to select which member of the sibling pair was randomised to the index or 
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sibling samples. This was done in order to reduce any possible bias from automatically 
allocating the sibling first recruited to the study into the index sample. 
 
3.6 Demographic characteristics 
Table 3.8 summarises the demographic characteristics of the sample. The mean age of the 
index sample was 49.0 years and the majority of participants were female (66.0%). All the 
sample was comprised of UK/Eire Caucasian individuals and 90.0% were (or had been) 
married or lived as though married. Most (62.0%) were living in their own home with a 
spouse and/or children. The majority (58.0%) were unemployed and receiving benefits but 
16.0% were employed full-time and 16.0% were retired. The main lifetime occupation 
categories that were most frequently reported were ‘legislator/senior officials, managers 
and professionals’ (24.0%) as well as ‘service, shop and market workers’ (20.0%).  
 
The demographic profile of the sibling sample was very similar to the index sample. The 
mean age was 48.5 years and most of the participants were female (60.0%). UK/Eire 
Caucasian individuals comprised the entire sample and 82.5% of individuals were (or had 
been) married or lived as though married. Most individuals (60.0%) were living in their own 
home with a spouse and/or children. The majority (60.0%) were unemployed and receiving 
benefits, although 12.5% were employed full-time and a further 16.0% were retired. The 
main lifetime occupation category that was most frequently reported was ‘legislator/senior 
officials, managers and professionals’ (22.5%) followed by ‘service, shop and market 
workers’ (20.0%).  
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Table 3.8 Demographic Characteristics of the index and sibling samples 
Demographics  Descriptives and Percentages 
Index Sample (N=50) Sibling Sample (N=40) 
Age (years)   
Mean (95% CI) 49.0 (46.5-51.5) 48.5 (45.5-51.5) 
Standard Deviation 9.0 11.1 
Range 28-76 24-73 
   
 N (%) N (%) 
Female 33 (66.0) 24 (60.0) 
   
Ethnic Origin   
UK/Eire Caucasian 50 (100.0) 40 (100.0) 
   
Marital status   
Has married/lived as married 45 (90.0) 33 (82.5) 
Has never married/lived as married 5 (10.0) 7 (17.5) 
   
Current Social Circumstances   
Lives in own home with spouse and/or children 31 (62.0)  24 (60.0) 
Lives alone 10 (20.0) 6 (15.0) 
Lives in home of parents or children 4 (8.0) 4 (10.0) 
Lives with partner of at least one year but not married 3 (6.0) 2 (5.0) 
Residential facility 0 (0.0) 3 (7.5) 
Other 2 (4.0) 1 (2.5) 
   
Current Employment Status   
Employed full time 8 (16.0) 5 (12.5) 
Employed part time 3 (6.0) 4 (10.0) 
Not working – receiving benefits 29 (58.0) 24 (60.0) 
Not working – not receiving benefits 0 (0.0) 1 (2.5) 
Homemaker  2 (4.0) 0 (0.0) 
Retired 8 (16.0) 6 (15.0) 
   
Main Lifetime Occupation   
Legislator/senior officials, managers and professionals 12 (24.0) 9 (22.5) 
Technicians and associate professionals 2 (4.0) 1 (2.5) 
Clerks 2 (4.0) 4 (10.0) 
Service workers & shop & market workers 10 (20.0) 8 (20.0) 
Craft & related trade workers  2 (4.0) 5 (12.5) 
Plant & machinery operators and assemblers 8 (16.0) 6 (15.0) 
Homemaker 2 (4.0) 1 (2.5) 
Never worked 0 (0.0) 1 (2.5) 
Other 12 (24.0) 5 (12.5)  
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The frequencies and percentages of the highest level of education qualifications achieved by 
the 50 individuals in the index sample and the 40 individuals in the sibling sample are 
summarised by age group in Tables 3.9 and 3.10 respectively. For the index sample, the 
majority of participants had obtained O-levels/CSEs or GCSEs (44.0%). Just over a quarter 
had achieved A-levels (28.0%) and nearly another quarter had no qualifications (22.0%). Four 
per cent of the index sample had a degree and 1 individual reported passing the 11+ as their 
highest educational qualification. Four out of the 5 index participants aged between 61 and 
80 had either no qualifications or the 11+ as their highest qualification whereas in all the 
other age group categories (21-30, 31-40, 41-50 and 51-60), the majority of individuals had 
obtained O-levels/CSEs or GCSEs (100%, 60.0%, 45.8%, 46.7%). 
 
Table 3.9 Highest Level of Educational Qualifications by Age Groups for the Index Sample, N = 50 
 Age at Interview 
 21-30 
N=1 
31-40 
N = 5 
41-50 
N = 24 
51-60 
N = 15 
61-70 
N = 4 
71-80 
N = 1 
All 
N = 50 
 N % N % N % N % N % N % N % 
No 
qualifications 
0 0.0 0 0.0 5 20.8 3 20.0 3 75.0 0 0.0 11 22.0 
11+ 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 1 2.0 
O-levels/CSEs/ 
GCSEs 
1 100.0 3 60.0 11 45.8 7 46.7 0 0.0 0 0.0 22 44.0 
A level/ HND/ 
BTEC 
0 0.0 2 40.0   7 29.2 4 26.7 0 0.0 1 100.0 14 28.0 
Degree  0 0.0 0 0.0 1 4.2 1 6.6 0 0.0 0 0.0    2 4.0  
 
 
Similarly to the index sample, the majority of participants in the sibling sample had obtained 
O-levels/CSEs or GCSEs (42.5%) as their highest level of educational qualification. Nearly a 
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third (30.0%) had no qualifications and 17.5% had achieved A-levels. A degree had been 
obtained by 5% of the sibling sample and 2 individuals reported passing the 11+ as their 
highest educational qualification. Six out of 7 of the sibling sample participants aged 
between 61 and 80 had either no qualifications or the 11+ as their highest qualification. 
However, in all the other age group categories, the highest level of educational qualification 
that was most frequently reported was O-levels/CSEs or GCSEs. 
 
Table 3.10 Highest Level of Educational Qualifications by Age Groups for the Sibling Sample, N = 40 
 Age at Interview 
 21-30 
N=1 
31-40 
N = 8 
41-50 
N = 17 
51-60 
N = 7 
61-70 
N = 5 
71-80 
N = 2 
All 
N = 40 
 N % N % N % N % N % N % N % 
No 
qualifications 
0 0.0 3 37.5 3 17.6 2 28.6 3 60.0 1 50.0 12 30.0 
11+ 0 0.0 0 0.0 0 0.0 0 0.0 1 20.0 1 50.0 2 5.0 
O-levels/CSEs/ 
GCSEs 
1 100.0 3 37.5 9 52.9 3 42.9 1 20.0 0 0.0 17 42.5 
A level/ HND/ 
BTEC 
0 0.0 2 25.0 4 23.5 1 14.3 0 0.0 0    0.0 7 17.5 
Degree  0 0.0 0 0.0 1 5.9 1 14.3 0 0.0 0 0.0    2 5.0  
 
3.7 HD Clinical Characteristics 
All participants from the index and sibling samples had a genetic diagnosis of HD. Forty-two 
of the 50 individuals in the index sample had also received a clinical diagnosis. Of the 8 
participants without a clinical diagnosis, 7 were considered pre-motor symptomatic from 
self-report at the time of the interview, their scores obtained on the UHDRS motor 
assessment (≤5) and review of their medical notes. A score of ≤5 on the UHDRS motor 
assessment (range 0-124) is the cut-off typically employed in HD research to differentiate 
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pre-motor manifest from HD manifest individuals (Tabrizi et al.,2011). One participant was 
considered to be symptomatic, although he had not received an official clinical diagnosis. 
The individual reported that he had not experienced any symptoms of HD, however, his 
partner said that she had noticed obvious “twitching” for the last year and chorea was 
apparent during the interview and UHDRS motor assessment (a score of 7), which indicated 
that he was symptomatic. Therefore, 43 participants in the index sample were considered to 
have manifest HD and 7 individuals were classified as pre-motor manifest.  
 
Thirty-two of the 40 individuals in the sibling sample had received both a genetic and clinical 
diagnosis of HD. Seven participants without a clinical diagnosis were classified as pre-motor 
manifest using the same criteria as described in the previous paragraph for the index 
sample.  One participant who had not yet received an official clinical diagnosis was 
considered to have manifest HD. The individual reported that she believed she was still pre-
motor symptomatic, however, observable chorea throughout the interview and a motor 
score of six suggested otherwise. Therefore, in the sibling sample, 33 individuals were 
classified as having manifest HD and 7 individuals were considered to be pre-motor 
manifest. 
 
3.7.1 Age at Onset of HD and duration of HD  
For those participants in both samples who were symptomatic, the age of motor onset of HD 
was obtained from self-report and then verified using their medical notes.  The descriptives 
and distributions for both the index and sibling samples are summarised in Table 3.11 and 
Figure 3.4. The median age of onset in the index sample was 44 years.  The youngest age of 
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onset was a male who was 25 when he first showed any symptoms and the oldest was a 
female who was symptom free until she was 75. The most common age of onset was 
between the ages of 41 and 50 (47% of individuals) and only 1 participant had an age of 
onset over 61 years. The median duration of having HD in the index sample was 5 years 
although the range of duration was from 1 year through to 16 years (a female in the 
advanced stages of the illness). 
 
Table 3.11 Age at Onset and Duration of HD (years) in the index and sibling samples. 
 N Median Range Inter quartile 
range 
Index Sample     
Age of Onset of HD 43 44 25-75 9.5 
Duration of HD 43 5 1-16 6.0 
     
Sibling Sample     
Age of Onset of HD 33 41 23-63 11.0 
Duration of HD 33 5 <1-24 11.0 
 
For the sibling sample, the median age of onset was 41 and the most common age of onset 
was between the ages 31 and 40 (39%).  The youngest age of onset in the sample was a male 
who was 23. The oldest age of onset was a male who remained symptom free until he was 
63 and he was also the only individual in the sibling sample with an age of onset greater than 
61 years. The median duration of having HD in the sibling sample was 5 years with a range of 
less than 1 year (someone who had become symptomatic in recent months) through to 24 
years (a female in the latter stages of the illness). 
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Figure 3.4 Age at onset of HD – distributions for a) the index sample, N = 43 and b) the sibling 
sample, N = 33 
3.7.2 Current severity of HD  
The current HD severity of the participants, determined using the Shoulson Fahn cut-offs on 
the Total Functional Capacity scale (as described earlier in the chapter in Table 3.6), is 
displayed in Table 3.12. The majority of individuals in the index sample (16, 37.2%) were 
classified as being in stage 1, i.e. the early stage of the illness. Fifteen individuals (34.9%) 
were in the early intermediate stage of HD (stage 2), 10 individuals (23.3%) were classified as 
being in the late intermediate stage (stage 3) and two individuals (4.7%) were classified as 
early advanced (stage 4).  
 
For the sibling sample, the majority of individuals (13, 39.4%) were classified as being in 
Stage 2, i.e. the early intermediate stage of the illness. Six individuals (18.2%) were in the 
early stage of HD (stage 1), eight (24.2%) were in the late intermediate stage of HD (stage 3), 
five (15.2%)  were classified as early advanced (stage 4) and one (3.0%), a 73 year old female, 
was in the advanced stages of HD (stage 5).  
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Table 3.12 Current severity of HD in the index and sibling samples, by sex. 
 Index Sample, N = 43 Sibling Sample, N = 33 
 Male 
N = 16 
Female 
N = 27 
Male 
N = 15 
Female 
N = 18 
N % N % N % N % 
Stage 1 – early HD 7 41.2 9 27.3 3 18.8 3 12.5 
Stage 2 – early intermediate 6 35.3 9 27.3 5 31.3 8 33.3 
Stage 3 – late intermediate 3 17.6 7 21.2 4 25.0 4 16.7 
Stage 4 – early advanced 0 0.0 2 6.0 3 18.8 2 8.3 
Stage 5 - advanced 0 0.0 0 0.0 0 0.0 1 4.2 
 
3.7.3 Duration of HD and current severity of HD  
The mean number of years of HD symptoms experienced by individuals in different stages of 
illness is displayed in Figure 3.5 a) for the index sample and b) for the sibling sample. For 
those individuals in Stage 1 of the illness (early HD), the mean duration of HD was 2.3 years 
and 1.8 years for the index and sibling samples respectively. The number of years of 
manifest HD increased with each successive stage up to 22 years for the individual in Stage 5 
of the illness in the sibling sample. 
 
 
Figure 3.5 Mean duration of HD in years according to current severity of illness for a) the index 
sample, N = 43 and, b) the sibling sample, N = 33 
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3.7.4 Motor ratings  
UHDRS motor scores were obtained for 43 of the 50 individuals in the index sample and 36 
of the 40 individuals in the sibling sample.  Table 3.13 summarises the motor data for both 
samples and Figure 3.6 displays the frequency distribution of the motor scores for the 
individuals. 
 Table 3.13 UHDRS motor scores in the index and sibling samples, by sex. 
UHDRS Motor 
Score 
Index Sample: N = 43 Sibling Sample: N = 36 
Total Male: N = 15 Female: N =28 Total Male: N =15  Female: N=21 
Median 25 25 23.5 26.5 28 25.0 
Range 0-85 2-63 0-85 0-75 5-75 0-74 
Inter Quartile 
Range 
29 13 34  46.5 38.0 45 
 
The median motor score for the index sample was 25. UHDRS motor scores were obtained 
for six of the seven pre-motor symptomatic participants in the index sample, which were all 
in the 0-5 range. The distribution of motor scores in this sample was positively skewed with 
65.1% of the sample having motor scores of 30 or less and the remaining 34.9% of the 
sample having scores ranging from 31 to 85. The participant with the highest motor score of 
85 was a female in Stage 4 of the illness. The median UHDRS motor scores were similar in 
males (25) and females (23.5). 
 
A similar positively skewed distribution was observed for the sibling sample with the 
majority of individuals (58.3%) having UHDRS motor scores of 30 or less. The median UHDRS 
motor score was 26.5 and the 6 pre-motor symptomatic individuals with UHDRS motor 
scores comprised the 0-5 score range. The median UHDRS motor score was slightly higher 
for males (27) than females (24.5) in the sibling sample.  
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Figure 3.6 Frequency distribution of the UHDRS motor scores for the index sample, N = 43 and 
sibling sample, N = 36. 
 
3.7.5 Cognitive scores 
Complete UHDRS cognitive scores were obtained for 38 individuals in the index sample and 
32 individuals in the sibling sample and are summarised in Table 3.14. In the index sample, 
one participant completed the Verbal Fluency test and Symbol Digit Modalities test but not 
the Stroop test and an additional participant completed the Verbal Fluency test and Stroop 
test but not the Symbol Digit Modalities test. Therefore, 40 participants completed the 
Verbal Fluency, 39 completed the Symbol Digit Modalities test and 39 individuals completed 
all 3 parts of the Stroop test. In the sibling sample, one participant completed the Verbal 
Fluency test and Symbol Digit Modalities test but not the Stroop test and an additional 2 
participants completed the Verbal Fluency test and Stroop test but not the Symbol Digit 
Modalities test. Therefore, 35 participants completed the Verbal Fluency, 33 completed the 
Symbol Digit Modalities test and 34 individuals completed all 3 parts of the Stroop test. 
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For the index sample, the mean total score on the cognitive tests was 181.1. The lowest total 
score obtained was 78, which was by a 51 year old female in Stage 1 of the illness and the 
highest score of 348 was obtained by a newly symptomatic 39 year old male. The mean 
scores on the Verbal Fluency, Symbol Digit Modalities test and the Stroop colour naming, 
Stoop word reading and Stroop interference were 22.3, 27.9, 45.0, 57.7 and 24.8 
respectively and are displayed in Figure 3.7. The total mean scores obtained on the cognitive 
tests were similar in males (186.7) and females (178.1).  
 
The mean total score obtained on the cognitive tests by the sibling sample was 177.1. The 
lowest total score was 71, which was by a 61 year old male in Stage 3 of the illness and the 
highest score of 307 was obtained by a 43 year old pre-motor manifest female. The mean 
scores on the Verbal Fluency, Symbol Digit Modalities Test and the Stroop colour naming, 
Stroop word reading and Stroop interference were 17.1, 27.1, 44.0, 57.2 and 24.6 
respectively and are displayed in Figure 3.7. The total mean scores obtained on the cognitive 
tests were slightly higher for females (179.7) than males (164.7).  
 
Table 3.14 UHDRS cognitive scores  
UHDRS Total Cognitive 
Scores 
Descriptives 
Index Sample Total: N=38 Male: N = 13 Female: N = 25 
Mean (95% C.I.) 181.1 (156.4-205.7) 186.7 (141.1-232.3) 178.1 (148.5-207.1) 
Standard deviation 77.5 83.9 75.54 
Range 78-348 81-348 78-325 
    
Sibling Sample Total: N=32 Male: N = 11 Female: N = 21 
Mean (95% C.I.) 174.6 (150.6-198.7) 164.7 (123.5-205.9) 179.7 (149.6-209.8) 
Standard deviation 69.4 69.7 70.4 
Range 71-307 71-271 74-307 
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Figure 3.7 Mean scores obtained on the individual cognitive tests for the index and sibling 
samples. 
 
Figure 3.8 displays the frequency distribution of the UHDRS cognitive scores for the 38 
individuals in the index sample and 32 individuals in the sibling sample with complete data. 
In the index sample, the largest proportion of individuals (31.6%) achieved a total score of 
between 101 and 150. Four of the five individuals that obtained a total score in the highest 
range of 301-350 were either not yet symptomatic or had only recently been diagnosed 
where as in the lowest range (51-100) of scores, the majority of the individuals (80%) were in 
Stage 2 or 3 of the illness. 
 
For the sibling sample, nine of the 32 individuals (28.1%) obtained a total cognitive score of 
between 151 and 200 and a further nine individuals (who were in Stages 2, 3 or 4 of the 
illness) only achieved a score of between 51 and 100. A pre-symptomatic female achieved a 
score in the highest range of 301-350.                                                  
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Figure 3.8 Frequency distribution of the UHDRS cognitive scores for the 38 individuals in 
the index sample and 32 individuals in the sibling sample with complete data. 
 
3.7.6 Comorbid Physical Medical Conditions  
Current comorbid physical medical conditions were reported for 26 of the 50 individuals in 
the index sample and 23 of the 46 individuals in the sibling sample and are summarised in 
Table 3.15. Individuals who had a current diagnosis of more than one illness in addition to 
HD, for example had a diagnosis of eczema and an underactive thyroid, are included in more 
than one comorbid medical condition category. For the index sample, there were 14 
individuals with one comorbid medical condition, six individuals with two comorbid medical 
conditions, five individuals with three comorbid medical conditions and 1 person had four 
comorbid medical conditions. Nine individuals had a current diagnosis of hypertension, 
which was the most frequently reported comorbid condition. The other conditions which 
were reported by more than 3 individuals include: asthma (5 individuals), arthritis (4 
individuals) and bladder problems (4 individuals). 
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Table 3.15 Frequency of comorbid medical conditions 
Comorbid Medical Conditions Index Sample 
N=50 
Sibling Sample 
N=40 
 N % N % 
Hypertension 9 18.0 2 5.0 
Asthma 5 10.0 4 10.0 
Arthritis 4 8.0 3 7.5 
Bladder problems 4 8.0 1 2.5 
High cholesterol 2 4.0 1 2.5 
Fibromyalgia 1 2.0 2 5.0 
Learning Disability 1 2.0 2 5.0 
Underactive thyroid 2 4.0 1 2.5 
Cardiac problems 2 4.0 1 2.5 
Hypotension 0 0.0 2 5.0 
Eczema 1 2.0 1 2.5 
Type II diabetes 2 4.0 0 0.0 
Circulatory Problems 1 2.0 1 2.5 
Myalgic Encephalitis 0 0.0 2 5.0 
Stroke 1 2.0 1 2.5 
Hearing Problems 1 2.0 1 2.5 
Psoriasis 1 2.0 1 2.5 
Spondylosis 2 4.0 0 0.0 
Migraines 0 0.0 1 2.5 
Prolapsed disc 1 2.0 0 0.0 
Childhood Epilepsy 0 0.0 1 2.5 
Poor Liver Function 1 2.0 0 0.0 
Crohn’s Disease 1 2.0 0 0.0 
Polycystic Ovary Syndrome 1 2.0 0 0.0 
Anaemia 0 0.0 1 2.5 
Sciatica 0 0.0 1 2.5 
Brain tumour 1 2.0 0 0.0 
Scoliosis 1 2.0 0 0.0 
Non-Epileptic Attack Disorder 1 2.0 0 0.0 
Note: Individuals are included in the table more than once in the instance when they have more than one 
comorbid medical condition.  
For the sibling sample, there were 15 individuals with one comorbid medical condition, 
seven individuals with two comorbid medical conditions and one individual with three 
comorbid medical conditions. Four individuals had a current diagnosis of asthma, which was 
the most frequently reported comorbid condition. The other conditions which were 
reported by 2 or more individuals include: arthritis (3 individuals), hypertension (2 
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individuals), fibromyalgia (2 individuals), myalgic encephalitis (2 individuals); learning 
disability (2 individuals) and hypotension (2 individuals). 
 
3.7.7 Medication 
The majority of participants were taking medication for their HD symptoms (61% of the 
index sample and 60% of the sibling sample).  Participants were also taking medication for 
their comorbid physical medical conditions, however, this is not reported here.  
Table 3.16 Symptomatic HD medication use in the index and sibling samples 
Medication class: 
Medication name 
Index sample 
N=50 
N (%) 
Sibling sample 
N=40 
N (%) 
Typical indications 
Anti-dyskinetic:    
Sulpiride 0 (0.0) 7 (17.5) Chorea/dyskinesia/irritability 
Risperidone 3 (6.0) 3 (7.5) Chorea/dyskinesia/aggression/psychosis 
Olanzapine 3 (6.0) 1 (2.5) Chorea/dyskinesia/aggression/psychosis 
Amantadine hydrochloride 0 (0.0) 2 (5.0) Chorea/dyskinesia 
Tetrabenazine 1 (2.0) 1 (2.5) Chorea/dyskinesia 
Anti-depressant:    
Citalopram 10 (20.0) 7 (17.5) Depression/irritability 
Fluoxetine 3 (6.0) 1 (2.5) Depression/irritability 
Paroxetine 1 (2.0) 0 (0.0) Depression/irritability 
Mirtazepine 2 (4.0) 1 (2.5) Depression/insomnia 
Venlafaxine 1 (2.0) 3 (7.5) Depression/anxiety 
Carbamazepine 1 (2.0) 2 (5.0) Depression/irritability 
Amitriptyline 1 (2.0) 0 (0.0) Depression/insomnia 
Sodium valproate 2 (4.0) 3 (7.5) Depression/irritability 
Anxiolytics:    
Diazepam 0 (0.0) 1 (2.5) Anxiety 
Clonazepam 0 (0.0) 1 (2.5) Anxiety 
Hydroxyzine 0 (0.0) 1 (2.5) Anxiety/insomnia 
Hypnotics/Sedatives:    
Zopiclone 1 (2.0) 3 (7.5) Insomnia 
Temazepam 2 (4.0) 1 (2.5) Insomnia 
Nutritional supplements:    
Vitamins/Folic acid/Omega 3 
triglycerides/Fortisip 
6 (12.0) 3 (7.5)  
  
Table 3.16 lists for both samples, the most frequently prescribed symptomatic HD 
medications by their respective medication class according to the Anatomical Therapeutic 
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Chemical (ATC) Classification System (WHO, 1976). The most commonly prescribed 
medication class in the index sample was anti-depressants (42.0%) followed by anti-
dyskinetics (14.0%), nutritional supplements (12.0%) and hypnotics/sedatives (6.0%). In the 
sibling sample, anti-depressants were also the medication class most frequently prescribed 
(42.5%) followed by anti-dyskinetics (35.0%), hypnotics/sedatives (10.0%), anxiolytics (7.5%) 
and nutritional supplements (7.5%). 
 
The following chapter (Chapter 4) describes the psychiatric phenotype in the index and 
sibling samples and will compare the depression phenotype in HD and individuals with 
unipolar depression without HD. 
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CHAPTER 4: DESCRIPTION OF THE PSYCHIATRIC PHENOTYPE IN 
HD WITH A FOCUS ON THE DEPRESSION PHENOTYPE. 
This chapter is concerned with describing the psychiatric phenotype in HD. It will detail the 
methodology and statistical analysis specific to this chapter before describing the psychiatric 
presentation of the index and sibling samples including: lifetime DSM-IV diagnoses, lifetime 
suicidal behaviour and ratings of other key psychiatric clinical variables. The chapter will 
then focus on depression in HD and will compare the depression phenotype in the HD index 
sample with a unipolar depression sample without HD. A discussion of the results will then 
follow. 
 
4.1 Introduction 
It is well established that people with HD frequently report significant behavioural and 
psychiatric symptoms as discussed in detail in Chapter 2. The most frequently reported 
neuropsychiatric symptoms in HD are depression, irritability, apathy and anxiety, each with 
prevalence rates between 33% and 76% (van Duijn et al., 2007). Reported prevalence rates 
vary greatly as a result of the use of different assessment methods with varying definitions. 
The main aim of this chapter is to describe the lifetime ever presence of operational 
psychiatric disorders according to DSM-IV (American Psychiatric Association, 2000) in the 50 
individuals with HD that comprise the index sample and the 40 individuals with HD of the 
sibling sample. In addition, although it has been known since George Huntington’s original 
description of HD that depression is a particularly common problem in HD, very little is 
known about the presentation of depression in HD and whether the phenotype exhibited is 
similar/dissimilar to that of individuals in the general population who have depression. 
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Therefore, in order to address this issue, the illness course data obtained for those HD 
patients with depression will be compared with data obtained from a large sample of 
individuals without HD recruited to a mood disorders research study. 
 
4.2 Methods 
The methods and clinical features of the index and sibling samples were described in 
Chapter 3. In addition to these samples of HD patients, a further sample was required 
consisting of individuals without HD but with a DSM-IV diagnosis of unipolar depression. This 
was to enable comparisons to be made between the presentation of depression in HD 
patients and depression in individuals without HD. This sample is described in section 4.5.1. 
 
4.3 Statistical analysis 
All statistical tests were performed using the statistical package SPSS version 19.0 (IBM 
Corp., 2010) and all statistical tests were considered significant at the p<0.05 level (two 
tailed). Normality of the data was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk 
tests and the significance of these results were used to inform whether parametric or non-
parametric tests were subsequently performed. 
Means and medians: 
Means were calculated for the variables that were normally distributed and where the data 
were not normally distributed, medians were used. 
Proportions: 
For all proportions calculated, 95% confidence intervals are also reported. 
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Categorical data: 
Relationships between categorical variables were calculated using Pearson’s chi square tests. 
In the instances where the expected cell count was less than 5, p-values were calculated 
using Fisher’s exact test.  
Continuous data:  
Parametric data: the independent samples t-test was used to compare differences between 
two groups. 
Non-parametric data: comparisons between two groups were made using the Mann-
Whitney U test. 
 
4.4 Results 
4.4.1 Lifetime Psychiatric Features in the HD Index and Sibling Samples 
4.4.1.1 Main Best-Estimate Lifetime DSM-IV Diagnoses 
Table 4.1 summarises the presence/absence of any lifetime DSM-IV diagnosis for the index 
and sibling samples. In the index sample, 33 individuals (66%) had a lifetime DSM-IV 
diagnosis. For one individual (classified as uncertain), it was suggested from the interview 
and the medical notes that there was a history of psychiatric illness, however, there was not 
enough information to determine a definite lifetime DSM-IV diagnosis. There was no 
significant difference between the proportion of females (69.7%) and males (58.8%) that had 
a lifetime DSM-IV diagnosis (χ2= 0.591, df = 1, p=0.44).   
 
Twenty-six individuals (65%) in the sibling sample had a lifetime DSM-IV diagnosis and a 
further three individuals were classified as uncertain, owing to a lack of information to 
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enable a definite lifetime DSM-IV diagnosis.  A significantly higher proportion of females 
(79.2%) than males (43.8%, 95%) had a lifetime DSM-IV diagnosis (χ2= 5.293, df = 1, 
p=0.021). 
 
Table 4.1 Summary of the presence/absence of any lifetime DSM-IV Diagnoses 
 Total Male Female 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Index sample N = 50 N = 17 N = 33 
Any DSM-IV Disorder 33 (66.0) 
52.9-79.1 
10 (58.8) 
35.4-82.2 
23 (69.7) 
54.0–85.4 
Uncertain 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
No DSM-IV Disorder 16 (32.0) 
19.1-44.9 
7 (41.2) 
17.8-64.6 
9 (27.3) 
12.1-42.5 
Sibling sample N = 40 N = 16 N = 24 
Any DSM-IV Disorder 26 (65.0) 
50.2-79.8 
7 (43.8) 
19.4-68.1 
19 (79.2) 
63.0-95.4 
Uncertain  3 (7.5) 
0.0-15.7 
1 (6.3) 
0.0-18.1 
2 (8.3) 
0.0-19.3 
No DSM-IV Disorder 11 (27.5) 
13.7-41.3 
8 (50.0) 
25.5-74.5 
3 (12.5) 
0.0-25.7 
CI; Confidence Interval 
 
The frequencies of the specific main best-estimate lifetime DSM-IV diagnoses for the index 
and sibling samples are summarised in Table 4.2. For both the index and sibling samples, 
depressive disorders were the most frequent main lifetime DSM-IV diagnoses (48% of the 
index sample and 57.5% of the sibling sample), followed by anxiety disorders (14% of the 
index sample and 7.5% of the sibling sample). There were no significant differences between 
the proportion of males and females with a specific main best-estimate lifetime DSM-IV 
diagnosis for both samples. 
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Table 4.2 Main Best-Estimate Lifetime DSM-IV Diagnoses 
 Index sample Sibling sample 
 
 Total 
N = 50 
Male 
N=17 
Female 
 N=33 
Total 
N = 40 
Male 
N = 16 
Female 
 N =24 
DSM-IV Diagnosis N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Major Depressive Disorder 
 
Recurrent Episodes 
 
Single Episode 
 
19 (38.0) 
24.6-61.5 
12 (24.0) 
12.2-35.8 
7 (14.0) 
4.4-23.6 
5 (29.4) 
7.7-51.1 
4 (23.5) 
3.3-43.7 
1 (5.9) 
0.0-17.1 
14 (42.4) 
25.5-59.3 
8 (24.2) 
9.6-38.8 
6 (18.2) 
5.0-31.4 
16 (40.0) 
24.8-55.2 
9 (22.5) 
9.6-35.4 
7 (17.5) 
5.7-29.3 
5 (31.3) 
8.6-54.0 
2 (12.5) 
0.0-28.7 
3 (18.8) 
0.0-37.9 
11 (45.8) 
25.9-65.7 
7 (29.2) 
11.0-47.4 
4 (16.7) 
1.8-31.6 
Depression NOS 5 (10.0) 
1.7-18.3 
2 (11.8) 
0.0-27.1 
3 (9.1) 
0.0-18.9 
7 (17.5) 
5.7-29.3 
2 (12.5) 
0.0-28.7 
5 (20.8) 
4.6-37.0 
Panic Disorder 
 
With Agoraphobia 
 
Without Agoraphobia 
 
2 (4.0) 
0.0-9.4 
0 (0.0) 
- 
2 (4.0) 
0.0-9.4 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
2 (6.1) 
0.0-14.3 
0 (0.0) 
- 
2 (6.1) 
0.0-14.3 
1 (2.5) 
0.0-7.3 
1 (2.5) 
0.0-7.3 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
1 (4.2) 
0.0-12.2 
1 (4.2) 
0.0-12.2 
0 (0.0) 
- 
Anxiety Disorder NOS 5 (10.0) 
1.7-18.3 
2 (11.8) 
0.0-27.1 
3 (9.1) 
0.0-18.9 
2 (5.0) 
0.0-11.8 
0 (0.0) 
- 
2 (8.3) 
0.0-19.3 
Alcohol Abuse 1 (2.0) 
0.0-9.4 
1 (5.9) 
0.0-17.1 
0 (0.0) 
0.0-18.9 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
Psychotic Disorder NOS 1 (2.0) 
0.0-9.4 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
Unknown 1 (2.0) 
0.0-9.4 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
3 (7.5) 
0.0-15.7 
1 (6.3) 
0.0-18.2 
2 (8.3) 
0.0-19.3 
Unaffected 16 (32.0) 
19.1-44.9 
7 (41.2) 
17.8-64.6 
9 (27.3) 
12.1-42.5 
11 (27.5) 
13.7-41.3 
8 (50.0) 
25.5-74.5 
3 (12.5) 
0.0-25.7 
NOS; Not Otherwise Specified, CI; Confidence Interval 
 
 
4.4.1.2 Co-morbid DSM-IV Diagnoses 
 
Sixteen of the 33 individuals (48.5%) in the index sample who had a psychiatric diagnosis and 
eleven of the 26 individuals (42.3%) in the sibling sample, had more than one lifetime DSM-
IV diagnosis. Table 4.3 summarises the co-morbid diagnoses for these participants. In the 
index sample, all 16 individuals had a comorbid depressive and anxiety disorder with two of 
these individuals also having a third lifetime DSM-IV diagnosis of alcohol abuse. In the sibling 
sample, of the eleven individuals with a co-morbid diagnosis, nine individuals had a DSM-IV 
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diagnosis of a depressive and anxiety disorder (one of whom also had a third lifetime DSM-IV 
diagnosis of alcohol abuse) and two individuals had a history of a depressive disorder and 
alcohol abuse.  
Table 4.3 Co-morbid DSM-IV Diagnoses 
 
Main DSM-IV Diagnosis Second DSM-IV Diagnosis Third DSM-IV 
Diagnosis 
Number 
of Cases 
Index sample 
Major Depressive Disorder (R) Panic Disorder with agoraphobia N/A 3 
Major Depressive Disorder (R) Panic Disorder with agoraphobia Alcohol Abuse 1 
Major Depressive Disorder (R) Panic Disorder without agoraphobia N/A 2 
Major Depressive Disorder (R) Anxiety Disorder NOS N/A 2 
Major Depressive Disorder (R) Anxiety Disorder NOS Alcohol Abuse 1 
Major Depressive Disorder (S) Panic Disorder with agoraphobia N/A 1 
Major Depressive Disorder (S) Panic Disorder without agoraphobia N/A 1 
Depression NOS Panic Disorder with agoraphobia N/A 1 
Panic Disorder without agoraphobia Major Depressive Disorder (S) N/A 2 
Anxiety Disorder NOS Depression NOS N/A 2 
    
Sibling sample 
Major Depressive Disorder (R) Panic Disorder with agoraphobia N/A 1 
Major Depressive Disorder (R) Panic Disorder without agoraphobia N/A 2 
Major Depressive Disorder (R) Panic Disorder without agoraphobia Social Phobia 1 
Major Depressive Disorder (R) Alcohol Abuse N/A 2 
Major Depressive Disorder (S) Agoraphobia without panic disorder Alcohol Abuse 1 
Major Depressive Disorder (S) Anxiety Disorder NOS N/A 1 
Panic Disorder with agoraphobia Major Depressive Disorder (S) N/A 1 
Anxiety Disorder NOS Depression NOS N/A 2 
R; recurrent episodes, S; single episode, NOS; not otherwise specified 
 
 
Table 4.4 includes the co-morbid diagnoses to give an overall frequency of the number of 
individuals with a specific lifetime DSM-IV diagnosis for both the index and sibling samples. 
Table 4.5 provides a summary of this data and this is also represented graphically in Figure 
4.1. In the index sample, 28 of the 50 (56%) participants had a lifetime diagnosis of a 
depressive disorder, 19 (38%) individuals were diagnosed as having a history of an anxiety 
disorder, 3 (6%) individuals had a diagnosis of alcohol abuse and a further individual (2%) 
had a diagnosis of psychotic disorder NOS. There were no significant differences between 
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the proportion of males and females with a particular DSM-IV lifetime diagnosis and 
although there were five times as many women with a history of panic disorder as men, this 
did not reach statistical significance (Fisher’s, p=0.073). There were also no significant 
differences between the proportion of females and males with any mood or anxiety 
disorder. 
Table 4.4 All Best-Estimate Lifetime DSM-IV Diagnoses 
 
 Index Sample Sibling Sample 
 Total 
N = 50 
Male 
N = 17 
Female 
N = 33 
Total 
N = 40 
Male 
N = 16  
Female 
N = 24 
DSM-IV Diagnosis N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Major Depressive Disorder 
 
Recurrent Episodes 
 
Single Episode 
 
21 (42.0) 
28.3-55.7 
12 (24.0) 
12.2-35.8 
9 (18.0) 
7.4-28.7 
5 (29.4) 
7.7-51.1 
4 (23.5) 
3.3-43.7 
1 (5.9) 
0.0-17.1 
16 (48.5) 
31.5-65.6 
8 (24.2) 
9.6-38.8 
8 (24.2) 
9.6-38.8 
17 (42.5) 
27.2-57.8 
9 (22.5) 
9.6-35.4 
8 (20.0) 
7.6-32.4 
5 (31.3) 
8.6-54.0 
2 (12.5) 
0.0-28.7 
3 (18.8) 
0.0-37.9 
12 (50.0) 
30.0-70.0 
7 (29.2) 
11.0-47.4 
5 (20.8) 
4.6-37.0 
Depression NOS 7 (14.0) 
4.4-23.6 
3 (17.6) 
0.0-35.7 
4 (12.1) 
1.0-23.2 
9 (22.5) 
9.6-35.4 
2 (12.5) 
0.0-28.7 
7 (29.2) 
11.0-47.4 
Panic Disorder 
 
With Agoraphobia 
 
Without Agoraphobia 
 
11 (22.0) 
10.5-33.5 
6 (12.0) 
3.0-21.0 
5 (10.0) 
1.7-18.3 
1 (5.9) 
0.0-17.1 
1 (5.9) 
0.0-17.1 
0 (0.0) 
- 
10 (30.3) 
14.6-46.0 
5 (15.2) 
3.0-27.5 
5 (15.2) 
3.0-27.5 
5 (12.5) 
2.3-22.8 
2 (5.0) 
0.0-11.8 
3 (7.5) 
0.0-15.7 
1 (6.3) 
0.0-18.2 
0 (0.0) 
- 
1 (6.3) 
0.0-18.2 
4 (16.7) 
1.8-31.6 
2 (8.3) 
0.0-19.3 
2 (8.3) 
0.0-19.3 
Agoraphobia without panic 
disorder 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
1 (2.5) 
0.0-7.3 
0 (0.0) 
- 
1 (4.2) 
0.0-12.2 
Social Phobia 0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
1 (2.5) 
0.0-7.3 
1 (6.3) 
0.0-18.2 
0 (0.0) 
- 
Anxiety Disorder NOS 8 (16.0) 
5.8-26.2 
4 (23.5) 
3.3-43.7 
4 (12.1) 
1.0-23.2 
3 (7.5) 
0.0-15.7 
0 (0.0) 
- 
3 (12.5) 
0.0-25.7 
Alcohol Abuse 3 (6.0) 
0-12.6 
2 (11.8) 
0.0-27.1 
1 (3.0) 
0.0-8.8 
3 (7.5) 
0.0-15.7 
0 (0.0) 
- 
3 (12.5) 
0.0-25.7 
Psychotic Disorder NOS 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
Unknown 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
3 (7.5) 
0.0-15.7 
1 (6.3) 
0.0-18.2 
2 (8.3) 
0.0-19.3 
Unaffected 16 (32.0) 
19.1-44.9 
7 (41.2) 
17.8-64.6 
9 (27.3) 
12.1-42.5 
11 (27.5) 
13.7-41.3 
8 (50.0) 
25.5-74.5 
3 (12.5) 
0.0-25.7 
CI; Confidence Interval 
Where individuals have more than one lifetime DSM-IV diagnosis, they are included in more than one category 
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In the sibling sample, 26 of the 40 (65%) individuals had a lifetime diagnosis of a depressive 
disorder, 9 (22.5%) individuals had a diagnosis of an anxiety disorder and 3 (7.5%) individuals 
were diagnosed as having a history of alcohol abuse. There were no significant differences 
between the proportion of males and females with a specific DSM-IV lifetime diagnosis, 
however, women (79.2%) were significantly more likely than men (43.8%) to have a lifetime 
DSM-IV diagnosis of any mood disorder (χ2= 5.293, df = 1, p=0.021). 
Table 4.5 Summary of all Lifetime DSM-IV Diagnoses 
 
 Index sample Sibling sample 
Total 
N = 50 
Male 
N = 17 
Female 
N = 33 
Total 
N = 40 
Male 
N = 16 
Female 
N = 24 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Any DSM-IV Mood Disorder 28 (56.0) 
42.2-69.8 
8 (47.1) 
23.4-70.8 
20 (60.6) 
43.9-77.3 
26 (65.0) 
50.2-79.8 
7 (43.8) 
19.5-68.1 
19 (79.2) 
63.0-95.4 
Any DSM-IV Anxiety 
Disorder 
19 (38.0) 
25.6-51.4 
5 (29.4) 
7.7-51.1 
14 (42.4) 
25.5-59.3 
10 (25.0) 
11.6-38.4 
2 (12.5) 
0.0-28.7 
8 (33.3) 
14.4-52.2 
Alcohol Abuse 3 (6.0) 
0.0-12.6 
2 (11.8) 
0.0-27.1 
1 (3.0) 
0.0-8.8 
3 (7.5) 
0.0-15.7 
0 (0.0) 
- 
3 (12.5) 
0.0-25.7 
Psychotic Disorder NOS 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
0 (0.0) 
- 
0 (0.0) 
- 
0 (0.0) 
- 
NOS; not otherwise specified 
Where individuals have more than one lifetime DSM-IV diagnosis, they are included in more than one category 
 
 
*Where individuals have more than one lifetime DSM-IV diagnosis, they are included in more than one category 
Figure 4.1 The proportion of individuals in the index and sibling samples with a lifetime 
DSM-IV diagnosis 
0
10
20
30
40
50
60
70
Depressive
Disorder
Anxiety Disorder Alcohol Abuse Psychotic Disorder
NOS
Index sample
Sibling Sample
*P
er
ce
n
ta
ge
 
Lifetime DSM-IV diagnoses 
91 
 
4.4.1.3 History of Suicidal Thoughts and Suicide Attempts 
 
The frequencies of individuals with a history of suicidal thoughts and suicide attempts are 
summarised in Table 4.6 for both samples and the percentages are illustrated in Fig 4.2. 
‘Suicidal thoughts’ includes those individuals with a history of tedium vitae, suicidal ideation 
or suicide attempt and ‘suicide attempts’ includes individuals who had made at least one 
suicide attempt. 
 
In the index sample, 18 individuals (36%) had experienced suicidal thoughts and of these, 
eight individuals (16%) had made a suicide attempt at some point during their lives. For one 
individual, there was a suggestion of a history of suicidal thoughts but there was not enough 
information to be certain and therefore this individual was classsified as unsure. There was 
no significant difference between the percentage of males (11.8%) and females (18.2%) who 
had made at least one attempt at suicide (Fisher’s, p =0.70) or who had a history of suicidal 
thoughts (males: 29.4%; females: 39.4%, χ2= 0.485, df = 1, p=0.49). 
 
In the sibling sample, 16 individuals (40%) had experienced suicidal thoughts and of these, 
five individuals (12.5%) had made a suicide attempt at some point during their lives. Two 
individuals (5%) were classified as unsure due to a suggestion of a history of suicidal 
thoughts but not enough information to be certain. There was no significant difference 
between the percentage of males (6.3%) and females (16.7%) who had made at least one 
attempt at suicide (Fisher’s, p =0.63) or who had a history of suicidal thoughts (males: 25%; 
females: 50%, χ2= 2.5, df = 1, p=0.11). 
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Table 4.6 History of Suicidal Thoughts and Suicide Attempts 
 
 Index Sample Sibling Sample 
Total 
N = 50 
Male 
N = 17 
Female 
N = 33 
Total 
N = 40 
Male 
N = 16  
Female 
N = 24 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Suicide attempt(s) 8 (16.0) 
5.8-26.2 
2 (11.8) 
0.0-27.1 
6 (18.2) 
5.0-31.4 
5 (12.5) 
2.3-27.8 
1 (6.3) 
0.0-18.2 
4 (16.7) 
1.8-31.6 
Suicidal thoughts 18 (36.0) 
22.7-49.3 
5 (29.4) 
7.7-51.1 
13 (39.4) 
22.7-56.1 
16 (40.0) 
24.8-55.2 
4 (25.0) 
3.8-46.2 
12 (50.0) 
30.0-70.0 
Unknown 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
1 (3.0) 
0.0-8.8 
2 (5.0) 
0.0-11.8 
1 (6.3) 
0.0-18.2 
1 (4.2) 
0.0-12.2 
None 31 (62.0) 
48.6-75.5 
12 (70.6) 
48.9-92.3 
19 (57.6) 
40.7-74.5 
22 (55.0) 
39.6-70.4 
11 (68.8) 
46.1-91.5 
11 (45.8) 
25.9-65.7 
CI; Confidence Interval 
 Individuals who had made an attempt at suicide are also included in the suicidal thoughts category 
 
 
Figure 4.2 Proportion of individuals in the index and sibling samples with a history of 
suicidal thoughts and suicide attempts. 
 
4.4.2 Age at Onset of Psychiatric Illness 
Ratings for the age of onset of psychiatric illness were made for the 33 individuals in the 
index sample and the 26 individuals in the sibling sample who had a lifetime diagnosis of any 
DSM-IV psychiatric disorder. For one individual in the sibling sample, the age of onset was 
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not known as the individual could not recall at which age her psychiatric symptoms started 
and the medical notes simply stated in an entry when she was 41 years old that there was a 
long history of depression. Therefore, Figure 4.3 displays the median age at onset for all 
lifetime DSM-IV diagnoses for 33 individuals in the index sample and 25 individuals in the 
sibling sample. For those individuals with more than one lifetime DSM-IV diagnosis, their age 
of onset is included for their main DSM-IV diagnosis as well as subsequent diagnoses. 
 
For the index sample, the median age at onset for any psychiatric symptom was 41 years and 
ranged from 13 to 55 years. The median ages at onset for individuals with a DSM-IV 
diagnosis of any depressive disorder, any anxiety disorder and for the one individual with 
psychotic disorder NOS were similar at 42 years, 41 years and 39 years respectively. The 
median age at onset for the three individuals with a DSM-IV diagnosis of alcohol abuse was 
lower at 29 years. 
 
Figure 4.3 Median age at onset for DSM-IV lifetime diagnoses for 33 individuals in the 
index sample and 25 individuals in the sibling sample. 
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For the sibling sample, the median age at onset for any psychiatric symptom was 34.5 years 
and ranged from 11 to 58 years. The median ages at onset were similar for all individuals 
with a lifetime DSM-IV diagnosis of any depressive disorder (33 years), any anxiety disorder 
(37 years) and alcohol abuse (34 years).  
 
4.4.2.1 Relationship between age of onset of psychiatric illness and age of onset of HD 
Table 4.7 summarises the difference in years between the age of onset of psychiatric illness 
and the age of onset of HD (defined as motor onset) for the index sample. Only individuals 
with a clinical diagnosis of HD were included in the sample. The median age of onset for the 
25 individuals with any depressive disorder was one year prior to the age of HD onset. For 
the 18 individuals with any anxiety disorder, the median age of onset was 6 months prior to 
HD onset and for the 2 individuals with a diagnosis of alcohol abuse who were HD 
symptomatic, the median age of psychiatric onset was 10 years prior to the age of HD onset. 
The pie charts in Figure 4.4 demonstrate that half or more of the individuals with a diagnosis 
of a depressive and/or anxiety disorder (56% and 50% respectively) experienced the onset of 
their psychiatric illness before their HD onset. 
Table 4.7 Difference in years between the age of onset of psychiatric illness and the age of 
onset of HD for the index sample 
DSM-IV Diagnosis N Median  Range Inter-Quartile 
Range 
Depressive disorder  25 -1 -25 - +10 9.0 
Anxiety disorder 18 -0.5 -26 - +12 9.25 
Alcohol Abuse 2 -10 -27 - -7 20.0 
Psychotic Disorder NOS 1 0 N/A N/A 
Negative value means onset of psychiatric illness was prior to HD onset 
Positive value means onset of psychiatric illness was post HD onset                                                                   
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Figure 4.4 Pie charts displaying the percentage of individuals whose onset of psychiatric 
illness was pre, post or at the same time as their HD onset for a) those with a DSM-IV 
lifetime diagnosis of a depressive disorder and, b) those with a DSM-IV lifetime diagnosis 
of an anxiety disorder for the index sample. 
 
Table 4.8 summarises the difference in years between the age of onset of psychiatric illness 
and the age of onset of HD for the sibling sample. Only individuals with a clinical diagnosis of 
HD were included in the sample. The median ages of onset of any depressive disorder and 
any anxiety disorder were 7 years and 4 years respectively prior to HD onset. For the three 
individuals with a DSM-IV diagnosis of alcohol abuse, the median age at psychiatric onset 
was at the same time as their HD onset. The pie charts in Figure 4.5 demonstrate that the 
majority of individuals with a diagnosis of a depressive and/or anxiety disorder (78.3% and 
60% respectively) experienced the onset of their psychiatric illness before their HD onset. 
Table 4.8 Difference in years between the age of onset of psychiatric illness and the age of 
onset of HD for the sibling sample 
DSM-IV Diagnosis N Median  Range Inter-Quartile 
Range 
Depressive disorder 23 -7 -25 - +2 11.5 
Anxiety Disorder 5 -4 -13 - +9 16.0 
Alcohol Abuse 3 0 -1 - +1 1.0 
Negative value means onset of psychiatric illness was prior to HD onset 
Positive value means onset of psychiatric illness was post HD onset 
Pre-HD onset
Post-HD
onset
Same age as
HD onset
14 (56%) 
3 (12%) 
8 (32%) 
Pre-HD onset
Post-HD
onset
Same age as
HD onset
9 (50%) 
3 (16.7%) 
6 (33.3%) 
a) b) 
96 
 
 
Figure 4.5 Pie charts displaying the percentage of individuals whose onset of psychiatric 
illness was pre, post or at the same time as their HD onset for a) those with a DSM-IV 
lifetime diagnosis of a depressive disorder and, b) those with a DSM-IV lifetime diagnosis 
of an anxiety disorder for the sibling sample. 
 
4.4.3 Problem Behaviours Assessment 
Lifetime prevalences of the neuropsychiatric symptoms irritability, aggression, apathy and 
perseverative thinking were obtained for 50 individuals in the index sample and 39 
individuals in the sibling sample and are displayed in Figure 4.6. Data were missing for one 
individual in the sibling sample as their illness was too advanced to accurately self-report, 
there was no partner/carer available to provide any information and there was no 
information concerning these symptoms in the participant’s case notes. Approximately fifty 
percent or more of individuals in both samples had a lifetime history of irritability, 
aggression, apathy and perseverative thinking. Irritability was the most common of the items 
experienced by individuals in the index sample, and apathy closely followed by irritability 
were the most frequently experienced items by individuals in the sibling sample. 
Pre-HD onset
Post-HD
onset
Same age as
HD onset
18 (78.3%) 
3 (13%) 
2 (8.7%) Pre-HD onset
Post-HD
onset
3 (60%) 
2 (40%) 
a) b) 
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Figure 4.6 Proportion of individuals in the index and sibling samples with a lifetime history 
of irritability, aggression, apathy and perseverative thinking. 
 
 
The median age of onset of these neuropsychiatric symptoms for the individuals in both 
samples who reported a positive lifetime history are recorded in Table 4.9. There was at 
least one individual in each category for whom the median age at onset was not known as 
they could not report an accurate age at onset and these symptoms are not routinely 
recorded in patients’ medical notes. The median age at onset was found to be in the 40s for 
both samples and for all neuropsychiatric symptoms. In both samples, the median age at 
onset was lowest for the symptom irritability and highest for the symptom perseverative 
thinking.  
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Table 4.9 The median age at onset of irritability, aggression, apathy and perseverative 
thinking for individuals in the index and sibling samples who reported a lifetime history of 
these symptoms.  
 
PBA item N Unknown Median Range Inter Quartile 
Range 
Index sample      
Irritability 35 1 43.5 27-65 10.75 
Aggression 26 1 45.0 27-61 10.0 
Apathy 27 3 45.0 32-61 12.0 
Perseverative thinking 25 5 47.5 27-62 10.5 
      
Sibling sample      
Irritability 25 1 41.5 24-65 12.5 
Aggression 19 1 42.5 28-68 11.0 
Apathy 26 4 46.0 24-71 17.5 
Perseverative thinking 18 4 46.5 34-68 11.5 
 
4.4.3.1 Relationship between the age at onset of irritability, aggression, apathy and 
perseverative thinking and the age at onset of HD. 
Table 4.10 summarises the difference in years between the age at onset of the PBA items 
irritability, aggression, apathy and perseverative thinking and the age at onset of HD 
(defined as motor onset) for the index sample. Only individuals with a clinical diagnosis of 
HD were included in the sample. The median age at onset for all four PBA items was after 
the onset of HD, with the median age of onset for the 32 individuals with a lifetime history of 
irritability and for the 24 individuals with a lifetime history of aggression being within a year 
of HD motor onset. For the 24 individuals with apathy, the median age at onset was four 
years after the age at HD onset and for the 20 individuals with a lifetime history of 
perseverative thinking, the median age at onset was 4.5 years after the onset of HD. The pie 
charts in Figure 4.7 demonstrate that half or more of the individuals in the index sample with 
a lifetime history of irritability, aggression, apathy and perseverative thinking experienced 
onset of their neuropsychiatric symptoms after the motor onset of their HD. 
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Table 4.10 Difference in years between the age at onset of irritability, aggression, apathy 
and perseverative thinking and the age of onset of HD for the index sample. 
PBA item N Median  Range Inter-Quartile 
Range 
Irritability  32 +0.5 -7 - +12 4.25 
Aggression 24 +1.0 -7 - +12 6.5 
Apathy 24 +4.0 -7 - +13 5.5 
Perseverative thinking 20 +4.5 -1 - +16 5.25 
Negative value means onset of psychiatric illness was prior to HD onset 
Positive value means onset of psychiatric illness was post HD onset                                                                   
 
 
 
Figure 4.7 Pie charts displaying the percentage of individuals whose onset of a) irritability, 
b) aggression, c) apathy and d) perseverative thinking was pre, post or at the same time as 
their HD onset for the index sample. 
 
Table 4.11 summarises the difference in years between the age at onset of the PBA items 
irritability, aggression, apathy and perseverative thinking and the age at onset of HD for the 
sibling sample. Only individuals with a clinical diagnosis of HD were included in the sample. 
For all four PBA items, the median age at onset of the neuropsychiatric symptoms was after 
the onset of HD. For the 22 individuals with a lifetime history of irritability, the median age at 
onset was 1.5years post HD onset, for the 16 individuals with a lifetime history of aggression 
and the 13 individuals with a lifetime history of perseverative thinking, the median age at 
onset was two years after the age at HD onset and for the PBA item apathy, the median age 
at onset was three years post HD onset. Figure 4.8 further demonstrates that the majority of 
individuals in the sibling sample with a lifetime history of irritability, aggression, apathy and 
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6 (25%) 6 (25%) 
18 (75%) 
3 
(12.5%) 
3 
(12.5%) 
18 (90%) 
1(5%) 
1 (5%) 
Post HD onset 
Pre HD onset 
Same age as HD onset 
a) b) c) d) 
100 
 
perseverative thinking experienced onset of their neuropsychiatric symptom(s) after the 
motor onset of their HD. 
Table 4.11 Difference in years between the age at onset of irritability, aggression, apathy 
and perseverative thinking and the age of onset of HD for the sibling sample. 
PBA item N Median  Range Inter-Quartile 
Range 
Irritability  22 +1.5 -9 - +20 8.25 
Aggression 16 +2.0 -9 - +20 9.25 
Apathy 21 +3.0 -1 - +17 10 
Perseverative thinking 13 +2.0 0 - +22 9 
Negative value means onset of psychiatric illness was prior to HD onset 
Positive value means onset of psychiatric illness was post HD onset                                                                   
 
 
 
 
Figure 4.8 Pie charts displaying the percentage of individuals whose onset of a) irritability, 
b) aggression, c) apathy and d) perseverative thinking was pre, post or at the same time as 
their HD onset for the sibling sample. 
 
 
4.5 Comparison between the depression phenotype in HD and individuals with 
unipolar depression and no HD 
 
4.5.1 Samples 
4.5.1.1 The HD sample 
Given that the index and sibling HD samples are not independent, only the index sample 
(which will be referred to as the HD sample in the following sections) was used in the 
comparative analyses with the sample of individuals with unipolar depression and no HD.  
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4.5.1.2 The Mood Disorders Research Group (MDRG) sample 
4.5.1.2.1 Recruitment of the MDRG sample 
Participants were recruited (by individuals other than myself) to an ongoing molecular 
genetic and clinical study of affective disorders run by the Mood Disorders Research Group 
(MDRG) based jointly at Cardiff University and the University of Birmingham. A total of 784 
unrelated individuals with a lifetime diagnosis of unipolar depression were recruited to the 
study via systematic and non-systematic methods. The main systematic recruitment method 
was via Community and Local Mental Health Team referrals, which accounted for 43.7% of 
the recruitment. The remaining 56.3% of the sample was recruited via non-systematic 
methods including adverts in local and national media (press, radio and TV) and via support 
organisations such as Depression Alliance. 
 
4.5.1.2.2 Inclusion and exclusion criteria 
The following inclusion and exclusion criteria were applied when recruiting the participants 
to the MDRG study: 
Inclusion criteria: 
 Aged 18 years or over 
 Of UK/Eire white ethnicity (due to the fact they were recruited for molecular genetic 
studies) 
 A best-estimate lifetime diagnosis of major recurrent depressive disorder according 
to DSM-IV 
Exclusion criteria: 
 A lifetime diagnosis of intravenous drug dependency 
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 An experience of affective illness only as a result of alcohol or substance misuse 
 An affective illness was experienced only secondary to medical illness or medication 
 Onset of affective symptoms after the age of 65 years 
 A first or second degree relative with a clear diagnosis of bipolar affective disorder or 
schizophrenia, schizotypal disorder, persistent delusional disorder, acute and 
transient psychotic disorders or schizoaffective disorder. 
 An experience of mood incongruent psychosis or psychosis outside of mood 
episodes. 
 
4.5.1.2.3 Neuropsychiatric assessment of MDRG participants 
The MDRG participants are an ideal, comparative sample as the same assessment tools were 
used as in the current study. Participants were interviewed using the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN) (Wing et al., 1990), which provided detailed 
information about lifetime psychopathology. Psychiatric and general practice case-notes 
where available were also reviewed. Based on these data, best-estimate lifetime diagnoses 
were made according to DSM-IV criteria and key clinical variables, such as age at onset and 
number of mood episodes, were rated. In addition, ratings of lifetime suicidal behaviour 
were made and the OPerational CRITeria diagnostic system (OPCRIT) (McGuffin et al., 1991), 
Bipolar Affective Disorder Dimension Scale (BADDS) (Craddock et al., 2004) and Global 
Assessment Scale (GAS) (Endicott et al., 1976) were completed (see Chapter 3.4.6 for further 
details of these assessments). 
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Diagnostic and clinical ratings were made by at least two members of the research team 
blind to each other’s rating and consensus was reached via discussion where necessary. 
Inter-rater reliability was formally assessed using 20 random cases. Mean kappa statistics 
were 0.85 for DSM–IV diagnoses and ranged between 0.81 and 0.99 for other key clinical 
categorical variables. Mean intra-class correlation coefficients were between 0.91 and 0.97 
for key clinical continuous variables. Team members involved in the interview, rating and 
diagnostic procedures were all research psychologists or psychiatrists. 
  
4.5.1.2.4 MDRG sample data 
Anonymised data for the 784 individuals with a DSM-IV diagnosis of unipolar depression 
were extracted from the MDRG database and included the following information:  
1) Demographic characteristics: age, gender, ethnicity, marital status, highest level of 
education, highest lifetime occupation. 
2)  Lifetime psychiatric features: DSM-IV diagnosis, suicidal behaviour (lifetime ever), 
OPCRIT ratings in context of depressed mood (lifetime ever), BADDS – depression 
subscale score, GAS scores for lifetime worst functioning in a depressive episode, age 
at first impairment due to depression (lifetime ever), number of episodes of 
depression (lifetime ever), longest duration of a depressive episode (lifetime ever) 
and number of hospital admissions due to depression. 
 
4.5.1.2.5 Sample descriptives 
The HD and MDRG samples comprised 12 and 784 individuals respectively with a lifetime 
diagnosis of a DSM-IV major depressive disorder – recurrent (MDDR). Given that a diagnosis 
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of MDDR, major depressive disorder – single episode (MDDS) and depression not otherwise 
specified (NOS) vary greatly in terms of severity, only individuals with a diagnosis of MDDR in 
the HD sample were used in the subsequent analyses, and the 16 individuals with MDDS 
(n=9) and depression NOS (n=7) were excluded. 
 
Furthermore, given that all 12 of the HD sample with MDDR were recruited via systematic 
methods, analyses were performed to determine whether there were any differences 
between those individuals with MDDR in the MDRG sample that were recruited via 
systematic and non-systematic methods. Although, no significant differences were found for 
the demographic characteristics, there were significant differences for some key illness 
course features and therefore, only those individuals recruited via systematic methods were 
included in the comparative analysis. This resulted in final samples of 12 individuals with HD 
and MDDR and 345 individuals with no HD and MDDR who were systematically recruited. 
 
4.5.2 Demographic characteristics of the HD and MDRG samples 
The demographics of the HD and MDRG sample are summarised in Table 4.12 and the 
samples were found to have similar demographic characteristics. The only significant 
difference between the samples was for the highest level of education attained where 
individuals in the HD sample were significantly more likely than individuals in the MDRG 
sample to have a lower level of educational attainment (χ2 = 16.79, df = 1, p=0.002). 
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Table 4.12 Demographic characteristics of the HD and MDRG samples  
Demographics  Descriptives and Percentages  
HD MDDR sample 
(N=12) 
MDRG sample  
(N = 345) 
p-value
a,b,c 
Age (years)
a    
Mean (95% CI) 47.6 (43.6-51.6) 47.5 (46.2-48.8) 0.95 
Standard Deviation 7.0 12.0  
Range 39-63 19-75  
    
Female
b N (%) (95% CI) N (%) (95% CI)  
 8 (66.7) (40.0-93.4) 228 (66.1) (61.1-71.1) 1.00 
    
Ethnic Origin
c    
White Caucasian 12 (100.0) (-) 345 (100.0) (-) 0.85 
    
Marital status
c    
Has married/lived as married 12 (100.0) (-) 289 (83.8) (79.9-87.7) 0.32 
Has never married/lived as married 0 (0.0) (-) 48 (13.9) (10.3-17.6) 
Unknown  0 (0.0) (-) 8 (2.3) (0.7-3.9) 
    
Highest Level Education
c    
No qualifications/11+ 1 (8.3) (0.0-23.9) 83 (24.1) (19.6-28.6) 0.002 
 O-levels/CSEs/ GCSEs 8 (66.7) (40.0-93.4) 67 (19.4) (15.2-23.6) 
A level/ HND/ BTEC 2 (16.7) (0.0-37.8) 54 (15.7) (11.9-19.5) 
Degree/Post-graduate degree 1 (8.3) (0.0-23.9) 81 (23.5) (19.0-28.0) 
Unknown 0 (0.0) (-) 60 (17.4) (13.4-21.4) 
    
Highest Lifetime Occupation
c    
Professionals 2 (16.7) (0.0-37.8) 113 (32.8) (27.9-37.8) 0.17 
Associate professionals 2 (16.7) (0.0-37.8) 73 (21.2) (16.9-25.5) 
Service workers * 6 (50.0) (21.7-78.3) 74 (21.4) (17.1-25.7) 
Plant & machinery operators  1 (8.3) (0.0-23.9) 10 (2.9) (1.1-4.6) 
Other** 1 (8.3) (0.0-23.9) 39 (11.3) (8.0-14.6) 
Unknown 0 (0.0) (-) 36 (10.4) (7.2-13.6) 
a 
Independent t-test was used; 
b
 Fisher’s exact test for significance (2-sided) was used; 
c
Chi square test was 
used. 
*Service workers category includes: shop, market, craft and related trade workers, skilled agricultural and 
fishery workers,**Other category includes: elementary occupations, armed forces, full-time student, 
homemaker, never worked. 
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4.5.3 History of Suicidal Thoughts and Suicide Attempts in the HD and MDRG 
samples 
 
Table 4.13 summarises the number of individuals in the HD and MDRG samples with a 
history of suicidal thoughts and suicide attempts (defined as outlined in section 4.4.1.3). As 
there were no significant differences found between males and females, only the total 
numbers of individuals are reported.  
Table 4.13 History of suicidal thoughts and attempts for the HD and MDRG samples 
 HD sample 
Total: N = 12 
MDRG sample 
Total: N = 345 
 N (%) 
95% CI 
N (%) 
95% CI 
Suicide attempt 6 (50.0) 
21.7-78.3 
111 (32.2) 
27.3-37.1 
Suicidal Ideation 12 (100.0) 
- 
290 (84.1) 
80.2-88.0 
Unknown 0 (0.0) 
- 
5 (1.4) 
0.2-2.6 
None 0 (0.0) 
- 
50 (14.5) 
10.8-18.2 
CI; Confidence Interval 
Individuals who had made an attempt at suicide are also included in the suicidal ideation category 
 
All of the HD sample had a history of suicidal ideation with half of these individuals (50%) 
having made an attempt at suicide at some point during their lifetime. The majority of the 
MDRG sample (84.1%) also had a history of suicidal ideation and nearly a third of the sample 
had made an attempt at suicide (32.2%).There were no significant differences found 
between the samples in the proportion of individuals with a history of suicidal ideation 
(Fisher’s, p=0.23), suicide attempt(s)(Fisher’s, p=0.21) or no suicidal behaviour (Fisher’s, 
p=0.23).  
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4.5.4 Age at onset of depression in the HD and MDRG samples 
The median age of onset of depression is reported in Table 4.14. The total numbers of 
individuals are reported only as there were no significant differences found between males 
and females. Individuals in the HD sample had a significantly older age of onset of 
depression than the MDRG sample (U=1063.5, p=0.005).  
Table 4.14 Median age of onset of depression (in years) for the HD and MDRG samples 
 N Median Range Inter-Quartile 
Range 
HD sample 12 41 18-47 7.25 
MDRG sample 345 27 9-61 16 
 
4.5.5 Frequency of depressive episodes per year of illness in the HD and MDRG 
samples 
Figure 4.9 summarises the frequency of episodes of depression per year of illness 
experienced by individuals in the HD and MDRG samples. This was calculated for all 12 
individuals in the HD sample and 336 of the individuals in the MDRG sample. Individuals in 
the HD sample were found to experience significantly more episodes of depression per year 
of illness than individuals in the MDRG sample (U=1082.0, p=0.006). 
 
Figure 4.9 Median frequency of depressive episodes per year of illness for individuals in 
the HD and MDRG sample. 
0
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4.5.6 Longest duration of a depressive episode in the HD and MDRG samples 
Figure 4.10 summarises the median length of the longest duration of a depressive episode 
(lifetime ever) in weeks for both samples. As there were no significant differences found 
between males and females, only the total numbers of individuals are reported. The longest 
duration of a depressive episode was known for eight of the 12 individuals in the HD sample 
and 340 of the 345 individuals in the MDRG sample. Although there was no significant 
difference found between the samples, the median length of the longest duration of a 
depressive episode was shorter for individuals in the HD sample than the MDRG sample and 
approached significance (U=833.0, p=0.06). 
Figure 4.10 Median length of the longest duration of a depressive episode (in weeks) for 
individuals in the HD and MDRG sample. 
 
 
4.5.7 Lifetime ever frequencies of OPCRIT depression items in the HD and 
MDRG samples 
 
All individuals in both samples had complete ratings for the presence or absence of the 
OPCRIT depression items. The total numbers of individuals are reported only as there were 
no significant differences found between males and females. Those items that were rated as 
unsure were considered absent for the purpose of this analysis. Table 4.15 displays the 
frequencies of the OPCRIT items for both samples.  
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Table 4.15 Lifetime frequencies of OPCRIT depression items for the HD and MDRG 
samples. 
 
OPCRIT depression 
items 
HD sample, N = 12 MDRG sample, N=345 
Symptom present 
N (%) 
95% CI 
Symptom present 
N (%) 
95% CI 
Dysphoria 12 (100) 
- 
342 (99.1) 
98.1-100.0 
Loss of Pleasure 
 
11 (91.7) 
76.1-100 
333 (96.5) 
94.6-98.4 
Diurnal Variation** 
 
1 (8.3) 
0.0-23.9 
158 (45.8) 
40.5-51.1 
Suicidal ideation 
 
12 (100) 
- 
299 (86.6) 
83.0-90.2 
Excessive self-reproach 
 
12 (100) 
- 
292 (84.6) 
80.8-88.4 
Poor concentration 
 
11 (91.7) 
76.1-100 
336 (97.4) 
95.7-99.1 
Slowed activity 
 
5 (41.7) 
13.8-69.6 
138 (40.0) 
34.8-45.2 
Loss of energy 
 
11 (91.7) 
76.1-100 
335 (97.1) 
95.3-98.9 
Poor appetite 
 
7 (58.3) 
30.4-86.2 
279 (80.9) 
76.8-85.1 
Weight loss 
 
7 (58.3) 
30.4-86.2 
194 (56.2) 
51.0-61.4 
Increased appetite* 
 
0 (0.0) 
- 
94 (27.2) 
22.5-31.9 
Weight gain 
 
1 (8.3) 
0.0-23.9 
84 (24.3) 
19.8-28.8 
Initial insomnia 
 
7 (58.3) 
30.4-86.2 
256 (74.2) 
69.6-78.8 
Middle insomnia* 
 
4 (33.3) 
6.6-60.0 
228 (66.1) 
61.1-71.1 
Early morning waking 
 
6 (50.0) 
21.7-78.3 
194 (56.2) 
51.0-61.4 
Excessive sleep 
 
1 (8.3) 
0.0-23.9 
65 (18.8) 
14.7-22.9 
Decreased libido 
 
2 (16.7) 
0.0-37.8 
123 (35.7) 
30.6-40.8 
Agitation 
 
2 (16.7) 
0.0-37.8 
101 (29.3) 
24.5-34.1 
*p<0.05, **p=0.01 
In general, the frequencies of the OPCRIT depression items were similar across the samples. 
Three significant differences were found between the HD and MDRG samples: 1) diurnal 
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variation: individuals in the HD sample were significantly less likely to have experienced 
diurnal variation during an episode of depression (χ2 = 6.59, df = 1, p=0.01), 2) increased 
appetite: individuals in the HD sample were significantly less likely to have experienced an 
increase in their appetite during a depressive episode (Fisher’s, p=0.041), and 3) middle 
insomnia: individuals in the HD sample were significantly less likely to have experienced 
middle insomnia during an episode of depression (Fisher’s, p=0.029).  
 
4.5.8 BADDS ratings – depression subscale in the HD and MDRG samples 
Table 4.16 displays the mean BADDS depression subscale scores (a lifetime measure of the 
frequency and severity of depressive episodes) for the individuals in the HD and MDRG 
samples.  As there were no significant differences found between males and females, only 
the total numbers of individuals are reported.  No significant difference was found between 
the samples for the BADDS depression score (t=-1.07, df = 355, p=0.29).  
Table 4.16 BADDS – mean depression subscale scores for the HD and MDRG samples. 
 N Mean Standard Deviation Range 
HD sample 12 61.3 11.2 40-81 
MDRG sample 345 64.3 9.7 35-93 
 
4.5.9 GAS ratings in the HD and MDRG samples 
GAS ratings were made for the level of functioning in the worst depressive episode and 
Table 4.17 displays the mean GAS scores for both samples. No significant differences were 
found between males and females and therefore, only the total numbers of individuals are 
reported. Individuals in the HD sample had a significantly higher level of functioning during 
their worst episode of depression than individuals in the MDRG sample (t=3.09, df = 355, 
p=0.002).   
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Table 4.17 Mean GAS scores for the worst episode of depression for individuals in the HD 
and MDRG sample. 
 
 N Mean Standard Deviation Range 
HD sample 12 41.8 8.8 30-60 
MDRG sample 345 35.4 7.0 9-54 
 
 
4.6 Discussion 
In this chapter, data have been presented which describe the psychiatric phenotype in HD. 
The following section will discuss the results obtained. This will include a comparison of the 
lifetime prevalence rates of psychiatric disorders in the HD index and sibling samples with 
previously reported prevalence rates in the HD population as well as with the general 
population. Comparisons of other neuropsychiatric features such as suicidality and age at 
onset of psychiatric illness will be made between this study sample, other HD samples and 
the general population. The depression phenotype in HD and how this compares with the 
MDRG sample will also be discussed. 
 
4.6.1 Lifetime prevalence of psychiatric disorders in HD 
Two thirds of individuals in the index and sibling samples had a lifetime DSM-IV psychiatric 
diagnosis (66% and 65% respectively). This finding is consistent with previous research 
reporting a high prevalence of psychiatric symptoms in HD (van Duijn et al., 2007). The 
majority of studies reporting prevalence rates in the HD population have not used formal 
diagnostic criteria and have looked at current, rather than lifetime psychiatric prevalence 
rates. However, one study of 106 HD gene mutation carriers found that 42% of the sample 
had a lifetime DSM-IV diagnosis at baseline and after a two year follow-up, 5.5% of the 
sample had experienced new onset of a DSM-IV psychiatric disorder (Reedeker et al., 2012). 
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Given that 38.7% of the sample in the Reedeker study were pre-motor symptomatic 
(compared with 14% of the index sample and 4% of the sibling sample in the current study), 
it is likely that if these individuals were followed up for an even longer period of time, the 
new incident rate of psychiatric diagnoses would also increase, perhaps to nearer the 
prevalences found in the current study.  
 
More females than males had a lifetime DSM-IV diagnosis in the index sample (69.7% versus 
58.8%) and sibling sample (72.2% versus 43.8%) but the difference only reached significance 
in the sibling sample. Van Duijn et al (2008) in their HD sample found no significant 
difference between genders in the presence of DSM-IV psychiatric disorders in the past 12 
months (although the raw data were not provided to show if there was a difference at all). 
However, the gender differences reported in this study are consistent with those reported in 
large epidemiological, general population studies (Alonso et al., 2004, Kessler et al., 2005). 
Women have a significantly higher risk than men of anxiety and mood disorders where as 
men are significantly more likely than women to experience substance use disorders (the 
only instance where these gender differences did not hold true in the current study was for 
alcohol abuse, where in the sibling sample, more women than men had a lifetime diagnosis 
of alcohol abuse) (Alonso et al., 2004, Kessler et al., 2005).  
 
Prevalence rates of specific psychiatric disorders determined from the results of this study 
will be compared with previously reported prevalence rates in the HD population as well as 
in the general population. However, there are no published data reporting lifetime 
prevalence rates of psychiatric illness in the UK population using methodology directly 
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comparable to this study. In 2007, the Adult Psychiatric Morbidity Study (APMS) was carried 
out by the National Centre for Social Research in collaboration with the University of 
Leicester, which collected data on mental health among 7461 adults aged 16 and over living 
in private households in England (Adult Psychiatric Morbidity Study, 2007).This assessed the 
presence of clinically significant psychiatric symptoms in the past week only except for 
suicidal thoughts and attempts, which reported lifetime prevalences.  
 
Alternative studies that are suitable for comparative purposes include the National 
Comorbidity Survey Replication (NCS-R) (Kessler et al., 2005) and the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) (Alonso et al., 2004). The NCS-R is a survey of 
9282 American individuals, aged 18 years and older and provides estimates of lifetime 
prevalence rates of DSM-IV disorders. Given the original article by Kessler and colleagues did 
not report gender differences, the 2007 update of the lifetime prevalence of DSM-IV 
disorders by sex will be that reported in the following sections (Kessler et al., 2007). The 
ESEMeD assessed 12-month and lifetime prevalence rates of mood, anxiety and alcohol 
disorders according to DSM-IV diagnostic criteria among 21,425 individuals aged 18 and over 
in six European countries (Belgium, France, Germany, Italy, the Netherlands and Spain). 
 
4.6.1.1 Mood disorders 
4.6.1.1.1 Depressive disorders 
Depressive disorders were the most frequent psychiatric illnesses with 56% of the index and 
65% of the sibling sample having experienced an episode of depression at some point during 
their lifetime. Depression NOS (a diagnosis for those individuals with some depressive 
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symptoms of lesser severity or temporality that do not meet the criteria for major 
depression yet still cause significant impairment and often require treatment) comprised a 
significant proportion of the DSM-IV depression diagnoses: one quarter of those individuals 
in the index sample with a diagnosis of depression and one third of those with depression in 
the sibling sample. A literature review on the prevalence of psychopathology in verified 
Huntington’s disease carriers found the prevalence of depressed mood varied from 33% to 
69% (van Duijn et al., 2007), which the results from this study support. However, of the six 
studies included in van Duijn et al’s review, only one used formal DSM-IV criteria (Leroi et al., 
2002). In the study by Leroi and colleagues (2002), of 21 individuals with HD, 42.8% of the 
sample were found to have a history of a depressive disorder: 28.6% with a lifetime DSM-IV 
diagnosis of major depression and 14.3% with non-major depression (this included 
diagnoses of brief recurrent depressive disorder, minor depressive disorder and dysthymia). 
In addition, a study of 89 pre-motor symptomatic HD mutation carriers found that 20% of 
the sample had a lifetime DSM-III diagnosis of major depression, 1% had a lifetime diagnosis 
of dysthymic disorder and a further 1% a lifetime diagnosis of cyclothymic disorder (Julien et 
al., 2007). Folstien et al (1983) using DSM-III criteria in a sample of 186 individuals with HD 
found that 33% of the sample had a diagnosis of major depressive disorder.  
 
Compared to the general population, the prevalence rates of mood disorders found in the 
present study are over twice as high in the index sample (56%) and three times as high in the 
sibling sample (65%) as that reported in the NCS-R (21.4%) and ESEMeD (14%). For major 
depressive disorder only, the prevalence rates for the NCS-R and ESEMeD studies were 
16.9% and 12.8% respectively. However, both these studies had a similar proportion of 
115 
 
males and females take part and given that like the present study, these large surveys also 
found females to have a higher prevalence of mood disorders, the lifetime prevalence rates 
of the current study will be inflated by the greater proportion of female participants (66% in 
the index sample and 58.7% in the sibling sample). Nevertheless, when comparing just 
female prevalence rates of mood disorders in all samples, the rates for the current study 
(60.6% in the index sample and 79.2% in the sibling sample) are as high relative to the two 
epidemiological studies (NCS-R: 24.9% and ESEMeD: 18.2%).   
 
As previously described, females were more likely than males to have a lifetime DSM-IV 
diagnosis of a depressive disorder in both the index sample (60.6% versus 47.1%) and sibling 
sample (79.2% versus 43.8%), although the gender difference only reached significance in 
the sibling sample. Indeed, a greater proportion of females were found to have a lifetime 
diagnosis of all specific depressive disorder diagnoses: recurrent major depression, single 
episode major depression and depression NOS. Leroi and colleagues (2002) found no 
significant gender difference in the lifetime prevalence of DSM-IV depressive disorders in 
their study of 21 individuals with HD. However, a cross-sectional analysis of 1267 HD 
patients from the Registry project of the European Huntington’s Disease Network found 
using the Unified Huntington’s Disease Rating Scales that females were significantly more 
likely to have past depression (Females: 60.2%; Males: 46.5%, p<0.001) and current 
depression (Females: 36.2%; Males: 29.2%, p=0.032; Zielonka et al., 2013). Depressive 
symptoms as measured by the Beck Depression Inventory II (BDI-II: Beck et al., 1996) have 
been significantly associated with female gender in a large prodromal HD sample (Epping et 
al., 2013). 
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4.6.1.1.2 Bipolar disorder 
No individuals in the present study had a diagnosis of bipolar disorder. Previous literature on 
the presence of bipolar disorder in the HD population is difficult to interpret. Mood states 
such as irritability and disinhibition are commonly observed in the HD population (for 
example, approximately two thirds of the index sample and the sibling sample in the present 
study had a lifetime history of irritability) but are rarely accompanied by elevated mood and 
associated symptoms of mania (Craufurd and Snowden, 2014). Studies that have used 
assessment tools that measure psychiatric symptoms rather than using diagnostic systems 
such as DSM are perhaps describing the increased prevalence of irritability and disinhibition 
rather than true mania. Indeed, studies that have used formal diagnostic criteria report a 
prevalence rate no higher than in the general population. Julien et al (2007) reported in a 
sample of 89 HD gene mutation carriers that no individuals had a lifetime DSM-III diagnosis 
of bipolar disorder and only one individual had a history of cyclothymia. Leroi et al (2002) 
reported a lifetime DSM-IV prevalence of 4.8% for bipolar disorder (1 individual in a sample 
of 21 HD patients) and van Duijn and colleagues (2008) found that 2.1% of their sample of 
140 HD mutation carriers had a 12-month DSM-IV prevalence of a “manic episode” that did 
not fulfil diagnostic criteria for bipolar disorder. These findings suggest the lifetime 
prevalence of bipolar disorder to be similar in individuals with HD and in the general 
population. The lifetime DSM-IV prevalence of bipolar disorder was found to be 4.4% in the 
NCS-R study (these data were not reported in the ESEMeD study) and in a review of studies 
reporting the epidemiology of bipolar disorder, a lifetime prevalence rate for males and 
females was found to be between 1-1.5% (Bebbington and Ramana, 1995). 
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4.6.1.2 Anxiety disorders 
Anxiety disorders were the next most frequently reported category of psychiatric illness with 
38% of the index and 25% of the sibling sample having a lifetime DSM-IV diagnosis of an 
anxiety disorder. Anxiety disorder NOS again comprised a significant proportion of the 
anxiety disorder diagnoses (42% of those individuals in the index sample and 30% of the 
individuals in the sibling sample with a lifetime DSM-IV diagnosis of an anxiety disorder). 
Panic Disorder was the most frequently reported category of anxiety disorder with almost a 
50:50 split between those who also experienced agoraphobia and those who did not in both 
the index and sibling samples. Lifetime prevalence rates for DSM-III anxiety disorders were 
found to be 17% in a sample of 89 pre-symptomatic HD patients (Julien et al., 2007) and van 
Duijn et al (2008) reported a 15.7% 12-month prevalence rate for all DSM-IV anxiety 
disorders in a sample of 140 HD mutation carriers. Four studies using either the UHDRS 
behaviour scale (Paulsen et al., 2001; Paulsen et al., 2005a and Murgod et al., 2001) or the 
Problem Behaviours Assessment (Craufurd et al., 2001) reported a range of between 37% 
and 61%, although all of these measures assess the presence of anxiety symptoms in the last 
month rather than a lifetime ever measure. The lifetime prevalence of anxiety disorders 
reported in the index sample is three times that reported in the general population ESEMeD 
study (total; 13.6%, females; 17.5%), although not much greater than that found in the 
general population NCS-R study (total; 31.2%, females; 36.4%). The lower prevalence of 
anxiety disorders in the sibling sample meant that this prevalence rate was nearly twice that 
reported in the ESEMeD study and lower than that found in the NCS-R epidemiological 
survey. 
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There were no significant differences found between the proportion of males and females 
that had a history of an anxiety disorder. However, five times as many women than men in 
the index sample had a lifetime DSM-IV diagnosis of panic disorder. There is no previous 
literature on gender differences in anxiety disorders in HD, although in the general 
population, women are more likely than males to experience anxiety disorders (any anxiety 
disorder: ESEMeD: males; 9.5%, females; 17.5% and NCS-R: males; 25.4%, females; 36.4%). 
This gender difference held true for both the NCS-R and ESEMed studies, not just for any 
anxiety disorder but for all specific DSM-IV diagnoses of anxiety disorders. 
 
No individuals in the index or sibling sample were found to have a diagnosis of obsessive 
compulsive disorder (OCD) even though obsessive and compulsive symptoms are often 
reported as being prevalent in the HD population. Marder et al (2000) found in a sample of 
960 patients with HD that 22.3% of these presented with obsessive and compulsive 
symptoms at their first clinic visit and Anderson et al (2001) using the Yale-Brown Obsessive 
Compulsive Scale reported that 14 of 27 HD patients endorsed at least one obsessive 
symptom (the most frequently reported being aggressive obsessions) and seven patients 
endorsed at least one current compulsive symptom (the most common being checking 
compulsions). However, only two of these patients fulfilled DSM-IV criteria for current OCD. 
Julien et al (2007) reported a lifetime DSM-III prevalence rate of 5% for OCD and van Duijn et 
al (2008) found a 12-month DSM-IV prevalence rate of 4.3% for OCD.  
 
Obsessive compulsive symptoms are without doubt common to HD patients, however, this 
differs greatly from Obsessive Compulsive Disorder. Even though no individuals in both the 
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index and sibling samples were found to have a lifetime DSM-IV diagnosis of Obsessive 
Compulsive Disorder (OCD), on initial questioning, many of the individuals did respond to 
having symptoms of OCD. For example, they would report having to regularly check if the 
front door was locked, gas taps were switched off etc but on further probing, it turned out 
this was in general because they couldn’t remember if they had locked the door or switched 
off the gas and there was no resistance to the checking, it did not cause any distress or 
significant functional impairment. Therefore, although on such questionnaires, many HD 
patients will report having obsessive compulsive symptoms, the prevalence of OCD is likely 
to be much lower. Indeed, even though there were no cases of OCD in this sample, 
approximately 50% of both the index and sibling samples reported a lifetime history of 
perseverative thinking or behaviour, which includes getting stuck on certain ideas or actions, 
getting obsessed about something, going on about it more than you should or doing 
something over and over again. 
 
The NCS-R reported a lifetime OCD prevalence rate of 2.3% whereas the ESEMeD did not 
report the prevalence rate for OCD. A further study of seven international epidemiologic 
surveys found that the lifetime prevalence rate for OCD was consistent across the different 
countries with most of the rates falling within the range of 1.9% (Korea) to 2.5% (Puerto 
Rico) (Weissman et al., 1994). 
 
4.6.1.3 Alcohol abuse 
Lifetime alcohol abuse was reported by 6% of the index sample (11.8% of males and 3% of 
females) and 7.5% of the sibling sample (0% of males and 12.5% of females).These figures 
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support findings in previous HD studies, which range between 3% and 30.9%. In a sample of 
42 individuals with HD, King et al., (1985) used DSM-III criteria to determine a lifetime 
prevalence of alcohol abuse of 16.7% (24% for males and 5.9% for females). In this sample, 
six of the seven individuals with a history of alcohol abuse had begun to drink heavily before 
the onset of the first symptoms in HD. This was also true of the sample in the current study, 
where all three of the individuals in the index sample with a lifetime diagnosis of alcohol 
abuse had problems with alcohol before the onset of their HD and two of the three in the 
sibling sample also drank heavily pre-HD onset (the other individual started drinking heavily 
a year after her HD onset when she had to give up work). Julien et al (2007) found a lifetime 
DSM-III prevalence rate of 3% for alcohol dependence in HD and Pflanz et al., (1991) used 
the Present State Examination to determine a 16% prevalence of alcohol abuse in HD males 
and 9% prevalence in HD females. A recent study found a lifetime alcohol abuse prevalence 
of 30.9% (43% for males and 19% for females) in the HD population (Byars et al., 2012). The 
study also found that lifetime alcohol abuse was associated with an earlier age of HD onset 
in women but not in men. However, a diagnosis of alcohol abuse was determined by 
participant and family definition only.  
 
Lifetime prevalence rates of 4.1% for alcohol abuse were found in the ESEMeD study and the 
NCS-R study reported a prevalence of 13.2% for alcohol abuse with/without dependence. In 
both studies, males were more likely than females to have a history of alcohol abuse (seven 
and a half times as likely in the ESEMeD study and over two and half times as likely in the 
NCS-R study). 
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4.6.1.4 Psychotic symptoms 
A DSM-IV lifetime diagnosis of a psychotic disorder was only found in one individual (a 
female) in the index sample to give a prevalence of 2% in the index sample and 0% in the 
sibling sample. However, two further individuals in the index sample (a male and a female) 
experienced psychotic symptoms as part of a severe depressive episode. Therefore, in a 
broader sense, 6% of the index sample and 0% of the sibling sample had experienced 
psychotic features. Julien et al (2007) found a lifetime DSM-III prevalence of 1% for 
schizophrenia in their sample of 89 pre-symptomatic HD patients. However, most studies 
that have investigated the prevalence of psychotic symptoms in HD have used instruments 
measuring current prevalence, which found a range of 3% (Craufurd et al., 2001) to 11% 
(Paulsen et al., 2001). Current prevalence of psychotic symptoms will be greatly influenced 
by the population from which the sample is selected e.g. an outpatient population versus an 
inpatient one. Caine and Shoulson (1983) found that three of 30 HD patients fulfilled DSM-III 
criteria for schizophrenic syndrome and a further two were diagnosed with atypical 
psychotic syndrome. However, this sample consisted of many individuals who had been 
referred due to “substantial behavioural disturbances”. Van Duijn et al (2008) found a 12-
month DSM-IV prevalence rate of 1.4% for nonaffective psychosis in their HD sample (the 
majority of the participants were recruited from Clinical Genetics or Neurology outpatient 
clinic). The NCS-R and the ESEMeD did not report the lifetime DSM-IV prevalence rates for 
psychosis. However, the UK general  population survey APMS 2007, found a prevalence of 
0.4% for psychotic disorders in the past year.  
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4.6.1.5 Co-morbid diagnoses 
The proportion of individuals with a lifetime DSM-IV diagnosis of more than one psychiatric 
disorder was high (32% of the index sample and 27.5% of the sibling sample). This represents 
almost half of those individuals with a lifetime DSM-IV diagnosis (66% of the index sample 
and 65% of the sibling sample). The majority of the comorbid diagnoses were a depressive 
and anxiety disorder (100% of the individuals with more than one psychiatric disorder in the 
index sample and 81.8% of the individuals in the sibling sample with comorbid diagnoses). 
Reedeker and colleagues (2012) reported in their study that some HD participants with a 
persistent psychiatric disorder at baseline had switched to another psychiatric disorder after 
two years. However, there is no previous literature indicating the prevalence of co-morbid 
psychiatric diagnoses in HD. The APMS 2007 UK general population study found that of the 
23.0% of the sample that met the criteria for one of the psychiatric diagnostic conditions, a 
third of these (i.e. 7.2% of the sample) had more than one psychiatric condition. Strong 
tetrachoric correlations were found between depressive episodes and both generalised 
anxiety disorder (0.68) and panic disorder/phobias (0.68). Indeed, the presence of an anxiety 
disorder is the single, greatest clinical risk for the development of depression and patients 
who have depression and anxiety comorbidity have higher chronicity, higher severity of 
illness and have significantly greater impairment in functioning at work as well as on a 
psychosocial level than patients not suffering from comorbidity (Hirschfield, 2001). 
 
4.6.1.6 Suicidal thoughts and suicide attempts 
In the index sample, 18 individuals (36%) had experienced suicidal thoughts (including 
tedium vitae and suicidal ideation) and of these, eight individuals (16%) had made a suicide 
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attempt. In the sibling sample, 16 individuals (40%) had a lifetime history of suicidal thinking 
and of these individuals, five (12.5%) had attempted suicide. This finding is consistent with 
George Huntington’s original description of the disease and with subsequent reports of a 
high prevalence of suicidal behaviour in HD. Patients with HD have been found to commit 
suicide approximately four times more often than the general population (Schoenfield et al., 
1984 and Farrer, 1986) and lifetime prevalence of suicide attempts for individuals with HD 
range from 5.3% (Brothers et al.,1964) to 17.7% (Farrer et al., 1986). The lifetime prevalence 
rate of suicidality (including suicidal thoughts and suicide attempts) was reported as 19.9% 
for a large, European cross-sectional study of 1280 motor symptomatic individuals (Orth et 
al., 2010). However, suicidality was assessed as present or absent as part of a general 
questionnaire on medical history and may under-report the true lifetime prevalence. Indeed, 
there may be a further underestimation of the true suicide rate due to recall bias or perhaps 
the fact that people may not want to admit to having had such thoughts in their lifetime. In 
the current study, there were two individuals who reported that they had no history of 
suicidal behaviour, yet their medical notes stated that they had attempted suicide 
previously. In the UK population study, the APMS, the lifetime prevalence rates of suicidal 
ideation and suicide attempts were higher for the self-completed questionnaire than for the 
face to face interview (Adult Psychiatric Morbidity Study, 2007). The lifetime prevalence 
rates of suicidal thoughts and attempts measured by face to face interview in the UK APMS 
study were 13.7% and 4.8% respectively.  The findings in the present study were much 
greater than those observed in the UK general population. Previous research has suggested 
that the presence of depressed mood (and not necessarily a formal DSM-IV diagnosis of 
depression) is a significant predictor of suicidality in HD mutation carriers (Orth et al., 2010; 
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Wetzel et al.,2011; Hubers et al., 2012). Given the high proportion of individuals with HD 
relative to the general population that experience depressed mood, it is perhaps not 
surprising that the suicidal behaviour rate is also higher in the HD population.  
 
4.6.1.7 Summary of the lifetime prevalence of psychiatric disorders in HD 
A summary of the lifetime DSM-IV prevalences of any mood disorder, major depression, 
bipolar I-II disorders, any anxiety disorder, panic disorder, OCD and alcohol abuse observed 
in the current study and reported in the NCS-R and ESEMeD general population studies are 
displayed in Table 4.18. Table 4.19 summarises the comparisons between the prevalence 
rates of suicidal thoughts and suicide attempts in the present study with the findings in the 
UK general population APMS study.  
 
The findings of the current study are in general consistent with the prevalence of psychiatric 
disorders previously reported in the HD literature and indicate the existence of strong 
population associations between HD and any mood disorder, major depression and panic 
disorder as well as moderate population associations between HD and any anxiety disorders. 
The findings also suggest that the lifetime prevalence rate of alcohol abuse is similar to the 
general population and that bipolar disorders may be less common in the HD population 
than in the general population. Although the current study found the prevalence of OCD to 
be lower than that in the general population, some previous studies have suggested that HD 
mutation carriers are significantly more likely to experience OCD than the general 
population (Anderson et al., 2001; van Duijn et al., 2008). However, it is not clear whether 
these figures reflect true OCD or obsessive-compulsive symptoms. 
125 
 
Table 4.18 Comparisons of the lifetime prevalence of mood disorders, anxiety disorders and alcohol abuse in the current study to the prevalence 
reported in two large general population studies. 
 
 Lifetime prevalence (%) 
 HD: Index sample HD: Sibling sample ESEMeD NCS-R 
DSM-IV Diagnosis     Total       Female only      Total      Female only Total         Female only Total       Female only 
Any Mood Disorder        56               60.6       65                79.2      14                18.2    21.4             24.9 
Major Depression        42               48.5     42.5               50.0    12.8              16.5    16.9             20.2 
Bipolar I-II Disorder        0                   0.0         0                 0.0        -                    -      4.4               4.5 
Any Anxiety Disorder       38                42.4       25               33.3    13.6               17.5     31.2            36.4 
Panic Disorder       22                30.3      12.5             16.7      2.1                2.5      4.7              6.2 
OCD        0                   0.0         0                 0.0        -                    -      2.3              3.1 
Alcohol Abuse        6                  3.0        7.5             12.5      4.1                 1.0      13.2            7.5* 
OCD; Obsessive Compulsive Disorder, ESEMeD; European Study of the Epidemiology of Mental Disorders (Alonso et al., 2004), NCS-R; National Comorbidity Survey-
Replication (updated data as of July 19, 2007) (Kessler et al., 2005). 
*This figure represents the lifetime prevalence of alcohol abuse with/without dependence. 
Table 4.19 Comparisons of the lifetime prevalence of suicidal thoughts and attempts in the HD index and sibling samples with the UK APMS Survey 
 Lifetime prevalence (%) 
 HD: Index sample 
Total  
HD: Sibling sample 
Total  
APMS Survey* 
Total  
Suicide Attempts 16 12.5 4.8 
Suicidal Thoughts** 36  40 13.7 
APMS; The Adult Psychiatric Morbidity Survey 2007  
*The APMS survey did not report the female and male differences in the prevalence rates for the face to face interview **Figures for the HD samples include individuals 
with a lifetime history of suicide attempts but it is not clear whether this is true for the APMS Survey
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4.6.2 Age at Onset of Psychiatric Illness 
The median age at onset for any psychiatric illness was 41 years for the index sample and 
34.5 years for the sibling sample. Compared with the general population survey the NCS-R, 
the median age of onset of mood disorders, anxiety disorders and alcohol abuse was much 
later in the HD samples as summarised in Table 4.20. Anxiety disorders most notably had a 
much later age of onset in the HD samples than the general population sample. However, 
unlike the mood disorders and substance abuse disorders, the age of onset distributions for 
specific anxiety disorders in the general population sample were more diverse. Separation 
anxiety disorder and specific phobias had a median age of onset of 7 years, social phobia had 
a median age of onset of 13 years where as other anxiety disorders had later median ages of 
onset of between 19 and 31 years. This could partly account for the differences in age of 
onset observed given that the individuals with a history of an anxiety disorder in the current 
study predominantly had a diagnosis of the ‘other anxiety disorders’ with a later median age 
of onset. However, the median ages of onset for the HD samples are still considerably later 
than those found in the general population.  
Table 4.20 Comparison of the median age of onset of psychiatric disorder in the HD 
samples and the NCS-R sample. 
 
 Age at onset (years) 
HD: Index sample 
Median (IQR) 
HD: Sibling sample 
Median (IQR) 
NCS-R sample 
Median (IQR) 
Any mood disorder 42 (31.25-46.25) 33 (25-45) 30 (18-43) 
Any anxiety disorder 41 (28.25-46.25) 37 (29.5-40) 11 (6-21) 
Alcohol abuse* 29 (24-39.5) 34 (33-39.5) 20 (18-27) 
IQR; Inter Quartile Range 
*For the NCS-R sample, alcohol abuse was reported under the general category of substance use disorders 
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4.6.2.1 Relationship between age at onset of psychiatric illness and age at onset of HD 
 
The majority of individuals in the HD index and sibling samples with a lifetime diagnosis of a 
depressive and/or anxiety disorder had an onset of their psychiatric disorder before the 
onset of their HD (defined by motor onset). In the index sample, there was at least one 
individual for all DSM-IV diagnoses other than anxiety disorder NOS with an age of 
psychiatric onset that preceded HD onset by at least 20 years. For the sibling sample, there 
was only an individual with a DSM-IV diagnosis of recurrent major depression and one with 
depression NOS who had a psychiatric onset at least 20 years prior to their HD onset. 
However, four of the other six DSM-IV diagnostic categories were only comprised of one or 
two individuals. This is consistent with previous findings in HD suggesting the onset of 
psychiatric symptoms may occur up to 20 years before the onset of motor symptoms 
(Folstein et al 1983). Folstein and colleagues found in their study of individuals with HD in 
Maryland, USA that 23 out of 34 patients for whom accurate onset data was available 
experienced depressive symptoms before the onset of chorea by an average of 5.1 years 
(Folstein et al., 1983). Studies that have used a pre-motor symptomatic HD population also 
find a high proportion of individuals with psychiatric symptoms (Julien et al., 2007, Kingma et 
al., 2008). Previous studies have reported a clustering of affective symptoms around the 
time of motor onset (Watt and Seller, 1993; Julien et al., 2007) and for symptomatic patients 
in Stage 2 of the illness (Paulsen et al., 2005). However, no such clustering was found in this 
study and instead the findings are consistent with the research that suggests symptoms of 
depression (including depressed mood, depressive cognitions, anxiety and suicidal ideation) 
occur with roughly equal frequency at all stages of the illness (Craufurd et al., 2001, Kingma 
et al., 2008). 
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4.6.2.2 Possible explanations for the older age at onset of psychiatric illness in HD and 
onset often prior to an HD clinical diagnosis. 
 
The results suggest that the age at onset of psychiatric disorders in HD is significantly later 
than in the general population and is often before the age of motor onset of HD. This 
suggests that the presence of psychiatric symptoms in HD cannot be fully explained as a 
psychological reaction to receiving a clinical diagnosis of HD and the motor and cognitive 
symptoms that ensue. Both biological and psychological explanations can account for these 
findings, which are not necessarily mutually exclusive. 
 
If neurobiological changes secondary to the HD gene mutation play a causal role in the 
development of psychiatric problems, then given that the typical age at onset of HD is in 
middle adult life (approximately age 30-50 years), the later age of onset of psychiatric 
disorders in the HD population could be partly explained by this. Many examples of 
particular structural brain changes and dysfunctional biological pathways common to both 
individuals with HD as well as individuals with psychiatric diagnoses and no HD have been 
described (see section 2.9.3 and 2.9.4), including: decreased caudate nucleus volume 
(Krishnan et al., 1992); decreased ventral striatal activation (Cummings, 1995; Epstein et al., 
2006); abnormal metabolic activity in the orbitofrontal cortex  and the anterior 
cingulate/caudal medial prefrontal cortex (Saxena et al., 2001); dysfunction of the frontal-
subcortical circuits (Bonelli and Cummings, 2007); dysregulation of the serotonin (5-HT) 
signalling system (Du et al., 2013); hyperactivity of the hypothalamic pituitary adrenal (HPA) 
axis (Du et al., 2013) and alterations in the dopamine system (Chen et al., 2013). Some HD 
associated neuropathological changes including significant changes in whole brain volume 
and regional grey and white matter differences are known to occur in HD gene carriers many 
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years before motor symptoms are apparent (Aylward et al., 2004; Paulsen et al., 2006b; 
Tabrizi et al., 2009; Tabrizi et al., 2011), which could account for psychiatric onset prior to an 
HD motor diagnosis.  
 
Psychological causes could also contribute to the finding that onset of psychiatric illness is 
older in individuals with HD and often prior to motor onset in HD. Psychosocial problems 
associated with having HD are indeed apparent many years before the symptoms of HD 
actually begin. Even from a young age, HD can considerably impact family life, especially for 
those young people at risk of HD. A study of young people’s experiences of growing up in a 
family affected by Huntington’s disease revealed that young people may often act as carers 
for an affected parent with HD, they may worry so much about their own risk for HD that it 
has a detrimental impact on their life physically and emotionally, and some young people 
may suffer directly from physical and/or sexual abuse by an affected family member (Forrest 
et al., 2007). Worrying about being at risk for HD and for some individuals choosing to 
undergo predictive testing brings with it further emotional and psychological problems 
before the onset of HD. An eleven year study of predictive testing for HD in Germany, found 
an average age at testing of 35 years (Bernhardt et al., 2009). Although surveys of attitudes 
toward predictive testing indicated that suicide would be contemplated by 11-15% of at-risk 
individuals if they received an increased-risk result (Kessler et al., 1987; Mastomauro et al., 
1987), research has suggested that catastrophic events (including suicide, attempted suicide 
and psychiatric hospitalisation) are seemingly rare following an HD predictive test result (a 
worldwide survey found that 0.97% in a cohort of 4,527 test participants had experienced a 
catastrophic event) (Almqvist et al.,1999). However, some studies have reported that 
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depressed mood and feelings of hopeleness are common following a positive predictive test 
result with one study reporting that 58% of carriers were experiencing current depressed 
mood even after a mean of 3.7 years following the test result (Gargiulo et al., 2009). A 
further study found that the one year prevalence post-testing of major depression was 6.0% 
in those who received a positive result (versus 3.0% in those with a negative result) and 
20.0% of the sample had clinically significant depressive symptoms (versus 12.6% in those 
with a negative test result) (Codori et al., 2004). Other studies have reported results to the 
contrary suggesting that although individuals who receive a positive predictive test result 
may suffer from general psychological distress short-term, longer-term their psychological 
adjustment is no different to their baseline measures (Wiggins et al., 1992; Codori et al., 
1997).  
 
HD continues to impact individuals psychologically throughout the preclinical phase prior to 
onset of motor symptoms.  A positive correlation has been found between levels of stress 
(measured using the Perceived Stress Scale) and depression (measured using the Beck 
Depression Inventory-II) in prodromal Huntington’s disease (Downing et al., 2012). Ho et al., 
(2011) found in their study of the impact of HD across the entire disease spectrum that in 
the pre-clinical phase, the concerns expressed by individuals gene positive for HD included 
anxiety regarding the impact of HD on their family and worry about themselves showing 
symptoms. Clearly there are numerous psychological issues that have the potential to result 
in clinically significant psychiatric problems even prior to an HD diagnosis. It is therefore of 
great importance that effective interventions are provided to the most vulnerable 
individuals throughout their lifespan. 
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4.6.3 Comparison between the depression phenotype in HD and unipolar 
depression 
 
Of all the behavioural problems observed in HD, depression constitutes a significant 
component of the overall psychiatric morbidity (Guttman et al., 2003). This was true for the 
current study with over half the participants in both the index and sibling sample having a 
lifetime DSM-IV diagnosis of a depressive disorder. The following sections will discuss the 
findings relating to the depression phenotype for the HD MDDR sample in the present study 
and will compare them with the findings in a sample of non-HD individuals with a lifetime 
history of MDDR: the MDRG sample. This is the first study to compare the clinical 
presentation of depression in individuals with and without HD. 
 
4.6.3.1 Suicidality and depression 
The majority of both depression samples were found to have a history of suicidal thoughts 
(100% index sample and 84.1% MDRG sample) and although the HD sample had a relatively 
higher proportion of individuals than the MDRG sample who had made at least one suicide 
attempt (50% versus 32.2%), this difference did not reach significance. This study further 
confirms the importance of prioritising assessment for suicidality in those HD individuals 
with a depressed mood whether they are pre-motor or motor symptomatic.  
 
4.6.3.2 Age at onset of depression 
The median age at depression onset was significantly older for individuals in the HD sample 
than the MDRG sample (41 years versus 27 years respectively) (U=1063.5, p=0.005). Both 
biological and psychological explanations can account for this finding as described in section 
4.6.2.2, which are unlikely to be mutually exclusive. 
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4.6.3.3 Frequency of episodes of affective illness per year 
Individuals in the HD sample were found to experience significantly more frequent episodes 
of depression (median = 0.432 episodes per illness year) than individuals in the MDRG 
sample (median = 0.28 episodes per illness year) (U=1082.0, p=0.006). This finding could be 
due to the fact that individuals with HD are also more likely to experience a depressive 
episode for a shorter duration (see 4.6.3.4) and therefore there is the opportunity for more 
episodes of depression per year.  
 
4.6.3.4 Longest duration of affective illness 
The median length of the longest duration of a depressive episode was less for individuals in 
the HD sample (39 weeks) than in the MDRG sample (65 weeks) and approached significance 
(p=0.06). Possible explanations for why episodes of depression in HD may be of shorter 
duration than in the general population include the fact that HD patients typically receive 
regular out-patient appointments and therefore may receive earlier treatment and care, HD 
patients may respond better and quicker to anti-depressants and/or this finding could 
represent a less severe depression observed in the HD population relative to individuals 
without HD. 
 
4.6.3.5 OPCRIT 
Individuals in both the HD and MDRG samples were most likely to experience the symptoms 
of depression most typically associated with sadness and low mood: dysphoria, loss of 
pleasure, excessive self-reproach, suicidal ideation and loss of energy. The lifetime 
frequencies of the “biological” items diurnal variation, increased appetite and middle 
insomnia were significantly lower for individuals in the HD sample than in the MDRG sample. 
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Additionally, although significance was not reached, individuals in the HD sample were less 
likely to experience poor appetite, weight gain and decreased libido as part of their 
depression than the MDRG sample.  
 
These findings suggest that people with HD experience fewer core biological symptoms of 
depression than individuals with depression and no HD. Major depression within the general 
population is a heterogeneous entity with individuals not necessarily experiencing the same 
symptoms, severity of symptoms or duration  (Goldberg, 2011). If depression in HD has a 
different aetiology to those with depression but no HD, it is quite possible that the 
phenotype could also be different.    
 
A possible contribution to this finding is measurement difficulties when assessing depression 
in individuals with HD. An inclusive method where all symptoms regardless of their cause 
(HD or depression) are considered part of the psychiatric presentation likely results in an 
overdiagnosis of people with depression and HD. Conversely, an exclusive method where 
depressive symptoms are attributed more to having HD likely results in an underdiagnosis of 
depression in HD. In this study, the semi-structured interview allowed for psychiatric 
symptoms to be fully explored and rated only if they were clearly associated with the 
temporal course of psychiatric disorder rather than HD. At times, this was difficult to 
determine and therefore the symptom was classified as unknown. This may have led to an 
underreporting of those symptoms which are common to both HD and depression (including 
change in sleep and appetite) and may contribute to the finding that these symptoms were 
less common in the HD sample compared to the MDRG sample. 
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4.6.3.6 The BADDS and GAS 
The BADDS and the GAS were useful dimensional scales that provided extra information on 
an individual’s lifetime experience of psychopathology relevant to depression. These scales 
were able to capture information that the more strict diagnostic categorical tools were not 
able to. For example, the BADDS and GAS provide ratings for the severity of depression and 
sub-clinical cases of depression, which available diagnostic categories are relatively 
unhelpful in doing.  
 
The scores obtained on the BADDS and GAS further support the possibility that depression in 
HD is less severe than that observed in the general population. Individuals in the HD sample 
had non-significant lower scores on the BADDS, indicating a less severe depressive illness 
course. For the GAS ratings, individuals in the HD sample had significantly less impairment of 
functioning during their worst episode of depression than individuals in the MDRG sample.  
 
The experience of less severe depression in individuals with HD could also be due to the 
explanations outlined in the previous section (section 4.6.3.5): depression in HD may have a 
different cause and therefore a different phenotype to the general population; and/or 
measurement difficulties. The contribution of genetic and environmental factors to the 
aetiology of psychiatric illness in HD will be further explored in the following chapter: the 
familiality of psychiatric symptoms in HD. 
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4.7 Summary and limitations 
This chapter has presented the findings of a systematic investigation of the psychiatric 
phenotype in HD using a battery of standardised categorical and dimensional measures. The 
main findings of the chapter are summarised below: 
Lifetime Prevalence of Psychiatric Features 
 56% of the index sample and 65% of the sibling sample had a lifetime DSM-IV 
diagnosis of a depressive disorder. 
 38% of the index sample and 25% of the sibling sample had a lifetime DSM-IV 
diagnosis of an anxiety disorder. 
 6% of the index sample and 7.5% of the sibling sample had a lifetime DSM-IV 
diagnosis of alcohol abuse. 
 No individuals in either HD sample were found to have a lifetime DSM-IV diagnosis of 
OCD or bipolar disorder, contrary to previous literature. 
 36% of the index sample and 40% of the sibling sample had a history of suicidal 
behaviour. 16% of the index sample and 12.5% of the sibling sample had made at 
least one previous attempt at suicide. 
Age of Onset of Psychiatric Illness 
 For the index sample and sibling samples, the median age of onset for any psychiatric 
illness was 41 and 34.5 years respectively.  
 The median age of onset for any depressive disorder was 42 years for the index and 
33 years for the sibling sample. 
 The median age of onset for any anxiety disorder was 41 years and 37 years for the 
index and sibling samples respectively. 
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 The median age of onset for alcohol abuse was 29 years for the index sample and 34 
years for the sibling sample. 
 At least half of the HD symptomatic individuals in both the index and sibling samples 
with a lifetime DSM-IV diagnosis of a depressive and/or an anxiety disorder, 
experienced onset of their psychiatric disorder prior to the motor onset of their HD. 
 
Comparison of the depression phenotype in HD with the non-HD MDRG sample 
Given that depression is consistently the most frequently reported psychiatric disorder 
observed in individuals with HD, the depression phenotype was a specific focus of this 
chapter with a sample of individuals from a large mood disorders study with MDDR being 
used as a comparative non-HD sample. The MDRG sample was an ideal comparative sample, 
owing to the fact that the same gold standard assessment tools were used in the 
neuropsychiatric assessment of both samples.  
 A lifetime history of suicidal behaviour was common to both the HD and MDRG 
samples but individuals with HD were more likely to have made a previous attempt at 
suicide. 
 The median age of onset for depression was significantly older in the HD index 
sample than the MDRG sample. 
 The HD individuals were significantly more likely to experience more frequent 
episodes of depression of a shorter duration than the MDRG individuals. 
 Individuals with HD experienced core biological symptoms of depression less 
frequently than individuals in the MDRG sample. This finding was significant for the 
items diurnal variation, increased appetite and middle insomnia. 
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 Individuals with HD may experience less severe depression than those with MDDR in 
the general population as evidenced by scores obtained on the GAS and BADDS. 
 
An important limitation of the study is the modest sample size of the index and sibling 
samples, which does mean that there is limited power to detect significant relationships. HD 
individuals were recruited to the current study solely on the basis that they had a sibling 
with a genetic diagnosis of HD, however, it is possible that individuals with psychiatric 
symptoms were more likely to be involved and well known to their HD service and 
consequently more likely to be recruited to the study, resulting in a recruitment-bias. 
Conversely, individuals with more severe psychiatric symptoms were likely to be under-
represented in the sample as they would perhaps be less likely to respond to an invitation to 
take part in the study.  
 
Other limitations include the retrospective reporting of an individual’s psychiatric history, 
which could have led to some inaccuracies within the data. However, to try and minimise 
this, data was collected from as many different sources as possible including caregivers and 
case notes. Difficulties with measuring symptoms of depression in HD patients (see section 
4.6.3.5) could have contributed to the finding that the depression phenotype in HD may be 
different to that in the non-HD population. Additionally, although the HD index sample and 
MDRG sample were well matched for age, gender and ethnic origin, individuals in the HD 
sample had a significantly lower level of educational attainment than individuals in the 
MDRG sample. Future studies should also match for education level to avoid potential 
confounding.  
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The findings observed in the current study require replication in a larger sample and for 
future research into the psychiatric phenotype of HD, a large sample of unrelated HD 
individuals should be much easier to recruit than the HD gene positive sibling sample 
required for this study. Nevertheless, the findings observed do highlight the prominent role 
psychiatric features play across the lifespan of an individual with HD and the importance of 
input from services to assess psychiatric well-being in HD families, especially those 
individuals at risk of suicide.  
 
The following chapter attempts to further elucidate the cause of psychiatric disorders in HD 
by focusing on the familial relationship between HD and psychiatric disorders/symptoms in a 
sample of HD-affected sibling pair families. 
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CHAPTER 5: THE FAMILIALITY OF PSYCHIATRIC SYMPTOMS IN 
HD 
 
This chapter will focus on the aetiology of the high prevalence of psychiatric symptoms in HD 
by investigating whether such psychiatric symptoms/disorders cluster in families with HD. 
The chapter will therefore outline the methodology and statistical analysis specific to this 
chapter before detailing the results of the analyses, which will include: the famililality of 
lifetime psychiatric diagnoses, the familiality of psychiatric ratings for depression and age at 
onset of any lifetime DSM-IV psychiatric illness as well as a description of the HD gene 
negative sample. This will be followed by a discussion of the results and limitations. 
 
5.1 Introduction 
It is consistently reported in the HD literature that the prevalence of psychiatric symptoms is 
greater in HD patients than in the general population (Paulsen et al., 2001) and the results 
obtained in the present study as described in the previous chapter support this finding. 
However, the reasons for this association are not yet known. Evidence to date suggests that, 
except for the neuropsychiatric symptom of apathy, the wide array of other behavioural 
changes observed in HD are not related to disease progression (Craufurd et al., 2001; 
Thompson et al., 2002) and the prevalence of psychiatric symptoms is independent of the 
length of the trinucleotide expansion (Naarding et al., 2001; Vassos et al., 2007). Other 
genetic and/or environmental factors that may influence the presence and severity of 
psychiatric phenotypes in HD have received little attention.  
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5.1.1 Aims 
Therefore, the main aims of this chapter are to: 
i) Determine whether a broad range of psychiatric syndromes and symptoms 
aggregate in families affected with HD by conducting a systematic, standardised 
psychiatric assessment on a large sample of sibling pairs with HD. 
ii) Further improve current understanding of the relative role the HD gene, other 
genetic factors and psychosocial factors may play in explaining the increased 
prevalence of psychiatric symptoms in HD. This will be achieved by administering 
the psychiatric assessment to unaffected siblings who have had a negative HD 
genetic test. 
 
5.1.2 Family studies  
Family studies are an important step towards understanding the contribution of familial and 
non familial factors to a particular phenotype. Familiality indicates that the phenotype under 
investigation clusters within families and although hints at a genetic basis, it can be caused 
by any of the following factors: shared genetic predisposition between family members, 
shared environmental factors within families or an interaction between shared genes and 
the shared environment. The few studies that have explored the familiality of psychiatric 
syndromes/symptoms in HD are discussed below. 
 
Tsuang et al (2000) investigated the familiality of psychotic symptoms in forty-four patients 
with HD, 22 with and 22 without psychosis. Of the 22 probands with psychosis, eight had 
psychosis only, eight had mixed affective and psychotic symptoms and six had psychotic 
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symptoms secondary to dementia. The HD patients with psychosis were found to be 
significantly more likely to have a first-degree relative with psychosis than the HD patients 
without psychosis. Furthermore, for eight of the nine HD probands with psychosis who had 
first-degree relatives with psychosis, the relatives’ psychosis co-occurred with HD. 
Consequently, it was estimated that the risk of first-degree relatives with HD developing 
psychosis was 36% for those relatives of probands with psychosis compared with an 8% risk 
for the relatives of probands without psychosis. The authors suggested that other genetic 
factors may predispose individuals in certain HD families to develop psychosis, for example, 
modifying genes may increase this susceptibility by interacting with the HD gene. 
 
Tsuang et al (1998) conducted a small case-control study investigating the aggregation of 
schizophrenia-like symptoms in two families, one where the juvenile onset HD proband had 
schizophrenia-like symptoms and one with a non-psychotic juvenile onset HD proband for 
comparison. The results demonstrated that in the family where the juvenile onset HD 
proband had schizophrenia-like symptoms, the proband’s father and possibly the paternal 
grandmother (a diagnosis was based on medical records) all exhibited schizophrenia-like 
symptoms, which co-occurred with HD. Conversely, none of the HD affected family members 
of the juvenile HD onset proband without schizophrenia-like symptoms presented with such 
symptoms. Like other studies (Berrios et al., 2001; Naarding et al., 2001; Vassos et al., 2008), 
the predisposition to develop schizophrenia-like symptoms appeared to be independent of 
the CAG expansion size and again implicates a role for shared familial factors in the disease 
presentation. 
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Lovestone et al (1996) described a family where four members with HD initially presented 
with a severe psychiatric disorder between three and nine years before any choreic 
symptoms were apparent. Three of the four family members were diagnosed with a 
schizophrenia-like syndrome and the other received a diagnosis of depression. Additionally, 
of two further family members who had no signs of motor symptoms at presentation, one 
was diagnosed with major depressive disorder and the other with schizoaffective disorder. 
Similarly, Heathfield (1967) described a family where a brother and sister with HD were 
diagnosed with identical paranoid schizophrenic psychoses, while another brother who did 
not develop choreiform movements, also suffered from this psychotic disorder. Correa et al. 
(2006) described an HD family where all known family members who carried the HD gene 
also developed psychotic symptoms at least five years prior to the onset of any significant 
motor or cognitive symptoms. The authors proposed that in these HD families, the HD gene 
may behave as a large effect schizophrenia gene in the presence of a low load of small effect 
schizophrenia genes (Correa et al., 2006). 
 
Folstein et al (1983), in order to investigate possible causes of depression in HD, interviewed 
first-and second-degree relatives of five consecutive HD probands with major affective 
disorder and five HD probands with no affective disorder, all ascertained from their 
Maryland case series. It was found that the HD affected relatives of the probands with HD 
and depression were significantly more likely themselves to have affective disorder (20 out 
of 23 relatives with HD) than the HD relatives of the probands without affective disorder 
(only 5 of 23 relatives had concurrent HD and affective disorder). The authors proposed that 
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the familial association of affective disorder with HD could be due to either genetic 
heterogeneity or genetic linkage between loci for HD and affective disorder. 
 
An association between obsessive-compulsive disorder (OCD) and pathological gambling 
with HD has been described in an Italian pedigree (De Marchi et al., 1998). Of the seven 
children of an affected parent with OCD and HD, two individuals were found to have a 
diagnosis of OCD and a further two a diagnosis of pathological gambling. In addition, all four 
children were found to carry the HD gene after mutation analysis. However, of the additional 
three children without an OCD or pathological gambling diagnosis, one was also found to be 
HD gene positive. The authors hypothesised that their findings might be accounted for by 
the HD gene contributing to the overall clinical picture of OCD or genetic linkage between 
the gene(s) for OCD and the HD gene.   
 
These studies demonstrate that familial factors may influence the psychiatric phenotype in 
HD. Therefore, in order to build on the findings of these previous small-scale family studies, 
data on lifetime psychiatric diagnoses and symptoms were obtained for 53 sibling pairs gene 
positive for HD and where possible the same data for siblings gene negative for HD were also 
collected. This study provides a larger sample size than previously reported, uses a 
systematic and more thorough methodology through the use of face-to-face standardised 
interviews together with medical notes and focuses on the full range of psychiatric 
symptoms and syndromes observed in HD.  
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5.2 Methods 
The methods and clinical description of the HD gene positive index and sibling samples were 
described in Chapter 4. The number of HD gene positive siblings recruited from any single 
family ranged from one to four, including one sibling from 10 families, two siblings from 35 
families, three siblings from four families and four siblings from one family. Using the 
independent sibling pair model of one affected sibling pair per family, this gave a total of 40 
sibling pairs. The six extra siblings from the five families where more than two siblings gene 
positive for HD were recruited to the study were included in the larger all possible sibling 
pairs model, which gave a total of 53 sibling pairs. The demographic characteristics of these 
six siblings are outlined in section 5.4.1 given that they have not been included in any 
previous analyses and therefore were not described in Chapter 4.  
 
The methods for ascertainment of the HD gene negative sample were described in section 
3.2.2 and the demographic characteristics of the gene negative sample are summarised in 
section 5.4.1. 
 
5.3 Statistical analysis 
HD gene positive sample 
All statistical tests were performed using the statistical package SPSS version 19 (IBM Corp, 
2010) and statistical tests were considered significant at the p<0.05 level. Initial analyses 
were performed using the all-possible sibling pairs model where sibling trios were treated as 
three sibling pairs and the family of four siblings was counted as six possible pairs making a 
total of 53 sibling pairs. Although this raises the issue of the second and additional sibling 
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pairs in a family not being independent of the initial pair, previous research (Kendler et al., 
1997, 2000) has suggested that the inclusion of sibships of up to four individuals results in 
comparable associations whether the non-independent sibling pairs are included or not. 
Where a significant result was found, the analysis was repeated using the independent 
sibling pair model (i.e. using just the index sibling and the sibling from the sibling sample per 
family). This determined if the significance still held when only the 40 independent sibling 
pairs were included. 
Categorical ratings: 
The kappa statistic was used to determine the concordance of categorical ratings between 
sibling pairs gene positive for HD for the following broad and narrow diagnostic criteria: i) 
any lifetime DSM-IV diagnosis (present/absent), ii) a lifetime DSM-IV diagnosis of any 
depressive disorder (present/absent), iii) a lifetime DSM-IV diagnosis of recurrent major 
depressive disorder (MDDR) (present/absent) and, iv) a lifetime DSM-IV diagnosis of any 
anxiety disorder (present/absent). Additionally, concordance between sibling pairs was 
determined for lifetime ratings of suicidality (present/absent) and for lifetime ratings of the 
Problem Behaviours Assessment (PBA) items; perseverative thinking, apathy, irritability and 
aggression (all present/absent). For the PBA, symptoms were considered present if the 
severity score for that item was two or more. Where a diagnosis or rating was not known for 
one or both of the siblings, this sibling pair was excluded from the analysis. 
Continuous ratings: 
Intra-class correlation coefficients (ICC) were used to determine the correlations between 
HD gene positive sibling pairs for continuous ratings, including: i) age at onset of first 
psychiatric impairment, ii) scores obtained on the Bipolar Affective Disorder Dimensional 
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Scale – Depression subscale (BADDS-D) and, iii) the Global Assessment Scale – worst ever 
functioning in a depressive episode (GAS). Sibling pairs were excluded from the analysis 
when one or both of the siblings either did not have a known rating, or for the age at onset 
and GAS analyses, when a sibling did not have a rating due to the fact they had no lifetime 
history of a DSM-IV psychiatric illness or DSM-IV depressive disorder respectively. 
 
HD gene negative sample: 
The mean age at the time of interview was reported and all other demographic 
characteristics were described in terms of frequencies and percentages. Given the small size 
of this sample (N=5), a descriptive approach reporting the presence/absence of any 
psychiatric symptoms/disorders in those individuals was adopted. 
 
5.4 Results 
5.4.1 Demographic characteristics of the additional six siblings gene positive for HD 
 
The demographic characteristics of the additional six gene positive siblings used in the all 
possible sibling pairs model are summarised in Table 5.1. Five of the six had a clinical 
diagnosis of HD alongside their genetic diagnosis. The mean age of the siblings was 48 years 
and half of the individuals were female. All were of UK/Eire Caucasian ethnicity and the 
majority of the sample were either married or had lived as married (83.3%). Two-thirds of 
the sample had A-levels as their highest level of education and the majority of the sample 
(66.7%) had worked as professionals. 
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Table 5.1 Demographic characteristics of the additional 6 gene positive individuals. 
Demographics  Descriptives and Percentages 
N = 6 
Age (years)  
Mean (95% CI) 48.0 (43.0-53.0) 
Standard Deviation 6.26 
Range 40-59 
  
Female N (%) (95% CI) 
 3 (50.0) (10.0-90.0) 
  
Ethnic Origin  
UK/Eire Caucasian 6 (100.0) (-) 
  
Marital status  
Has married/lived as married 5 (83.3) (44.9-100) 
Has never married/lived as married 1 (16.7) (0-53.5) 
  
Highest Level Education  
A level/ HND/ BTEC 4 (66.7) (29.0-100) 
Degree 2 (33.3) (0-71.0) 
  
Highest Lifetime Occupation  
Professionals, senior officials and managers 4 (66.7) (29.0-100) 
Plant & machinery operators and assemblers 1 (16.7) (0-53.5) 
Armed forces 1 (16.7) (0-53.5) 
 
5.4.2 Familial clustering of categorical ratings 
Lifetime DSM-IV diagnoses were known for 50 sibling pairs, which were from 37 different 
families (32 families contributed 1 sibling pair, 4 families contributed 3 sibling pairs and 1 
family contributed six sibling pairs).  
5.4.2.1 Concordance between sibling pairs for any lifetime DSM-IV disorder 
The presence/absence of a lifetime DSM-IV disorder was known for 50 sibling pairs and using 
this broad diagnostic category, 35 sibling pairs were concordant and 15 sibling pairs were 
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discordant, resulting in a fair but significant level of agreement as shown in Table 5.2 (κ = 
0.302, p=0.031). 
Table 5.2 Concordance between all possible sibling pairs (N = 50 pairs) for any lifetime DSM-IV 
psychiatric diagnosis. 
 Sibling 2 
No DSM-IV diagnosis 
Sibling 2 
DSM-IV diagnosis 
Sibling 1 
No DSM-IV diagnosis 
8 6 
Sibling 1 
DSM-IV diagnosis 
9 27 
κ = 0.302, p=0.031 
This analysis was repeated using only the 37 independent sibling pairs. As shown in Table 
5.3, 26 sibling pairs were concordant and 11 sibling pairs were discordant, which resulted in 
a non-significant level of agreement (κ = 0.27, p=0.10). 
Table 5.3 Concordance between independent sibling pairs (N=37 pairs) for any lifetime DSM-IV 
psychiatric diagnosis. 
 
 Sibling 2 
No DSM-IV diagnosis 
Sibling 2 
DSM-IV diagnosis 
Sibling 1 
No DSM-IV diagnosis 
5 5 
Sibling 1 
DSM-IV diagnosis 
6 21 
κ = 0.27, p=0.10 
5.4.2.2 Concordance between sibling pairs for a lifetime DSM-IV diagnosis of any 
depressive disorder 
Associations between all the possible sibling pairs (50 sibling pairs) for a lifetime DSM-IV 
diagnosis of any depressive disorder, including a lifetime DSM-IV diagnosis of i) major 
recurrent depression (MDDR), ii) single episode major depression (MDDS) and iii) depression 
not otherwise specified (depression NOS), revealed a moderate and significant level of 
familial clustering (κ = 0.444, p=0.002) with 37 sibling pairs concordant for any depressive 
disorder and 13 sibling pairs discordant (Table 5.4). 
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Table 5.4 Concordance between all possible sibling pairs (N=50 pairs) for a lifetime DSM-IV 
diagnosis of any depressive disorder 
 Sibling 2 
No DSM-IV depression 
Sibling 2 
DSM-IV depression 
Sibling 1 
No DSM-IV depression 
12 8 
Sibling 1 
DSM-IV depression 
5 25 
κ = 0.444, p=0.002 
When this analysis was repeated using only the 37 independent sibling pairs, 28 sibling pairs 
were concordant for any depressive disorder and 9 sibling pairs were discordant (Table 5.5), 
which still resulted in a moderate and significant level of familial clustering, (κ = 0.46, 
p=0.004). 
Table 5.5 Concordance between independent sibling pairs (N=37 pairs) for a lifetime DSM-
IV diagnosis of any depressive disorder 
 Sibling 2 
No DSM-IV depression 
Sibling 2 
DSM-IV depression 
Sibling 1 
No DSM-IV depression 
8 6 
Sibling 1 
DSM-IV depression 
3 20 
κ = 0.46, p=0.004 
 
5.4.2.3 Concordance between sibling pairs for a lifetime DSM-IV diagnosis of recurrent 
major depressive disorder (MDDR) 
Associations between all sibling pairs for a lifetime DSM-IV diagnosis of MDDR revealed that 
34 sibling pairs were concordant for MDDR (although only 2 sibling pairs were concordant 
for having a lifetime DSM-IV diagnosis of MDDR) and 16 sibling pairs were discordant for 
MDDR, which was not significant as displayed in Table 5.6 (κ = 0.010, p=0.942). Therefore, 
the analysis was not repeated using the independent sibling pairs. 
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Table 5.6 Concordance between all possible sibling pairs (N=50 pairs) for a lifetime DSM-IV 
diagnosis of recurrent major depression (MDDR). 
 Sibling 2 
No DSM-IV MDDR 
Sibling 2 
DSM-IV MDDR 
Sibling 1 
No DSM-IV MDDR 
32 6 
Sibling 1 
DSM-IV MDDR 
10 2 
κ = 0.010, p=0.942 
 
5.4.2.4 Concordance between all sibling pairs for a lifetime DSM-IV diagnosis of any 
anxiety disorder. 
 
Table 5.7 displays the concordance between all possible sibling pairs (N=50) for a lifetime 
DSM-IV diagnosis of any anxiety disorder, which included i) panic disorder with agoraphobia, 
ii) panic disorder without agoraphobia, iii) agoraphobia without panic disorder, iv) social 
phobia and, v) anxiety disorder not otherwise specified (NOS). Twenty-eight sibling pairs 
were found to be concordant for an anxiety disorder and 22 sibling pairs were found to be 
discordant, which was not significant (κ = -0.017, p=0.899). 
Table 5.7 Concordance between all possible sibling pairs (N=50 pairs) for a lifetime DSM-IV 
diagnosis of any anxiety disorder. 
 
 Sibling 2 
No DSM-IV anxiety 
Sibling 2 
DSM-IV anxiety 
Sibling 1 
No DSM-IV anxiety 
24 7 
Sibling 1 
DSM-IV anxiety 
15 4 
κ = -0.017, p=0.899 
 
5.4.2.5 Familial clustering of lifetime suicidality in HD 
Fifty-one sibling pairs from a total of 38 families with at least two sibling pairs with ratings on 
lifetime suicidal behaviour were included in the following analyses. 
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5.4.2.5.1 Concordance between sibling pairs for lifetime suicidal ideation 
Associations between all possible sibling pairs (51 sibling pairs) for lifetime suicidal ideation, 
which includes a history of suicidal thoughts with or without suicide attempts, found 33 
sibling pairs to be concordant for lifetime suicidal ideation and 18 sibling pairs to be 
discordant, which was not significant (κ = 0.261, p=0.062) (Table 5.8). 
Table 5.8 Concordance between all possible sibling pairs (N=51 pairs) for lifetime suicidal 
ideation. 
 Sibling 2 
No suicidal ideation 
Sibling 2 
Suicidal ideation 
Sibling 1 
No suicidal ideation 
22 10 
Sibling 1 
Suicidal ideation 
8 11 
κ = 0.261, p=0.062 
 
5.4.2.5.2 Concordance between sibling pairs for lifetime suicide attempts. 
Table 5.9 demonstrates that using a more narrow definition of a history of at least one 
suicide attempt, 38 sibling pairs were concordant and 13 sibling pairs were discordant for 
lifetime suicide attempts. However, of the 38 sibling pairs that were concordant, 37 of these 
were concordant for no history of attempted suicide, resulting in no significant concordance 
(κ = -0.015, p=0.913). 
Table 5.9 Concordance between all possible sibling pairs (N=51 pairs) for lifetime suicide 
attempts. 
 Sibling 2 
No suicide attempts 
Sibling 2 
Suicide attempts 
Sibling 1 
No suicide attempts 
37 6 
Sibling 1 
Suicide attempts 
7 1 
κ = -0.015, p=0.913 
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5.4.2.6 Familial clustering of lifetime Problem Behaviours Assessment (PBA) items 
 
Lifetime ratings (the presence or absence) of PBA items were available for 52 sibling pairs 
from 39 families and were included in the following analyses. 
 
5.4.2.6.1 Perseverative thinking 
Table 5.10 displays the concordance between siblings for a lifetime history of perseverative 
thinking. Thirty three siblings were found to be concordant for a history of perseverative 
thinking and nineteen sibling pairs were found to be discordant (κ = 0.263, p=0.053), which 
approached significance. When only the independent sibling pairs were used in the analysis 
(N=39), 24 sibling pairs were concordant for perseverative thinking and 15 were discordant, 
resulting in a non-significant p-value (κ = 0.230, p=0.152). 
Table 5.10 Concordance between all possible sibling pairs (N=52 pairs) for a lifetime 
history of perseverative thinking 
 Sibling 2 
No perseverative thinking 
Sibling 2 
Perseverative thinking 
Sibling 1 
No perseverative thinking 
20 7 
Sibling 1 
Perseverative thinking 
12 13 
κ = 0.263, p=0.053 
 
5.4.2.6.2 Apathy 
Associations between all possible sibling pairs for a lifetime history of apathy revealed that 
29 sibling pairs were concordant for apathy and 23 sibling pairs were discordant, which was 
not significant as shown in Table 5.11 (κ = 0.105, p=0.432). 
 
 
153 
 
Table 5.11 Concordance between all possible sibling pairs (N=52 pairs) for a lifetime 
history of apathy 
 Sibling 2 
No apathy 
Sibling 2 
Apathy 
Sibling 1 
No apathy 
10 15 
Sibling 1 
Apathy 
8 19 
κ = 0.105, p=0.432 
 
5.4.2.6.3 Irritability 
Associations between all possible sibling pairs (52 sibling pairs) for a lifetime history of 
irritability revealed a fair yet significant level of familial clustering (κ = 0.341, p=0.013) with 
36 sibling pairs concordant for a history of irritability and 16 sibling pairs discordant (Table 
5.12). 
Table 5.12 Concordance between all possible sibling pairs (N = 52 pairs) for a lifetime 
history of irritability 
 Sibling 2 
No irritability 
Sibling 2 
Irritability 
Sibling 1 
No irritability 
11 6 
Sibling 1 
Irritability 
10 25 
κ = 0.341, p=0.013 
 
When only the independent sibling pairs were analysed (N = 39 pairs), a similar fair and 
significant level of association between siblings for a lifetime history of irritability was found 
(κ = 0.357, p=0.024). Twenty-eight sibling pairs were concordant for irritability and 11 sibling 
pairs were discordant (Table 5.13). 
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Table 5.13 Concordance between the independent sibling pairs (N=39 pairs) for a lifetime 
history of irritability 
 Sibling 2 
No irritability 
Sibling 2 
Irritability 
Sibling 1 
No irritability 
7 4 
Sibling 1 
Irritability 
7 21 
κ = 0.357, p=0.024 
 
5.4.2.6.4 Aggression 
For a lifetime history of aggression, 37 sibling pairs were found to be concordant and 15 
sibling pairs were found to be discordant, which resulted in a moderate level of familial 
clustering, as shown in Table 5.14 (κ = 0.418, p=0.003). 
Table 5.14 Concordance between all possible sibling pairs (N = 52 pairs) for a lifetime 
history of aggression 
 
 Sibling 2 
No aggression 
Sibling 2 
Aggression 
Sibling 1 
No aggression 
21 7 
Sibling 1 
Aggression 
8 16 
κ = 0.418, p=0.003 
This association between the sibling pairs for a lifetime history of aggression remained 
significant (albeit with a reduced Kappa value, κ = 0.384, p=0.016) when only the 
independent sibling pairs (N=39 pairs) were used in the analysis (Table 5.15). 
Table 5.15 Concordance between the independent sibling pairs (N=39 pairs) for a lifetime 
history of aggression 
 Sibling 2 
No aggression 
Sibling 2 
Aggression 
Sibling 1 
No aggression 
14 6 
Sibling 1 
Aggression 
6 13 
κ = 0.384, p=0.016 
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Tables 5.16 and 5.17 summarise the Cohen’s kappa and associated p-values for the 
categorical ratings between all possible sibling pairs gene positive for HD and for the 
independent sibling pairs gene positive for HD respectively. 
 
Table 5.16 Summary of the concordance between all possible sibling pairs gene positive for HD for 
all categorical ratings. 
 
Rating N* κ 95% CI p-value 
Any lifetime DSM-IV diagnosis 50 0.302 0.006-0.586 0.031 
A lifetime DSM-IV diagnosis of any depressive 
disorder 
50 0.444 0.189-0.699 0.002 
A lifetime DSM-IV diagnosis of MDDR 50 0.010 -0.262-0.282 0.942 
A lifetime DSM-IV diagnosis of any anxiety 
disorder 
50 -0.017 -0.274-0.240 0.899 
A history of suicidal ideation 51 0.261 -0.008-0.530 0.062 
A history of suicide attempts 51 -0.15 -0.415-0.115 0.913 
A lifetime history of perseverative thinking 52 0.263 0.004-0.523 0.053 
A lifetime history of apathy 52 0.105 -0.156-0.366 0.432 
A lifetime history of irritability 52 0.341 0.080-0.602 0.013 
A lifetime history of aggression 52 0.418 0.171-0.665 0.003 
MDDR; Recurrent Major Depressive Disorder, CI; Confidence Interval 
*Number of sibling pairs included in the analysis 
 
Table 5.17 Summary of the concordance between the independent sibling pairs gene positive for 
HD for the categorical ratings that demonstrated within-pair correlations. 
 
Rating N* κ 95% CI p-value 
Any lifetime DSM-IV diagnosis 37 0.269 -0.066-0.604 0.101 
A lifetime DSM-IV diagnosis of any depressive 
disorder 
37 0.460 0.164-0.756 0.004 
A lifetime history of irritability 39 0.357 0.051-0.663 0.024 
A lifetime history of aggression 39 0.384 0.094-0.674 0.016 
CI; Confidence Interval 
*Number of sibling pairs included in the analysis 
 
5.4.3 Familial clustering of continuous variables 
5.4.3.1 Age at onset of psychiatric illness 
From the all possible sibling pairs sample of 53 pairs, there were 27 sibling pairs with a 
lifetime DSM-IV diagnosis for whom the age at onset of psychiatric illness was known. The 
correlation between siblings for the age at psychiatric onset was weak (ICC = 0.12, p=0.223). 
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5.4.3.2 BADDS-D 
BADDS-D ratings were made for 50 sibling pairs. There was a fair but significant correlation 
between siblings for BADDS-D scores (ICC = 0.36, p=0.005). When only the sample of 
independent sibling pairs was analysed (N=37 pairs), the within-pairs correlation was 
moderate and significant (ICC = 0.47, p=0.002).  
 
5.4.3.3 GAS – worst ever level of functioning in a depressive episode 
There were 25 sibling pairs who had a lifetime DSM-IV diagnosis of a depressive disorder and 
for whom GAS ratings were available. The correlation between siblings for GAS scores was 
very weak (ICC = 0.021, p=0.460).  
 
Tables 5.18 and 5.19 summarise the intra-class correlation coefficients (ICCs) for the 
continuous variables: age at psychiatric illness onset, BADDS-D, and GAS - worst ever 
functioning in a depressive episode between all possible sibling pairs and the independent 
sibling pairs respectively. 
 
Table 5.18 Summary of the intra-class correlations (ICC) of the continuous ratings between 
all possible sibling pairs gene positive for HD. 
 
Rating N* ICC 95% CI P value 
Age at Onset of Psychiatric Illness 27 0.147 -0.225 - 0.488 0.223 
BADDS-D 50 0.360 0.091-0.580 0.005 
GAS - WEDE 25 0.021 -0.370 – 0.405 0.118 
ICC; Intra-Class Correlations, BADDS-D; Bipolar Affective Disorder Dimensional Scale – Depression subscale, GAS 
– WEDE; Global Assessment Scale – worst ever functioning in a depressive episode, CI; Confidence Interval 
*Number of sibling pairs included in the analysis. 
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Table 5.19 Summary of the intra-class correlations (ICC) of the continuous ratings between 
the independent sibling pairs gene positive for HD. 
Rating N* ICC 95% CI P value 
BADDS-D 37 0.47 0.17 - 0.68 0.002 
ICC; Intra-Class Correlations, BADDS-D; Bipolar Affective Disorder Dimensional Scale – Depression subscale, CI; 
Confidence Interval, *Number of sibling pairs included in the analysis. 
 
5.5 Description of the HD gene negative sample  
The HD gene negative sample comprised five individuals from five different families 
recruited to the study. All individuals were aware growing up that they had a positive family 
history of HD and therefore were themselves at 50% risk for inheriting the disease. For three 
of these families where the gene negative sibling was the only sibling to not carry the gene, 
the gene negative sibling had taken on the responsibility of looking after their sibling(s). 
 
5.5.1 Demographic characteristics of the gene negative sample 
The demographics of the HD gene negative sample are summarised in Table 5.20. The mean 
age of the sample was 45.4 years and four of the five individuals were female. All were 
UK/Eire Caucasian and 80% were married or had lived as married. Two individuals had 
obtained a degree, one individual had O-levels as her highest level of education and two 
individuals had left school without any qualifications.  Although two of the five individuals 
were now full time carers for their siblings, they were both previously service workers. One 
female was a carer for her sister but also held down a full-time job as a charity worker and 
the additional two individuals were working full-time in professional and associate 
professional jobs. 
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Table 5.20 Demographic characteristics of the 5 gene negative individuals. 
Demographics  Descriptives and 
Percentages 
N = 5 
Age (years)  
Mean (95% CI) 45.4 (37.9-53.0) 
Standard Deviation 8.62 
Range 34-58 
  
 N (%) (95% CI) 
Female 4 (80.0) (44.9-100) 
  
Ethnic Origin  
UK/Eire Caucasian 5 (100.0) (-) 
  
Marital status  
Has married/lived as married 4 (80.0) (44.9-100) 
Has never married/lived as married 1 (20.0) (0-55.1) 
  
Highest Level Education  
No qualifications 2 (40.0) (0-82.9) 
O-levels/CSEs/ GCSEs 1 (20.0) (0-55.1) 
A level/ HND/ BTEC 0 (0.0) (-) 
Degree 2 (40.0) (0-82.9) 
  
Highest Lifetime Occupation  
Professionals, senior officials and managers 2 (40.0) (0-82.9) 
Technicians and associate professionals 1 (20.0) (0-55.1) 
Service workers & shop & market workers 2 (40.0) (0-82.9) 
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5.5.2 Description of the psychiatric histories of the HD unaffected siblings 
5.5.2.1 Family 005: Participant 005-2A 
Lifetime DSM-IV diagnosis: None  
Background: 
A 47 year old female with an HD affected older brother and older sister. She lives with her husband 
and two children and received her negative predictive test result aged 35. 
Family psychiatric history: 
The HD affected older sister has a lifetime DSM-IV diagnosis of recurrent major depression and panic 
disorder without agoraphobia. The HD affected older brother has a history of anxiety NOS and also 
has two children aged 21 and 15 years who both suffer with severe OCD (they are at 50% risk of 
carrying the HD gene). Her mother had HD and suffered with depression and anxiety as well as 
hallucinations/delusions and was admitted to a psychiatric hospital twice before she was diagnosed 
with HD (this information was provided by participant 005-2A and could not be verified by medical 
records). 
Psychiatric history: 
Summary: 
Age 13: first symptoms of low mood, self-harm and obsessional symptoms.  
Age 30: further period of low mood and onset of panic attacks following bereavement 
Age 36: additional period of low mood following bereavement 
As a teenager, she had her first symptoms of low mood and self-harmed for 2-3 years. She also had a 
few obsessional symptoms (mainly keeping possessions in a certain order/place), which she said gave 
her some control in an otherwise very uncontrollable home environment. 
She had two further periods of low mood aged 30 when her Mum (who had HD) died and then aged 
36 when her father passed away. She described her depressive symptoms as mainly mild and she 
managed to carry on with her work and everyday activities. 
She also experienced panic attacks two or three times a week for three months after her mother died 
but again they did not interfere with her daily life and she perceived them to be a reaction to her 
Mother’s death. 
None of these periods of low mood and anxiety were severe enough to reach DSM-IV diagnosis. 
Psychiatric medication: she was prescribed anti-depressants aged 30 after her mother died. 
Contact with psychiatric services: none 
Suicidal behaviour: she has never attempted suicide but as a teenager she self-harmed for 2-3 years 
by cutting herself with a razor blade. She said it was more for a release and was not because she did 
not want to live. 
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5.5.2.2 Family 009: Participant 009-2A 
Lifetime DSM-IV diagnosis: None 
Background: 
A 45 year old female with an older sister, younger sister and non-identical twin sister all HD 
symptomatic. She lives and cares for her elder sister as well as her disabled husband. She also lives 
next door to her mother and affected twin sister, who she also sometimes has to care for as well as 
holding down a full-time job. She had the negative predictive test aged 40. 
Family psychiatric history: 
Her non-identical twin sister has a lifetime DSM-IV diagnosis of anxiety NOS, her eldest sister has a 
lifetime DSM-IV diagnosis of major depressive disorder, single episode and her younger sister has a 
lifetime DSM-IV diagnosis of both major depressive disorder, single episode and anxiety NOS. 
Psychiatric history: 
Summary: 
No particular psychiatric history. She has the occasional down day but nothing more than that. They 
have a strong Christian faith as a family, which she believes has played a role in her being better able 
to deal mentally with her family’s situation.  
Psychiatric medication: none 
Contact with psychiatric services: none 
Suicidal behaviour: no lifetime history of suicidal thoughts or attempts. 
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5.5.2.3 Family 021: Participant 021-2A 
Lifetime DSM-IV diagnosis: None 
Background: 
A 34 year old, single male with an older brother, older sister and younger sister all with positive 
predictive test results. He was the first of his siblings to undergo genetic testing aged 18, which he 
found a very stressful experience. 
Family psychiatric history: 
Both of his sisters, although not yet symptomatic, have a lifetime DSM-IV diagnosis of major 
depressive disorder (one with a single episode and the other with recurrent episodes). The sister 
with a lifetime DSM-IV diagnosis of recurrent major depressive disorder also had a lifetime DSM-IV 
diagnosis of panic disorder without agoraphobia. His mother and maternal grandmother had HD and 
both appeared to suffer with depression (his mother was on anti-depressants) as well as irritability 
and aggression (this information was provided by participant 021-2A and could not be verified by 
medical records).  
Psychiatric history: 
Summary:  
Age 18: onset of binge drinking 
Between the ages of about 18 and 23, he would drink up to 70 units of alcohol a week but only 
socially and he would also occasionally take ecstacy when at a social event. When he was drunk he 
would start feeling low about money problems, relationship problems and family issues and when he 
was very low he would have feelings of tedium vitae and suicidal ideation. These feelings of low 
mood would only happen under the influence of alcohol and therefore only lasted for a few hours at 
the end of an evening. 
Psychiatric medication: none 
Contact with psychiatric services: none 
Suicidal behaviour: When he went through this period of drinking heavily he sometimes thought that 
life wasn’t worth living and he might harm himself when drunk but he never acted on these 
thoughts. 
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5.5.2.4 Family 024: Participant 024-2A 
Lifetime DSM-IV diagnoses: MDDR, Anxiety NOS, Alcohol Abuse 
Background: 
A 58 year old unaffected female who is the eldest of seven siblings. One brother has died of HD, two 
HD affected sisters are in a nursing home, another sister is mid-stage HD, one brother committed 
suicide (he did not know his genetic status) and another brother has not had the genetic test but is 
not yet showing any symptoms of HD. She received her negative predictive test result aged 42 years. 
Family psychiatric history: 
Of the two siblings with HD who took part in the current study, one had a lifetime DSM-IV diagnosis 
of recurrent major depressive disorder and panic disorder with agoraphobia and for the other, 
diagnosis was unknown due to the fact she was in the later stages of HD and living in a nursing home. 
One other sister with HD is in a low-secure psychiatric unit, one brother committed suicide and no 
psychiatric diagnoses were known for the other two brothers (one who died of HD and one whose 
genetic status is unknown). 
Psychiatric history: 
Summary:  
Age 13: onset of depression and anxiety 
Age 28: onset of alcohol abuse. 
She has had up to 10 episodes of severe depression since she was a teenager. Her home life was very 
difficult as a teenager. Her parents both experienced depression and alcoholism and were violent. 
She had psoriasis, which greatly affected her confidence and her mother and grandmother had HD. 
Being the eldest, she felt she had to look after her younger brothers and sisters. 
She has experienced anxiety since her teenage years and has had a difficult life since including trying 
to look after her siblings, having many family members die with HD, her sister who was having a 
psychotic episode once tried to break into her house and kill her and she lived with an abusive 
partner for many years.  
She was around alcohol a lot as a child as both her mother and father had alcohol problems. In her 
late 20s/early 30s, she drank a lot, which started as being socially drinking lots and then became 
drinking when stressed to try and escape from what was going on in her life to later relying on 
alcohol to get her through the day. She thinks she drank as a result of her depression as it was a way 
for her to block it out. During her heaviest period of drinking, she would drink about 50cl vodka most 
nights a week. 
Psychiatric medication: anti-depressant, citalopram 20mg once a day. 
Contact with psychiatric services: none 
Suicidal behaviour: she has had recurrent thoughts of suicide throughout her life. Once she planned 
for her death by sorting out all her belongings and making sure everything was in order. Then she 
was going to leave her house keys with the GP and take an overdose but she decided not to go 
through with it. 
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5.5.2.5 Family 035: Participant 035-2A 
Lifetime DSM-IV diagnoses: MDDR, Panic Disorder with Agoraphobia. 
Background: 
A 43 year old HD unaffected female with two younger sisters both with genetic and clinical HD 
diagnoses. She is a full-time carer for both her sisters and she received her negative predictive test 
result when she was 21 years old.  
Family psychiatric history: 
One sibling with HD has a lifetime DSM-IV diagnosis of recurrent major depressive disorder, panic 
disorder with agoraphobia and alcohol abuse and the other HD affected sibling has a lifetime DSM-IV 
diagnosis of single episode major depressive disorder, agoraphobia without panic disorder and 
alcohol abuse. 
Psychiatric history: 
Summary: 
Age 16: Onset of depression and panic attacks. 
Her mother was diagnosed with HD aged 31 and became quite violent. Her Dad was an alcoholic and 
so life around this time was very chaotic; she had to spend a lot of time looking after her Mum rather 
than having a typical teenage life. Aged 17, she was taken into care with her sisters, though she 
ended up living with her Aunt. Her sisters were subsequently fostered into the same family. 
She believes she has had 10+ episodes of depression lasting longer than 2 weeks with her first 
episode aged 16 and her worst episode aged 19. She believes her depression had significant 
interference with her everyday life as she had to stop work for a while and didn’t want to go out. 
Onset of panic attacks happened when she was 16 but her worst episode was about 5 years ago, 
which lasted for about 4 months. She hasn’t had an attack for about 4 years now. She said that her 
panic attacks had a severe interference with her everyday life as she stopped working (she found her 
job very stressful and although after some counselling she went back to her job, she then left it). She 
also found it hard to leave the house and would not drive for this time. 
Psychiatric medication: anti-depressant, citalopram 60mg once daily. 
Contact with psychiatric services: none 
Suicidal behaviour: she had moments during her worst episode of depression of contemplating 
ending her life, but she did not act on these thoughts. 
 
A summary of the lifetime psychiatric history of the five individuals gene negative for HD is 
provided in Table 5.21.
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Table 5.21 Summary of the lifetime psychiatric history of the five gene negative individuals  
Participant Gender Age at HD 
genetic 
test 
Age at onset of 
first psychiatric 
symptoms 
Age at onset of 
first psychiatric 
impairment 
Contact with 
psychiatric 
services 
DSM-IV 
Main 
Diagnosis 
DSM-IV 
Other 
Diagnoses 
Psychiatric 
Medication 
Family 
psychiatric 
history 
Suicidal 
thoughts 
Suicide 
Attempts 
005-2A Female 35 13 n/a No None None Yes Yes No No 
009-2A Female 40 n/a n/a No None None No Yes No No 
021-2A Male 18 18 n/a No None None No Yes Yes No 
024-2A Female 42 13 23 No MDDR Anxiety NOS, 
Alcohol 
Abuse 
Yes Yes Yes No 
035-2A Female 21 16 19 No MDDR PD with 
agoraphobia 
Yes Yes Yes No 
MDDR; recurrent major depressive disorder, Anxiety NOS; Anxiety disorder not otherwise specified, PD; Panic disorder 
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5.6 Discussion 
The data presented in this chapter report the familiality of psychiatric syndromes and 
symptoms in siblings gene positive for HD. In addition, a description of the psychiatric history 
of siblings gene negative for HD from 5 of the HD families was detailed. The following 
discussion will compare the results found in the present study with previous family studies in 
the HD population as well as discussing possible explanations for the evidence of familial 
clustering of depression, irritability and aggression. Additionally, gene positive/gene negative 
comparative studies of psychiatric syndromes/symptoms in HD will be discussed. 
 
5.6.1 Familiality of psychiatric disorders/symptoms in HD 
The results of this study demonstrate familial influences on the psychiatric presentation of 
HD in a well-characterised sample of siblings gene positive for HD. In particular, evidence for 
familial clustering was found for any lifetime DSM-IV diagnosis (κ = 0.296, p=0.04) and for a 
lifetime DSM-IV diagnosis of any depressive disorder (κ = 0.44, p=0.002). When restricting 
the analysis to the independent sibling pairs, the significant association held for a lifetime 
DSM-IV diagnosis of any depressive disorder (κ = 0.460, p=0.004). There was no evidence for 
familiality of any narrower definitions of lifetime DSM-IV disorders including MDDR and any 
anxiety disorder as well as for suicidal behaviour. 
 
For the lifetime ratings of the PBA items perseverative thinking, apathy, irritability and 
aggression, fair and moderate significant within all possible sibling-pair associations were 
found for the neuropsychiatric symptoms of irritability (κ = 0.341, p=0.013), and aggression 
(κ = 0.418, p=0.003) respectively. These associations remained fair and significant when just 
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the independent siblings were included in the analysis (κ = 0.357, p=0.024 and κ = 0.384, 
p=0.016 respectively). No further significant associations were found, although there was a 
non-significant trend for a lifetime history of perseverative thinking (κ = 0.263, p=0.053) 
when the all possible sibling-pairs were used.  
 
The correlations between siblings for key psychiatric ratings found a moderate and 
significant correlation between all-possible sibling pairs for the frequency and severity of 
depressive episodes as measured by the depression subscale of the BADDS (ICC = 0.360, 
p=0.005). This significance held when just the independent sibling pairs were included in the 
analysis (BADDS-D: ICC = 0.47, p=0.002). The age at onset of psychiatric illness and the level 
of functioning in a depressive episode were not significantly correlated between siblings.  
 
5.6.2 Previous family studies in HD 
These findings support previous HD studies (outlined in section 5.1.1) suggesting that familial 
factors play a role in the presence and course of psychiatric disorders in the HD population. 
Of the few familiality studies that have been previously conducted in the HD population, the 
majority have focused on the more severe psychiatric disorders including psychosis and 
schizophrenia-like symptoms (Lovestone et al., 1996; Tsuang et al., 1998; Tsuang et al., 
2000). Given that there was only one individual in the present sample that had a lifetime 
DSM-IV diagnosis of a psychotic disorder, it was not possible to investigate the familiality of 
psychotic disorders.   
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The findings in this study for familial aggregation of depressive disorders and the frequency 
and severity of depressive episodes builds on Folstein and colleagues (1983) previous work 
in HD families where HD affected relatives of five probands with HD and affective disorder 
were significantly more likely to have affective disorder than the HD relatives of the five 
probands with HD and no affective disorder (Folstein et al., 1983).  
 
Familial factors were also found to influence the presence/absence of irritability and 
aggression in the current study. There have been no previous HD family studies of irritability 
and aggression; however, in the non-HD population, aggression and anti-social behaviour 
have been demonstrated to run in families (Jary and Stewart, 1985; McCartney et al., 1990; 
Rowe et al., 1992; Miles and Carey, 1997). Possible hypotheses to account for these findings 
in the current study that the presence and course of depression, irritability and aggression 
seem to aggregate in certain HD families will be discussed below.  
 
There have been no previous family studies of apathy and perseverative thinking in the HD 
population. The absence of evidence for familiality of apathy and perseverative thinking in 
the current study could be as a result of the fact that these neuropsychiatric symptoms 
(unlike depression and anxiety) seem to correlate with disease progression. A longitudinal 
analysis of an Apathy subscale and Irritability subscale as well as its constituent symptoms 
demonstrated highly significant linear effects for all seven items for the Apathy subscale as 
well as the perseverative preoccupations item of the Irritability subscale, with these 
symptoms increasing in severity over time (Thompson et al., 2012). Therefore, if the 
presence of these symptoms is strongly influenced by the duration of HD, given that siblings 
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were often in different stages of disease (due in part to their different ages), it is perhaps not 
surprising that these symptoms did not appear to correlate between siblings. 
 
A pedigree has been described demonstrating an association between OCD and pathological 
gambling with HD (De Marchi et al., 1998). Although there were no individuals in the current 
study with a lifetime DSM-IV diagnosis of OCD, no evidence was found for family clustering 
of any anxiety disorder.  In the non-HD population, in contrast to the findings in this study, 
family studies have demonstrated a three-fold increased risk in the development of anxiety 
disorders in first-degree relatives of patients with panic disorder (Maier et al., 1993), 
generalised anxiety disorder (GAD) and specific phobias (Hettema et al., 2001), which 
increases to a 17 times increased disease risk for panic disorder with an age at onset before 
20 years (Goldstein et al., 1997). Heritability estimates for anxiety disorders from twin 
studies range from approximately 30% for GAD and simple phobias, to 48% for panic 
disorder and 67% for agoraphobia (Kendler et al., 1999; Hettema et al., 2001). Given that 
only just over a third of the index sample and a quarter of the sibling sample had a lifetime 
diagnosis of an anxiety disorder (38% and 25% respectively), it is possible that the sample 
size of individuals with a history of an anxiety disorder was not large enough to detect any 
familiality (of the 28 sibling pairs that were concordant for a lifetime diagnosis of any anxiety 
disorder, only four of these were concordant for a lifetime diagnosis). Therefore, it would be 
recommended for this study to be replicated in a larger number of sibling pairs with a 
lifetime DSM-IV diagnosis of an anxiety disorder to confirm the findings of this study.  
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5.6.3 Possible explanations for the familiality of psychiatric syndromes/symptoms in 
HD 
 
The aetiology of psychiatric symptoms/syndromes in HD is undoubtedly complex. However, 
the results of this study have provided useful information regarding the fact that the 
presence and course of depression and irritability and aggression appear to run in HD 
families. Given that irritability in HD may sometimes be secondary to the presence of a 
depressive disorder (Craufurd and Snowden, 2014), it is possible that the evidence for 
familiality of irritability/aggression is consequent to the finding that the presence and course 
of depression is also familial in HD. There are several possible hypotheses to account for the 
demonstration of familiality in the current study. 
 
It has been proposed (Folstein et al., 1983) that genetic heterogeneity at the HD locus may 
account for the familiality of psychiatric disorders/illness. However, this theory now seems 
unlikely since the discovery that HD is caused by a CAG repeat expansion in gene IT15 on the 
short arm of chromosome 4 (HD Collaborative Research Group, 1993) and that the 
probability of developing psychiatric symptoms is independent of the CAG repeat length 
(Naarding et al., 2001; Vassos et al., 2008). There may, however, be as yet undetected 
differences in the HD gene, which alter the effects of the CAG repeat expansion (Lovestone 
et al., 1998). 
 
It could be that a gene predisposing to depression, irritability and/or aggression is in linkage 
disequilibrium with the HD gene. However, this has yet to be demonstrated by research and 
it seems increasingly likely the genetic basis of psychiatric disorders is complex and 
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multifactorial and that no single gene is necessary and sufficient for their onset (Lohoff et al., 
2010).  
 
It is possible that shared environmental factors contribute to the familiality of depression, 
irritability and/or aggression in HD. Significant life events and stressors are known 
contributors to the aetiology of depression (Kendler et al., 1999b) and individuals from HD 
families likely experience a great deal of psychological stress. It is possible that some HD 
family environments are more harmful and stressful than others and/or that coping 
mechanisms to deal with the stressful life events differ between families and consequently 
contributes to the familial aggregation of such psychiatric symptoms.    
 
In the non-HD population, genetic effects are considered the most important contributor to 
familial aggregation (Sullivan et al., 2000) and twin studies in depression suggest that shared 
environmental factors are small or non-existent (McGuffin et al., 1996; Sullivan et al., 2000). 
Also, in the non-HD population, it has been proposed that in adults, shared environmental 
factors are negligible in promoting similarity in aggression among family members whereas 
heritability plays a much more significant role (Miles and Carey, 1997). It is therefore also 
possible that in the HD population, the evidence for familial aggregation of depression, 
irritability and aggression could be due to a shared genetic predisposition.  
 
This more plausible explanation is that the presence and course of depression, irritability 
and/or aggression may cluster in families because genes predisposing to psychiatric illness 
are more likely to be expressed in the presence of the HD gene. For example, in the case of 
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depression, if someone is carrying genes that cause hyperactivity of the hypothalamic 
pituitary adrenal (HPA) axis (which is one of the most consistent biological findings of major 
depression in the non-HD population, Pariante and Lightman, 2008) and one of the 
neuropathological changes associated with HD is also hyperactivity of the HPA axis (Heuser 
et al., 1991; Leblhuber et al., 1995; Aziz et al., 2009, and van Duijn et al., 2010), it is possible 
that together, this interaction results in sufficient disruption of the HPA axis to contribute to 
the development of depression, which may not have otherwise occurred had the HD gene 
and its effects not been present. Reduced serotonin signalling could in a similar way account 
for the familiality of irritability/aggression. Low levels of the neurotransmitter serotonin (5-
HT) have been associated with impulse aggression in studies of humans and animals 
(Linnoila and Virkkunen, 1992; Seo et al., 2008). In mouse models of HD, serotonin levels 
have been found to be decreased by up to 50% compared to non-HD mice by age 12 weeks 
(Reynolds et al., 1999). Therefore, if some HD families have a genetic predisposition to 
reduced serotonin signalling and one of the effects of the HD gene is also decreased levels of 
serotonin, then this interaction may result in the emergence of an irritable/aggressive 
phenotype.  
 
To further understand the aetiology of psychiatric disorders in the HD population, the 
inclusion of gene negative siblings from the HD families included in the current study provide 
a useful control sample to correct for the environmental stress experienced by HD family 
members and to assess the importance of the HD gene in the psychopathology of HD. 
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5.6.4 HD gene negative/gene positive comparative studies 
In the present study, of the five gene negative siblings recruited and interviewed, four had a 
psychiatric history but only two individuals had symptoms severe enough to reach a formal 
DSM-IV diagnosis. Both of these individuals had MDDR as their main lifetime psychiatric 
diagnosis with one individual having additional lifetime DSM-IV diagnoses of anxiety disorder 
NOS and alcohol abuse and the other individual had an additional lifetime DSM-IV diagnosis 
of panic disorder with agoraphobia. Also, both individuals had at least one sibling with HD 
who also had a lifetime DSM-IV diagnosis of MDD with a co-morbid anxiety disorder. 
Although, the sample size of five is small, the proportion of the gene negative sample with a 
lifetime DSM-IV disorder is higher than that reported in the European general population 
study, ESEMeD (the European Study of the Epidemiology of Mental Disorders (Alonso et al., 
2004), where the lifetime DSM-IV prevalence rate was 14% for any mood disorder, 13.6% for 
any anxiety disorder and 4.1% for alcohol abuse). It is also useful to compare the prevalence 
rates of all lifetime DSM-IV diagnoses for the gene negative siblings with the gene positive 
siblings (see Table 5.22). 
Table 5.22 Summary of all lifetime DSM-IV diagnoses for the gene positive individuals of the index 
and sibling samples and the gene negative siblings. 
 
 Index sample 
N = 50 
Sibling sample 
N = 40 
Gene negative siblings 
N = 5 
 N (%) 
95% CI 
N (%) 
95% CI 
N (%) 
95% CI 
Any DSM-IV Mood 
Disorder 
28 (56.0) 
42.2-69.8 
26 (65.0) 
50.2-79.8 
2 (40.0) 
0-82.9 
Any DSM-IV Anxiety 
Disorder 
19 (38.0) 
25.6-51.4 
10 (25.0) 
11.6-38.4 
2 (40.0) 
0-82.9 
Alcohol Abuse 3 (6.0) 
0.0-12.6 
3 (7.5) 
0.0-15.7 
1 (20.0) 
0-55.1 
Psychotic Disorder NOS 1 (2.0) 
0.0-5.9 
0 (0.0) 
- 
0 (0.0) 
- 
NOS; not otherwise specified 
Where individuals have more than one lifetime DSM-IV diagnosis, they are included in more than one category 
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The finding in the current study that the lifetime frequency of any anxiety disorder and 
alcohol abuse was higher in the gene negative than the gene positive individuals and that 
the gene positive individuals had a higher lifetime frequency of any mood disorder, 
replicates findings by Julien et al., (2007). In this comprehensive study, Julien and colleagues 
assessed lifetime and current psychiatric histories in 204 individuals at risk for HD (89 were 
HD gene carriers and 115 were non-gene carriers). At the time of their semi-structured 
psychiatric interview, both participants and interviewers were blind to the individuals’ gene 
status. Lifetime rates of DSM-III diagnoses did not differ significantly between the gene 
carriers and non-gene carriers with regards the prevalence of both major psychiatric 
disorders and sub-threshold psychiatric disturbances. However, the non-carriers had a 
higher lifetime prevalence than the gene carriers for any DSM-III anxiety disorder (25% 
versus 17%) and alcohol dependence (6% versus 3%) whereas the gene carriers had a higher 
lifetime prevalence of any affective disorder (23% versus 15%).  
 
Another study (Berrios et al., 2002) using formal diagnostic criteria and where both the 
interviewer and participants were blinded to their genetic status found no significant 
differences between the gene positive and gene negative individuals for the prevalence of 
lifetime psychiatric diagnoses (31.3% and 27.3% respectively). However, a non-significant 
trend towards higher depression scores on the Beck Depression Inventory (BDI) for the gene 
positive group was found. Gene carriers were also found to have significantly higher levels of 
irritability than the non-gene carriers, which supports previous findings suggesting that 
irritability is an important component of the psychiatric presentation in pre-motor manifest 
individuals (Duff et al., 2007). Baxter et al (1992) also found no significant differences for any 
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formal lifetime psychiatric diagnoses between a sample of 52 chorea-free individuals, who 
were either “more” or “less” likely to develop HD. 
 
Other studies that have compared the prevalences of psychiatric disorders/symptoms in 
gene positive and gene negative individuals have looked at current prevalence rates only, 
with equivocal findings (Kirkwood et al., 2002a; Kirkwood et al., 2002b; Soliveri et al., 2002; 
Duff et al., 2007; van Duijn et al., 2008). Some of these studies have found that HD gene 
carriers have significantly higher levels of current psychiatric symptoms (in particular 
irritability and hostility) than non-gene carriers (Kirkwood et al., 2002a; Duff et al., 2007). 
Others have found no significant differences between the gene positive and gene negative 
individuals for current psychiatric syndromes/symptoms (Kirkwood et al., 2002b; Soliveri et 
al., 2002; van Duijn et al., 2008), although in two of these three studies, the gene positive 
individuals had more current DSM-IV psychiatric disorders (van Duijn et al., 2008) and higher 
depression and anxiety levels (Soliveri et al., 2002) than the gene negative individuals.  
 
This methodology, although useful in determining current psychiatric status in at-risk gene 
carriers for HD and whether there are any correlations between psychiatric symptomatology 
and estimated time to disease onset in the gene positive individuals, does not allow for 
conclusions to be drawn as to whether gene positive individuals experience more (or less) 
psychiatric syndromes/symptoms over their lifetime than gene negative individuals. Indeed, 
although the study by Julien et al., (2007) found no significant differences in terms of 
lifetime prevalence of psychiatric disorder, the gene positive individuals did report a higher 
prevalence of current affective symptoms.   
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Furthermore, all of these studies, except the one by van Duijn and colleagues (2008), have 
used rating scales to measure psychiatric symptoms rather than formal diagnostic criteria. 
These scales (such as the BDI, Hamilton rating scale for depression and anxiety, the 
Minnesota Multiphasic Personality Inventory, and the Symptom Checklist 90-Revised) are 
undoubtedly useful for identifying the more subtle psychiatric symptoms observed in HD 
(such as irritability, aggression and apathy). However, given the overlap of certain psychiatric 
symptoms and certain symptoms of HD, it is difficult to be sure that the scales are measuring 
the psychiatric rather than the HD symptomatology. The difficulties associated with using 
depression rating scales in HD will be discussed further in Chapter 6. 
 
Additionally, unlike the current study and those by Soliveri et al (2002) and van Duijn et al 
(2008), all of the other gene positive/gene negative comparative studies discussed here used 
unrelated individuals, which does not control for shared environmental and non-HD shared 
genetic factors in the aetiology of psychiatric disorders/symptoms.  
 
5.6.4.1 Age at onset of psychiatric illness in the gene negative siblings 
An interesting result from the current study was the finding that unlike the gene positive 
siblings, the age of onset of the first psychiatric symptoms and impairment in the gene 
negative siblings was much more similar to that observed in the general population (Alonso 
et al., 2004; Kessler et al., 2005). Whereas the median age at onset for depressive disorders 
and anxiety disorders was 42 and 41 years respectively for the gene positive siblings in the 
index sample and 34 and 37 years respectively for the gene positive siblings in the sibling 
sample (see section 4.4.2), for the two gene negative siblings with lifetime DSM-IV 
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diagnoses, their age at onset of first psychiatric impairment was aged 19 and 23 years and 
for the two other gene negative individuals with a psychiatric history but no lifetime DSM-IV 
diagnosis, their age at onset of first psychiatric symptoms was 13 and 18 years. This is 
suggestive of a role for the HD gene in contributing to the older age at onset of psychiatric 
disorders/symptoms in the HD population.  The possibility that the aetiology of psychiatric 
syndromes/symptoms is different in the HD population whereas HD gene negative 
individuals experience a more “typical” psychiatric illness as seen in the non HD population 
would also fit with the findings in Chapter 4. These results suggested that depression and 
anxiety disorders may be phenotypically different in HD with between 25% and 42% of DSM-
IV lifetime diagnoses of depressive and anxiety disorders comprising NOS diagnoses (see 
section 4.4.1) and also differences in the proportion of individuals experiencing particular 
depressive symptoms as rated on the OPCRIT between the HD MDDR sample and the non-
HD MDRG sample (see section 4.5.7). If the aetiology of psychiatric disorders is different in 
HD, then it would not be surprising for the phenotype to be different too.  
 
The results from the current study demonstrate familial influences on the psychiatric 
presentation of HD (most notably the presence and course of depression and the presence 
of irritability and aggression) in a well-characterised sample of siblings gene positive for HD. 
The finding that psychiatric symptoms may also be frequent in the gene negative siblings 
suggests that the familial influences may be unrelated to the HD gene and not secondary to 
having HD. Other shared genetic and shared environmental factors are likely to contribute, 
which are not necessarily mutually exclusive.  
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5.7 Summary and Limitations 
The data presented in this chapter have built on previous research investigating the 
familiality of psychiatric symptoms in HD by using an increased sample size, a gold standard 
methodology to elicit an accurate psychiatric history and by investigating the full range of 
psychopathology in HD. The main findings of the chapter are summarised below: 
 
Familiality of psychiatric syndromes/symptoms in HD 
 Using the all possible sibling pairs model, between fair and moderate familial 
clustering was found for a lifetime history of any DSM-IV diagnosis (κ = 0.302, 
p=0.031), any depressive disorder, (κ = 0.444, p=0.002) (including the frequency and 
severity of depressive episodes, BADDS-D, ICC=0.36, p=0.005), irritability (κ = 0.341, 
p=0.013) and aggression (κ = 0.418, p=0.003).  
 When using the independent sibling pairs only, the significant associations remained 
for a lifetime history of any depressive disorder (κ = 0.46, p=0.004) (including the 
frequency and severity of depressive episodes, BADDS-D, ICC = 0.47, p=0.002), 
irritability (κ = 0.357, p=0.024), and aggression (κ = 0.384, p=0.016). 
 No significant familiality was found for a lifetime history of anxiety disorders, apathy, 
perseverative thinking or for any other lifetime psychiatric ratings. 
 
Gene negative siblings: 
 Two of the five gene negative siblings had a lifetime history of DSM-IV disorders, with 
both having a main DSM-IV diagnosis of MDDR. 
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 Both of these individuals had at least one sibling with HD who also had a lifetime 
DSM-IV diagnosis. 
 Three of the five individuals had a lifetime history of suicidal ideation but none of the 
sample had ever made a previous attempt at suicide. 
 The age at onset of first psychiatric symptoms and first impairment in the gene 
negative siblings was very similar to the non-HD population and much earlier than 
the gene positive siblings in this study. 
 
Aetiology of psychiatric syndromes/symptoms in HD 
 The aetiology of psychiatric symptoms/syndromes in HD is undoubtedly complex and 
multifactorial. 
 However, it is likely that the familiality observed for depression (and maybe 
irritability and aggression) cannot be entirely explained by the HD gene and that 
other shared genetic factors and shared environmental factors contribute, which are 
not necessarily mutually exclusive. 
 
The results should be interpreted with a degree of caution given the significant findings were 
only moderate levels of association and the 95% confidence intervals were very large. The 
sample size of this study is modest but is nearly twice as large as any known previous sibling 
study in HD. The findings reported here require replication in a larger sample of siblings with 
HD. Alternatively, by focusing on recruiting probands with HD and a specific co-morbid 
psychiatric disorder (perhaps depression given the findings from this study) as well as 
probands and no psychiatric history together with the probands’ first-degree relatives, this 
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methodology may increase the power to detect familial influences on the psychiatric 
phenotype in HD. 
 
Multiple comparisons were not corrected for in view of the small sample sizes and the 
exploratory nature of the study. Nevertheless, when using a more stringent p-value cut-off 
of p<0.01, the moderate within-pair associations for a lifetime DSM-IV diagnosis of any 
depressive disorder (p=0.004) as well as the correlation between sibling pairs for the severity 
and frequency of depressive episodes (BADDS-D, p=0.002) are still classified as significant. 
The small sample size also meant that it was not possible to perform multi-variate analyses 
to investigate, for example, female-female sibling pairs versus male-male sibling pairs and 
early age at psychiatric onset versus later age at psychiatric onset sibling pairs. This would be 
interesting for future studies to investigate further. 
 
Further limitations of the study include the fact that the reporting of all psychiatric history 
was retrospective, which could have led to some inaccurate details being provided. 
However, in order to minimise this, information about an individual’s psychiatric history was 
gathered from as many different sources as possible including: the patients, carer, other 
family members, GP casenotes and HD casenotes. A prospective study, although ideal in 
terms of providing the most reliable information, would take a considerable length of time 
and also would be expensive. 
 
The additional rater was not blinded to the participants’ sibling status when making ratings 
from the vignettes for consensus diagnoses. In future studies, this would be an important 
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factor to address as it could have resulted in psychiatric diagnoses of siblings being biased. 
However, given that consensus ratings were made with the input of a third rater who was 
blinded to the participant’s sibling status where necessary, this should not have led to biased 
ratings being made.  
 
It was particularly difficult to recruit the HD gene negative sample, as many of the siblings 
who were not showing any symptoms of HD did not know their genetic status rendering it 
impossible to assign them to either the gene positive or gene negative sample. Also, 
recruitment of the gene negative sibling was reliant on the gene positive sibling passing on 
information about the study, which limited recruitment of this sample. It is also possible that 
those individuals gene negative for HD that did take part in the study were those that were 
particularly interested in research/mental health research (perhaps due to their own 
psychiatric history) and therefore led to a sample bias. However, these issues regarding 
recruitment of the gene negative individuals are difficult to avoid (Tibben et al., 1992) and 
this group of individuals still provide a very useful sample for better understanding the 
aetiology of psychiatric symptoms of HD.  
 
The evidence that depression, irritability and aggression seem to cluster in HD families has 
implications for clinical practice, research and nosology. It is important that an individual’s 
family history of psychiatric disorders is recorded to identify possible increased risks. Future 
research should focus on confirming the results of this study with the prospect of 
investigating possible genetic risk variants for psychiatric disorders/symptoms in HD. It is 
crucial that when research is carried out on the psychopathology of HD that the scales used 
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are measuring what they are supposed to i.e. the presence of psychiatric symptoms rather 
than the presence of HD symptoms. This is important if research into the psychiatric 
phenotype of HD is to progress and this forms the content of the following chapter, Chapter 
6: The validation of self-report measures of depression in HD. 
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CHAPTER 6: VALIDATION OF SELF-REPORT MEASURES OF 
DEPRESSION IN HD 
 
This chapter will discuss the use of self-report depression rating scales in HD. It will outline 
the rationale for the study and the recruitment, methodology and results concerned with 
validating self-report measures of depression in HD. This will be followed by a discussion of 
the results obtained and their implications.  
 
6.1 Introduction 
The data presented in chapter 4 confirm the association between HD and psychiatric 
disorders, of which depressive disorders are most prevalent (Julien et al., 2007; van Duijn et 
al., 2007; Reedeker et al., 2012). It is also apparent that the reported prevalence rates of 
depression in HD vary greatly due mainly to methodological differences including: the use of 
different rating scales, varying definitions of depression (depressed mood, depressive 
symptoms or depressive disorder), the use of different time scales (point, period or lifetime 
prevalence rates), and study populations at different stages of disease. Given that 
depression is common in HD, it is significantly associated with reduced quality of life (Ho et 
al., 2009) and functional decline (Marder et al., 2000) yet is relatively treatable, it is 
important that depression is accurately measured in this population. 
 
Ideally, depressive disorder is diagnosed according to the gold standard that is the criteria of 
the major classification systems, the Diagnostic and Statistical Manual, Fifth Edition (DSM-V) 
and the International Classification of Diseases, Tenth Edition (ICD-10). These formal 
diagnoses are best accomplished by a comprehensive clinical interview and examination. 
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However, this thorough, yet time consuming and expensive method is often not feasible in 
clinical practice and research. Consequently, self-report rating scales have become a 
popular, cheap and convenient alternative method for measuring the clinical construct of 
depression and have been used for screening purposes, diagnostic purposes as well as for 
measuring change in severity of depression over time. 
 
There are over 30 scales in the English language that have been designed to assess the 
presence of depression (Snaith, 1993). Depression rating scales are often selected arbitrarily 
and administered on the assumption that they all measure the same symptoms of 
depressive disorder. However, some scales place greater emphasis on particular areas of 
psychopathology than others, necessitating careful consideration of the most valid rating 
scale for a particular population. This is particularly the case in HD, where a diagnosis of 
depression is complicated greatly by considerable overlap between the core symptoms of 
depression and core symptoms of HD. Symptoms that are part of the operational diagnostic 
criteria for depressive disorder such as decreased interest or pleasure (Levy et al., 1998; 
Naarding et al., 2009), fatigue or loss of energy, significant weight change or change in 
appetite (Kremer, 2002; Aziz et al., 2008), change in sleep (Hansotia, 1985; Silvestri et al., 
1995), change in activity (Starkstein et al., 1992; Dubois et al., 1998) and reduced 
concentration or indecisiveness (Sprengelmeyer et al., 1995) can all be observed in non-
depressed HD patients. 
 
Self-report by HD patients is also complicated by dysarthria and progressive cognitive 
impairment, with one study demonstrating that inter-rater agreement between HD patients 
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and caregivers for the presence of depressed mood was highest for those patients whose 
cognition was most intact (Chaterjee et al., 2005). Additionally, HD patients have been 
demonstrated to persistently and selectively underestimate their degree of executive 
dysfunction by 26% (Ho et al., 2006). 
 
Another important consideration when measuring depression in HD patients is the cognitive 
complexity of scales (measured in terms of length of items, readability, linguistic problems 
related to syntax and structure, and number of items) (Shumway et al., 2004). Self-report 
measures of depression differ in terms of their cognitive complexity, and in HD patients with 
cognitive difficulties the more complex scales are likely to limit comprehension and reduce 
measurement accuracy (Shumway et al., 2004). However, self-report measures of 
depression are important and widely-used tools in research and practice and it is therefore 
necessary that such measures of depression are validated in a sample of the target 
population in which they are to be used.  
  
As yet, depression rating scales have not been validated in patients with HD even though 
they have been used in various research and clinical settings. For example, the Beck 
Depression Inventory has been used in many studies (Berrios et al., 2002; Holl et al., 2010; 
Downing et al., 2012; Smith et al., 2012; Epping et al., 2013), including the European 
Huntington’s Disease Network REGISTRY study, a longitudinal, multi-centre, multinational 
observational study with more than 10 000 participants enrolled (Handley et al., 2011). 
However, without sensitivity (patients with depression who test positive) and specificity 
(patients without depression who test negative) being calculated for any depression rating 
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scale in the HD population, it is unknown whether they can be utilised as accurate measures 
of the presence/absence of depression in this population.  Consequently, the aim of this 
study is to assess the concurrent validity of three self-report measures of depression in a 
sample of individuals with manifest HD against a gold-standard interview measure and ICD-
10 operational diagnostic criteria. 
 
6.2 Methods 
6.2.1 Selection of scales 
After a thorough review of the literature, the rating scales were selected for this study based 
on the following criteria: i) their current use in HD or other neurological disorders, and ii) 
their potential utility in HD due to their item content (that is minimising the overlap between 
HD and depressive symptoms). Therefore, this study evaluated the validity of the Beck 
Depression Inventory-II, BDI-II (Beck et al., 1996), the Hospital Anxiety and Depression Scale, 
HADS (Zigmond and Snaith, 1983) and the Depression Intensity Scale Circles, DISCs (Turner-
Stokes et al., 2005) in measuring depression presence or absence in HD when compared with 
the Schedules for Clinical Assessment in Neuropsychiatry, SCAN (Wing et al., 1990).  
 
The BDI is a 21 item self-report rating scale that was designed to provide a quantitative 
assessment of the severity of depression in the past week (Beck et al., 1961). Each item is 
scored 0-3, with a total score range from 0-63. The following cut-off scores have been 
suggested to interpret the BDI (Beck et al., 1961): minimal depression = 0-9; mild depression 
= 10-18, moderate depression = 19-29 and severe depression = 30-63. It is one of the most 
widely used self-report measures for depression in clinical practice and was the initial 
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measure of depression used by the European Huntington’s Disease REGISTRY study. The BDI 
has been validated for use as a screening instrument for depression in patients with 
Parkinson’s Disease (Leentjens et al., 2000), multiple sclerosis (Sullivan et al., 1995) and in 
stroke patients (Aben et al., 2002). It has high internal consistency and high test-retest 
reliability in a range of patient groups (Beck et al., 1988). The revised version of the BDI, the 
BDI-II (Beck et al., 1996, Appendix Biii pg. 264), was developed in response to the publication 
of the DSM-IV. This resulted in the BDI-II introducing new items relating to agitation, 
concentration difficulties and loss of energy, which replaced items in the BDI concerning 
hypochondria, changes in body image and difficulty working. Additionally, the items 
involving loss of sleep and appetite were altered to reflect any change in appetite and sleep. 
Consequently, the BDI-II rather than the BDI was selected to be validated in this study. Like 
the BDI, each item is scored 0-3 to give a total range from 0-63. However, the BDI-II is 
designed to assess the presence and severity of depression in the past two weeks and has 
the following standardised cut-offs (Beck et al., 1996): minimal depression = 0-13; mild 
depression = 14-19, moderate depression = 20-28 and severe depression = 29-63. The BDI-II 
contains several items relating to somatic symptoms and has high overall cognitive 
complexity (Shumway et al., 2004).  
 
The HADS is a 14 item self-administered rating scale that consists of two sub-scales assessing 
the presence and severity of depression and anxiety (seven items for each subscale) over the 
past week (Zigmond and Snaith, 1983, Appendix Biv pg. 269). Each item is scored 0-3 with 
the total score being the sum of the 14 items (range from 0-42) and for each subscale, the 
score is the sum of the respective seven items (range from 0-21). In the authors’ original 
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study, Zigmond and Snaith (1983) recommended a score of 8 or more on each subscale to 
indicate possible depression/anxiety. The scale was designed to diminish the effects of 
somatic illness and consequently does not include physical or cognitive symptoms, although 
it also does not include the more severe symptoms of depression such as suicidal ideation. 
The depressive symptoms instead focus on the emotional experiences of depression and 
anhedonia (Zigmond and Snaith, 1983). The HADS has been validated as a useful screening 
instrument for depression in stroke patients (Aben et al., 2002) and in chronic fatigue 
syndrome (Henderson and Tannock, 2005). It has good internal consistency and test-retest 
reliability (Mykletun et al., 2001) and its overall cognitive complexity was rated as medium 
(Shumway et al., 2004). Both the total HADS as a global measure of mood as well as just the 
depression sub-scale of the HADS were validated in this study. 
 
The DISCs is a simple screening and severity measure for depression in patients with 
cognitive or communicative deficits (Turner-Stokes et al., 2005, Appendix Bv pg. 272). It is a 
6-point graphic rating scale (score range 0-5) portraying six circles with an increasing 
proportion of grey shading, which is designed to improve accuracy of assessment of mood in 
patients who may find more cognitively complex assessment tools difficult to complete. It 
assesses someone’s current mood state by asking them how sad or depressed they feel 
today and a cut-off of 2 or more is used to identify cases of depression. The DISCs has been 
validated as a simple screening tool for depression in patients with cognitive or 
communicative deficits following acquired brain injury (Turner-Stokes et al., 2005). It also 
has excellent test-retest reliability (Turner-Stokes et al., 2005). 
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6.2.2. Participants and setting 
Fifty patients with a clinical and genetic diagnosis of HD were recruited from the HD service, 
Birmingham, UK. All suitable participants received information about the research project 
(Appendix Bi, pg. 258) during their routine HD clinic appointment and those interested in 
taking part opted into the study by returning a reply to slip to JDS (Appendix Bi, pg. 260). 
Patients were excluded from the study if they were sufficiently cognitively impaired to 
prevent them from giving informed consent, were less than 18 years of age or were not 
fluent in English. Participants gave written informed consent for the study (Appendix Bi, pg. 
261), which was approved by the Solihull Local Research Ethics Committee (reference: 
06/Q2706/38) and their GP was informed of their participation in the study (Appendix Bi, pg. 
262). All participants were assessed at their homes in a single session lasting approximately 
an hour and a half.  
 
6.2.3. Demographic information 
Information was obtained on a variety of demographic variables (see Appendix Bii, pg. 263), 
including: date of birth, gender, ethnicity, years of education, and age at HD motor symptom 
onset. 
 
6.2.4 Neuropsychiatric assessment 
Psychiatric assessment was performed using section 6 (depressed mood and ideation), 
section 7 (thinking and concentration, energy and interests) and section 8 (bodily functions) 
of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN, Wing et al., 1990). The 
SCAN is a widely used semi-structured interview aimed at assessing, measuring and 
classifying the psychopathology associated with major psychiatric disorders for DSM-IV or 
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ICD-10 diagnoses (see section 3.4.5.2). For the purpose of this study, the presence of current 
depressive disorder was made according to the standardised operational diagnostic criteria 
of the ICD-10, which was considered the gold standard for this study. Structured vignettes 
were written for each participant using information obtained from the psychiatric interview 
and all ratings were made independently by JDS and KGS to ensure that consensus was 
reached. Participants also completed the BDI-II, HADS and DISCs by themselves during the 
home visit. 
 
6.2.5. Statistical analysis 
The sensitivity, specificity, positive predictive values (PPV) and negative predictive values 
(NPV) were calculated using the recommended cut-off points for each scale as well as for all 
the cut-offs in the mid-range of the scales in order to determine the optimal cut-off for the 
scales. The optimal cut-off score is the point at which the scale best discriminates ‘caseness’ 
in the population. This is determined by the cut-off with the maximal sum of sensitivity and 
specificity.  Receiver Operating Characteristics (ROC) curves were obtained by plotting the 
sensitivity against 1-specificity for each score on each depression rating scale. The “area 
under the curve” (AUC) provides an indication of the discriminative property of a scale and 
this was also calculated for each rating scale. The analyses were conducted using SPSS 
version 14.0 (SPSS Inc, 2005). 
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6.3 Results 
6.3.1 Demographic characteristics 
Fifty patients with motor manifest HD participated in this study and Table 6.1 summarises 
the demographic characteristics of the sample. The mean age of the sample was 51.2 years; 
approximately half of the participants were female (48%); the mean number of years of 
education was 12.26 years; and, all of the participants were UK/Eire Caucasian (100%). The 
mean age at disease onset was 44.12 years and the mean number of years since disease 
onset was 6.78 years.  
Table 6.1 Demographic characteristics of the 50 participants 
Demographics 
 
Descriptives and Percentages 
N=50 
Age (years)  
Mean (95% CI) 51.2 (48.3-54.1) 
Standard Deviation 10.4 
Range 22-67 
  
Education (years)  
Mean (95% CI) 12.3 (11.8-12.8) 
Standard Deviation 1.8 
Range 9-17 
  
Age at disease onset (years)  
Mean (95% CI) 44.1 (41.2-47.0) 
Standard Deviation 10.6 
Range 19-62 
  
Duration of illness (years)  
Mean (95% CI) 6.8 (5.8-7.9) 
Standard Deviation 3.8 
Range 2-14 
  
Female N (%) 24 (48.0) 
  
Ethnic Origin N (%)  
UK/Eire Caucasian 50 (100.0) 
CI: Confidence Interval 
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6.3.2 Performance of the depression rating scales 
Using the SCAN, six out of 50 patients met ICD-10 criteria for current mild depressive 
disorder, five met criteria for current moderate depressive disorder and one met criteria for 
current severe depressive disorder to give an overall prevalence of 24% (12/50). The average 
and range of scores obtained on each depression rating scale for the depressed and non-
depressed patients are displayed in Table 6.2. As expected, the depression rating scales 
resulted in more cases of depression than formal diagnoses obtained from the SCAN (see 
Table 6.3).  
 
Table 6.2. Depression rating scales: properties and basic statistics 
Depression 
rating scale 
Range Items Depressed patients 
(N=12) 
Mean (S.D., range) 
Non-depressed patients 
(N=38) 
Mean (S.D., range) 
BDI-II 0-63 21 26.08 (13.97, 11-58) 8.84 (8.89, 0-29) 
HADS 0-42 14 21.25 (6.90, 14-36) 7.55 (7.82, 0-32) 
HADS-D 0-21 7 11.17(2.72, 7-17) 3.50 (3.94, 0-13) 
DISCs 0-5 1 2.83 (0.83, 1-4) 0.79 (0.81, 0-3) 
 
 
Using the ICD-10 diagnoses as the gold standard, sensitivity, specificity, positive and negative 
predictive values and the areas under the curves were calculated for the standard cut-off 
scores for the BDI-II, HADS, HADS-D and DISCs (Table 6.3).  The sensitivity, specificity, 
positive and negative predictive values were also calculated for all cut-off scores in the mid-
range for each depression rating scale (Tables 6.4, 6.5, 6.6 and 6.7). Figure 6.1 displays these 
results in the form of a ROC curve. 
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Table 6.3. Performance of the depression rating scales using standard cut-offs. 
Depression 
measure 
Cut-off Depression 
cases 
AUC Sensitivity Specificity PPV  NPV  
SCAN  12 (24%) Gold Standard 
BDI-II 13/14 21 (42%) 0.856 0.83 0.71 0.48 0.93 
HADS 14/15 16 (32%) 0.900 0.75 0.82 0.56 0.91 
HADS-D 7/8 16 (32%) 0.923 0.92 0.87 0.69 0.97 
DISCs 1/2  18 (36%) 0.943 0.92 0.82 0.61 0.97 
AUC – Area Under Curve, PPV – Positive Predictive Value, NPV – Negative Predictive Value  
 
Fig 6.1 Receiver Operating Characteristics (ROC) curves for the depression rating scales 
 
6.3.2.1. BDI-II 
From the ROC curve, it is clear to see that with the lowest AUC of 0.856, the BDI-II 
performed least well in discriminating between depressed and non-depressed patients. 
Although the standard cut-off for the BDI-II is 13/14, this study found an optimal cut off of 
10/11 (sensitivity 1.00, specificity 0.66) for the BDI-II, where a score of 11 or more is 
indicative of depression presence and a score of 10 or less indicates the absence of 
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depression (see Table 6.4). At this optimal cut-off with perfect sensitivity and NPV, the BDI-II 
makes an excellent screening measure for depression. However, this is at a cost to the 
specificity of the scale, which means that many non-depressed patients are misdiagnosed by 
the BDI-II as having depression. For diagnostic purposes, a high specificity and PPV are 
required and with the PPV never exceeding 0.50, the BDI-II does not meet this criterion for 
the HD population. 
 
Table 6.4. Sensitivity, specificity, positive and negative predictive values at different cut-off 
scores for the BDI-II. 
Cut-off 10/11 11/12 12/13 13/14* 14/15 15/16 16/17 17/18 18/19 
Sensitivity 1.00 0.92 0.83 0.83 0.75 0.58 0.58 0.58 0.58 
Specificity 0.66 0.68 0.71 0.71 0.76 0.76 0.76 0.76 0.76 
PPV 0.48 0.48 0.48 0.48 0.50 0.44 0.44 0.44 0.44 
NPV 1.00 0.96 0.93 0.93 0.91 0.85 0.85 0.85 0.85 
BDI-II, Beck Depression Inventory-II; PPV, positive predictive value; NPV, negative predictive value. 
--Maximum sum of sensitivity and specificity 
*Standard cut-off of BDI-II 
 
6.3.2.2 HADS 
Overall, the HADS as a global measure of mood performed better than the BDI-II with an 
AUC of 0.900. At the standard cut-off of 14/15 (sensitivity 0.75, specificity 0.82), the 
sensitivity of the scale was not as high as any of the other measures (see Table 6.5). 
However, at the optimal cut-off of 1 point lower at 13/14, the sensitivity becomes perfect 
whilst retaining good specificity (sensitivity 1.00, specificity 0.79). Like the BDI-II, the HADS 
makes a much better screening than diagnostic measure. Although at higher cut-off scores 
the specificity improves, the PPV remains low and the sensitivity drops off markedly. 
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Table 6.5. Sensitivity, specificity, positive and negative predictive values at different cut-off 
scores for the HADS. 
Cut-off 13/14 14/15* 15/16 16/17 17/18 18/19 19/20 20/21 
Sensitivity 1.00 0.75 0.67 0.67 0.67 0.58 0.50 0.50 
Specificity 0.79 0.82 0.84 0.86 0.86 0.86 0.92 0.92 
PPV 0.60 0.56 0.57 0.62 0.62 0.58 0.67 0.67 
NPV 1.00 0.91 0.89 0.89 0.89 0.86 0.85 0.85 
HADS, Hospital Anxiety and Depression Scale; PPV, positive predictive value; NPV, negative predictive value.  
--Maximum sum of sensitivity and specificity 
*Standard cut-off of HADS 
 
 
6.3.2.3. HADS-D 
When only the depression subscale of the HADS is analysed, the self-report measure 
performs even better at discriminating between depressed and non-depressed patients, 
with an AUC of 0.923. At the standard cut-off of 7/8 (sensitivity 0.92, specificity 0.87), it is 
the best scale at discriminating ‘caseness’ in the population with both high sensitivity and 
specificity (see Table 6.6). The optimal cut-off, however is 6/7 where the sensitivity increases 
to the maximum of 1.00 and the specificity remains good at 0.82. The HADS-D only reaches 
the specificity and PPV required for a diagnostic test at a cut-off 12/13. This is however, at 
the cost of a very low sensitivity (0.33), meaning that many depressed patients would be 
missed. 
Table 6.6. Sensitivity, specificity, positive and negative predictive values at different cut-off 
scores for the HADS-D. 
 
Cut-off 6/7 7/8* 8/9 9/10 10/11 11/12 12/13 13/14 
Sensitivity 1.00 0.92 0.92 0.58 0.58 0.50 0.33 0.08 
Specificity 0.82 0.87 0.87 0.87 0.90 0.92 0.97 1.00 
PPV 0.63 0.69 0.69 0.58 0.64 0.67 0.80 1.00 
NPV 1.00 0.97 0.97 0.87 0.87 0.85 0.82 0.78 
HADS-D, Hospital Anxiety and Depression Scale – depression section; PPV, positive predictive value; NPV, negative 
predictive value. 
 --Maximum sum of sensitivity and specificity, *Standard cut-off of HADS-D 
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6.3.2.4 DISCs 
With an AUC of 0.943, the DISCs performed best overall in detecting depression in HD 
patients, although this difference is unlikely to be clinically relevant. The standard cut-off of 
1/2 (sensitivity 0.92, specificity 0.82) was also the optimal cut-off (see Table 6.7). At a cut-off 
at 2/3 (sensitivity 0.75, specificity 0.97), the PPV is also high at 0.90, which would mean that 
the DISCs is the only self-report rating scale that could be considered a useful screening and 
diagnostic measure.   
Table 6.7. Sensitivity, specificity, positive and negative predictive values at different cut-off 
scores for the DISCs. 
Cut-off 0/1 1/2* 2/3 3/4 
Sensitivity 1.00 0.92 0.75 0.17 
Specificity 0.42 0.82 0.97 1.00 
PPV 0.35 0.61 0.90 1.00 
NPV 1.00 0.97 0.93 0.79 
DISCs, Depression Intensity Scale Circles; PPV, positive predictive value; NPV, negative predictive value.  
--Maximum sum of sensitivity and specificity 
* Standard cut-off of DISCs 
 
6.4. Discussion 
It is important in terms of clinical management and research that unpleasant affective states 
as symptoms can be distinguished from depression as a clinical syndrome. In this way, self-
report rating scales play an extremely important role as quick, cheap and easy to use 
measures of depression. However, in HD, diagnostic distinction can be confounded by the 
presence of somatic complaints as well as cognitive impairment and dysarthria. This was the 
first study to date that has validated self-report rating scales for depression in the HD 
population, despite their common use in research and clinical practice. 
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Of all the self-report rating scales validated in this study, the BDI-II was the one with highest 
overall cognitive complexity and contained the greatest number of items relating to somatic 
symptoms. The fact that the BDI-II was found to be the least suitable scale for discriminating 
between depressed and non-depressed HD patients confirms the criticism of the use of such 
rating scales in the HD population. However, it is possible that the use of the BDI-II with 
certain items of the scale removed would improve the psychometric properties of the scale. 
For example, a Rasch analysis of the BDI-II in stroke survivors found that the removal of five 
items from the original 21 item scale that did not demonstrate acceptable goodness-of-fit to 
the Rasch model (items 10 (crying), 16 (changes in sleeping pattern), 17 (irritability), 18 
(changes in appetite) and 21 (loss of interest in sex)), improved the reliability and validity of 
the scale (Lerdal et al., 2014). In a neurorehabilitation sample, a Rasch analysis of the BDI-II 
resulted in three items being deleted from the original BDI-II (item 16 (changes in sleeping 
pattern), 18 (changes in appetite) and 21 (loss of interest in sex) in order for the scale to 
have good overall fit to the Rasch model (Siegert et al., 2010). 
 
It was anticipated that the HADS would be a good instrument at detecting depression in HD 
patients, owing to the fact it was designed for use with physically ill patients and omits 
somatic items. The results discussed in an earlier chapter (see section 4.5.7) demonstrated 
that HD individuals with MDDR were significantly less likely to experience certain somatic 
symptoms (diurnal variation, increased appetite and middle insomnia) as part of their 
depressive symptomatology when compared to a non-HD population sample with MDDR. 
These results suggest that such somatic symptoms common to both HD and depressive 
disorder may be more associated with HD symptomatology than depression and therefore, 
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the HADS, which excludes these items may have good face validity in the HD population. 
However, there is still one item on the scale (item 8, “I feel as if I am slowed down”), which 
could relate to the commonly observed symptom of bradykinesia in HD and result in inflated 
scores. Additionally, whereas the BDI-II is more reflective of operational diagnostic criteria 
for major depressive disorder (MDD), the HADS focuses on the depressive symptoms of 
mood and anhedonia and consequently omits two core items of MDD (suicidal ideation and 
excessive and inappropriate guilt). However, the HADS performed better than the BDI-II at 
discriminating depressed from non-depressed HD patients as shown by the larger AUC and 
without including the anxiety subscale, the sensitivity and specificity of the scale were 
further improved.  
 
The purpose of including the DISCs in this study was to use a simple, graded scale that may 
be more accessible for those patients with more severe cognitive and/or communicative 
deficits. The results confirm that a score ≥2 accurately predicted ‘cases’ of depression 
according to ICD-10 criteria.  Perhaps surprisingly, the DISCs had the highest overall AUC and 
was the only scale that performed well as both a screening and diagnostic instrument.  
 
The results of this study compare favourably to research on the use of depression rating 
scales in other neurological disorders with associated somatic symptoms. Leentjens et al. 
(2000) concluded that the psychometric properties of the BDI are not ideal for individuals 
with Parkinson’s disease, which also holds true for the Huntington’s population. The 
discriminant property of the BDI-II in the current study was found to be very similar to that 
determined by Leentjens et al (2000) in their evaluation of the BDI in Parkinson’s Disease 
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patients, with AUCs of 0.856 and 0.857 respectively. Sullivan and colleagues (1995) 
concluded that the BDI should be used with caution in individuals with MS due to high false 
negative rates. Kang and colleagues (2013) recommended the use of the HADS over the BDI 
in screening for depression in a post-stroke population.  
 
The optimal cut-off scores in this study for the BDI-II and HADS-D were lower than the 
recommended cut-off scores for primary care patients with major depression (Beck et al., 
1996; Zigmond and Snaith, 1983). This reflects findings in other studies of patient 
populations with somatic symptoms. For example, Aben et al (2002) and Kang et al (2013) in 
screening for depression in post-stroke patients, found the HADS-D to be optimal at a cut-off 
of 6/7. In patients with Parkinson’s Disease, for screening purposes, a cut-off on the BDI of 
8/9 (Leentjens et al., 2000) and 6/7 on the BDI-II (Williams et al., 2012) have been 
recommended.  
 
The predictive validity of the DISCs was even greater in the HD population than in patients 
with acquired brain injury (ABI), the population for which it was initially designed (HD: 
sensitivity 0.92, specificity 0.82; ABI: sensitivity 0.60, specificity 0.87, Turner-Stokes et al., 
2005). Few studies have been carried out on the reliability and validity of the DISCs; 
however, a single-item screening question has been demonstrated to be as valid as the 
HADS in screening for depression in individuals with chronic back pain (Reme et al., 2004). 
From the results obtained in this study, it would be useful for the DISCs to be validated in 
other patient groups such as people with Parkinson’s disease.  
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With the use of any rating scale, there will always be a trade-off between sensitivity and 
specificity. The optimal cut-off point of a scale should depend on the purpose for which it is 
to be utilised. Given the evidence that depression can exacerbate functional decline and 
reduce quality of life in HD patients, it could be argued that it would be better to choose a 
lower cut-off where most ‘cases’ can be identified even at the cost of a relevant number of 
false positives. Additionally, because self-report rating scales give a dimensional rather than 
categorical representation of mood, they should be used as indicators of a probable 
psychiatric ‘case’ rather than giving a definitive diagnosis. This is confirmed by the findings 
from this study as all scales performed much better as screening than diagnostic measures.  
 
There will also be various settings such as clinical trials where a scale is needed to detect 
changes in severity of depression over time.  Such as scale needs to contain some items that 
are unstable over time and are sensitive to mild, moderate and severe depression (Kellner, 
1992). The DISCs is unlikely to be suitable at detecting change over time given that it only 
has a score range of 0-5, the HADS does not contain items that accurately assesses severe 
depression and the BDI-II measures attitudes and cognitions, which are typically stable over 
time among depressed patients (Cusin et al., 2010). For this purpose, the development of a 
scale using an iterative process whereby various interview questions are tested in the target 
population, and the data obtained then used to determine which items to test further and 
which to discard, should allow for the development of a valid rating scale able to detect 
changes in symptom severity. This is the purpose of the Functional Rating Scale Taskforce for 
pre-Huntington’s Disease (FuRST-pHD) who are in the process of developing a rating scale 
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aimed at assessing depression, anxiety and apathy in prodromal and early HD (Vaccarino et 
al., 2011).  
 
Higher rates of current depression in HD patients than would be expected in the general 
population were also reported in this study. This is in keeping with the findings in chapter 4 
(see Table 4.4 in section 4.4.1.2) where the lifetime prevalence rate for DSM-IV major 
depressive disorder was up to three times as high as those reported in general population 
studies (index sample=42%, sibling sample=42.5%, National Comorbidity Survey Replication, 
NCS-R=16.9% (Kessler et al., 2005) and the European Study of the Epidemiology of Mental 
Disorders, ESEMeD=12.8% (Alonso et al., 2004)). Sixty percent of participants in this HD 
sample reported themselves as having current feelings of low mood, although only 24% 
fulfilled the criteria for formal ICD-10 diagnosis. In the 2007, Adult Psychiatric Morbidity 
Survey in the UK (see section 4.6.1), only 2.3% of the sample met ICD-10 diagnostic criteria 
for a current depressive episode (a further 9.0% had a current ICD-10 diagnosis of a mixed 
anxiety and depressive disorder). However, the figure of 24% is comparable to other point 
prevalence rates of major depression in HD. Caine and Shoulson (1983) reported that 20.8% 
of their small sample of HD patients had current depression according to DSM-III (a further 
25.0% were experiencing dysthymia), Julien et al (2007) also using DSM-III found a current 
prevalence rate of 15% for major depression in a sample of pre-symptomatic individuals and 
van Duijn et al (2008) reported a DSM-IV 12-month prevalence rate of 17.9%  for major 
depressive disorder in a sample of 140 mutation carriers. 
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6.5. Summary and limitations 
This chapter has discussed the validation of self-report depression rating scales in HD and 
provides evidence that the somatic items of depression add little value to the differential 
diagnosis of depression in HD. The main findings are as follows: 
 The depression subscale of the HADS with a high sensitivity and specificity at a cut-off 
of 6/7 was the most suitable scale for discriminating between depressed and non-
depressed patients in the HD sample. 
 The BDI-II performed the least satisfactorily of all scales at detecting “cases” of 
depression in the HD sample but if the low specificity of the scale can be accepted, 
then a cut off of 10/11 should be used. 
 The high predictive validity of the DISCs using a cut-off of 1/2 makes this an ideal 
instrument to use in HD patients with more complex cognitive and communicative 
difficulties. 
 The self-report rating scales should not be used as diagnostic instruments for 
depression and following screening, the identification of a possible ‘case’ requires 
further investigation.   
 
Limitations of the study arise from the modest sample size and it is therefore important for 
the findings to be replicated with a larger sample size, which would also enable the sample 
to be stratified by severity of HD and depression. The majority of depressed patients had 
either mild or moderate depression and consequently the scales were not so rigorously 
tested in patients with severe depression. As already indicated, the HADS does not include 
items associated with more severe depression including suicidal ideation, somatic symptoms 
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and psychotic symptoms and therefore may prove to have lower validity in patients who are 
severely depressed.   
 
Additionally, those patients with severe cognitive deficits were excluded from this study, 
owing to their presumed inability to consistently respond meaningfully and reliably, thus 
limiting the generalisability of these results to the entire HD population. HD individuals with 
depression may be under-represented in this sample given that very depressed individuals 
are less likely to be invited to take part in research and all participants were registered with 
the HD service in Birmingham and consequently, any patients presenting with low mood are 
likely to be followed up closely with intervention prescribed as necessary. Some may also 
criticise the use of ICD-10 diagnoses obtained from the SCAN interview as a gold standard, 
owing to the fact that five of the criteria for depression concern somatic items (decreased 
energy, diminished ability to think or concentrate, change in psychomotor activity, sleep 
disturbance and change in appetite). However, the use of a semi-structured interview 
allowed for the depressive symptoms only to be rated if they were clearly associated with 
low mood rather than the temporal course of HD (see section 4.6.3.5), which may have led 
to underreporting of certain items and therefore possible underdiagnosis of depression in 
this sample.  
 
The sample consisted entirely of HD symptomatic individuals. However, it is possible that in 
pre-symptomatic individuals, the absence of motor symptoms and fewer cognitive 
difficulties may be less likely to result in spuriously raised scores on the scales. Therefore, 
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self-report depression rating scales also need to be validated in the pre-symptomatic HD 
population. 
 
The following chapter (chapter 7) is the final chapter. It will summarise the key findings of 
the studies, discuss the limitations and implications of these results and make suggestions 
for further research. 
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CHAPTER 7: MAIN FINDINGS AND FINAL CONCLUSIONS 
This final chapter will summarise the main findings and final conclusions of the investigations 
into the psychiatric phenotype of Huntington’s disease (HD) presented in this thesis. The 
implications of the findings and limitations of the work will then be discussed followed by 
suggestions for future research. 
 
7.1 Main findings  
Psychiatric symptoms have long been recognised as part of the clinical phenotype of 
Huntington’s disease (Huntington, 1872). Given the presence of neuropsychiatric symptoms 
is known to cause more distress to both patients and caregivers than the motor and 
cognitive aspects of the disease (Craufurd and Snowden, 2002) and they contribute to 
reduced quality of life (Ho et al., 2009) as well as functional (Hamilton et al., 2003) and 
cognitive decline (Nehl et al., 2001; Smith et al., 2012), further investigation into the 
aetiology of psychiatric symptoms in HD is warranted. 
 
Previous studies investigating possible associations between the behavioural changes in HD 
and the HD gene have demonstrated no relationship between the presence and severity of 
psychiatric symptoms and the length of the trinucleotide repeat (Weigell-Weber et al., 1996; 
Naarding et al., 2001; Vassos et al., 2007). However, other studies have demonstrated 
clustering of psychiatric symptoms/syndromes in some HD families, suggesting that familial 
factors may influence the psychiatric phenotype in HD (Heathfield, 1967; Folstein et al., 
1983; Lovestone et al., 1996; Tsuang et al., 1998; De Marchi et al., 1998; Tsuang et al., 2000; 
Correa et al., 2006). Nevertheless, these previous studies used small sample sizes (often only 
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describing one or two family pedigrees), have had methodological problems and have mainly 
focused on the familial association between HD and psychosis. These limitations led to the 
two main aims of this thesis as well as three secondary aims, and the main findings from this 
study associated with these aims are summarised below. 
 
7.1.1 Main Aims 
7.1.1.1 First Aim 
To determine whether a broad range of psychiatric syndromes and symptoms aggregate in 
families affected with HD by conducting a systematic, standardised psychiatric assessment 
on a large sample of sibling pairs with HD. 
 
This thesis reported on the familiality of psychiatric syndromes and symptoms in siblings 
gene positive for HD using gold-standard methodology and the largest sample to date. 
Evidence was found for familial aggregation of the presence of depressive disorders, 
irritability and aggression as well as the frequency and severity of depressive episodes. 
Previous familiality studies in HD have focused on psychotic-like symptoms, which was not 
possible in the current study as only one individual had a lifetime diagnosis of a psychotic 
disorder. The results from this study support the single previous study published over 30 
years ago suggesting that affective disorders may cluster in some HD families (Folstein et al., 
1983) and this is the first study to report that familial factors may influence the presence of 
irritability and aggression in HD.  
 
No evidence of familiality was found for anxiety disorders, suicidal behaviour, apathy, 
perseverative thinking, age at onset of psychiatric symptoms, or level of functioning in a 
depressive episode. 
206 
 
7.1.1.2 Second Aim 
To further improve current understanding of the relative role the HD gene, other genetic 
factors and psychosocial factors may play in explaining the increased prevalence of 
psychiatric symptoms in HD. This will be achieved by administering the psychiatric 
assessment to unaffected siblings who have had a negative HD genetic test. 
 
Of the five gene negative siblings from five different families who participated in this study, 
all with a psychiatric history in their HD relatives, four had experienced psychiatric 
symptoms, three had a history of suicidal ideation and two had lifetime DSM-IV diagnoses.  
The frequency of psychiatric disorders was higher in the gene negative sample than 
prevalence rates reported in large general population epidemiological studies. When 
compared to the gene positive HD samples, the frequency of lifetime DSM-IV depressive 
disorders was higher in the HD gene positive samples than the gene negative sample 
whereas the frequency of lifetime DSM-IV anxiety disorders and alcohol abuse was higher in 
the gene negative sample. The age at onset of psychiatric symptoms in the gene negative 
individuals was more similar to that observed in general population studies than that found 
in the gene positive siblings. Taken together, these findings suggest that the familial 
influences on the psychiatric presentation of HD cannot be entirely explained by the HD 
gene. 
 
7.1.2 Secondary Aims 
7.1.2.1 First Aim 
To assess and determine the lifetime prevalence rates of a broad range of psychiatric 
symptoms and syndromes defined using DSM-IV criteria in a large sample of unrelated 
individuals with HD.  
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This thesis reported a systematic investigation of the psychiatric phenotype in HD using a 
battery of standardised assessment measures, including gold-standard semi-structured 
interview methodology. Depressive disorders were the most frequent psychiatric illness in 
the HD sample with lifetime DSM-IV prevalence rates of 56% for the index sample and 65% 
for the sibling sample. This was followed by anxiety disorders with a lifetime DSM-IV 
prevalence rate of 38% for the index sample and 25% for the sibling sample. This finding is in 
keeping with previous HD studies suggesting that the prevalence of depressive and anxiety 
disorders is over-represented in the HD population when compared to the general 
population. However, contrary to some previous HD studies, there were no HD individuals in 
the current study with a lifetime DSM-IV diagnosis of bipolar disorder or obsessive 
compulsive disorder (OCD). 
 
7.1.2.2 Second Aim 
To compare the depression phenotype in this HD sample with that in a large sample of 
individuals with unipolar depression without HD. 
 
This was the first study to compare the depression phenotype in HD with a non HD sample. 
The non-HD sample of individuals with major recurrent depressive disorder (MDDR) used in 
this study was an ideal comparative sample given that the same assessment measures were 
used in the neuropsychiatric assessment of both samples and both samples were recruited 
systematically. The main finding from this investigation was that the depression phenotype 
in HD may be different to that in the non-HD population. When compared to the non-HD 
MDDR sample, individuals with a lifetime DSM-IV diagnosis of MDDR in the HD sample had a 
significantly older age at onset of depression, experienced significantly more frequent 
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episodes of depression (and episodes of shorter duration, although this finding approached 
significance), experienced significantly less impairment of functioning during their worst 
episode of depression and  were significantly less likely to experience core biological 
symptoms in episodes of depression. These findings suggest that the HD gene, whether 
directly and/or indirectly through the psychosocial stresses associated with having HD, 
influences the presentation and course of depression in these individuals. 
 
7.1.2.3 Third Aim 
To validate the use of self-report depression rating scales in HD so that depression can be 
more accurately assessed in this population. 
 
This was the first study to validate the use of self-report depression rating scales in the HD 
population despite their widespread use in research and clinical practice. The scales were 
validated against a gold standard interview, the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN), which was used to assess the presence and severity of clinical 
symptoms associated with depressive disorder for ICD-10 diagnosis. The results 
demonstrated that the depression subscale of the Hospital Anxiety and Depression Scale 
(HADS-D, Zigmond and Snaith, 1983) at a cut-off of a score of 7 or more was the most valid 
self-report measure at discriminating between depressed and non-depressed individuals 
with HD. Interestingly, the Beck Depression Inventory-II (BDI-II, Beck et al., 1996), which is 
the most commonly used self-report measure of depression in the HD population was the 
least useful at detecting “cases” of depression in the HD sample. 
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7.2 Final conclusions 
In conclusion, investigations into the psychiatric phenotype of HD as presented in this thesis 
have found evidence to suggest that familial factors (most likely genetic factors other than 
the HD gene) contribute to the lifetime presence and course of depression, irritability and 
aggression in HD. Although the HD gene cannot alone account for the high prevalence of 
psychiatric disorders/symptoms in HD given the significant proportion of HD family members 
gene negative for HD who also have a lifetime psychiatric history, having the HD gene does 
appear to influence the presentation and course of psychiatric symptoms, most notably the 
age at onset of psychiatric illness and the depression phenotype.  
 
7.3 Implications 
The results of this study have important implications both in terms of clinical management 
and treatment of individuals with HD and psychiatric disorders as well as those HD family 
members gene negative for HD. 
 
7.3.1 Clinical management of individuals with HD 
The evidence from this study for the clustering of depression, irritability and aggression in 
some HD families, emphasises the requirement for an individual’s psychiatric family history 
to be taken to inform of possible increased risks. The high lifetime prevalence of psychiatric 
disorders including depressive and anxiety disorders as well as neuropsychiatric symptoms 
including irritability, aggression, perseverative thinking and apathy observed in this sample 
highlights the need for HD individuals to be regularly screened for psychiatric illness. 
Furthermore, a significant proportion of individuals with a lifetime history of depression 
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and/or anxiety had a “not otherwise specified” (NOS) diagnosis, where DSM-IV criteria were 
not met for a specific disorder. Recognition of individuals with HD and NOS diagnoses is 
important as they may require different clinical management than those HD individuals with 
more typical depression/anxiety disorders.  
 
The fact that many individuals experienced onset of their psychiatric symptoms prior to 
motor onset emphasises the importance of assessing for the presence of psychiatric 
syndromes/symptoms throughout the prodromal phase. HD individuals also need to be 
regularly screened for suicidal ideation. Effective screening is the first step in reducing the 
morbidity associated with psychiatric symptoms in HD. For depression, it is recommended 
that the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) at a cut-
off score of 7 or more is used in the HD population and the Depression Intensity Scale Circles 
(DISCs) is used at a cut-off of 2 or more to screen for depression in those individuals with 
more severe communicative deficits. Use of these quick, cheap yet valid screening tools in 
HD could be particularly useful given the recent evidence suggesting that depression is 
under-treated in HD (Epping et al., 2013; van Duijn et al., 2014). For those individuals who 
score above the recommended cut-offs on the scales, further assessment for formal 
psychiatric diagnosis according to DSM-V/ICD-10 is recommended.  
 
7.3.2 Treatment implications for individuals with HD 
The findings from this study suggest that the depression phenotype and therefore possibly 
the aetiology of depression is different in HD than in the non-HD population. This has 
important treatment implications as it could be that in order to treat depression successfully 
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in individuals with HD, different treatments are required. Additionally, for those individuals 
with depression NOS, an important question arises as to whether these individuals should be 
treated in the usual way with anti-depressants or if other treatment methods including non-
pharmacotherapy would be more beneficial. Further research is needed to evaluate this. 
 
7.3.3 Psychiatric illness in gene negative individuals 
Evidence in this study that individuals within HD families who are gene negative for HD also 
suffer from psychiatric illness more frequently than the general population highlights that 
this is also an important population in which to regularly screen for psychiatric 
symptoms/syndromes. Such screening would be important throughout the lifespan and not 
just around the time of genetic testing.  
 
7.4 Limitations 
Limitations pertaining to the methodology of chapters 4, 5 and 6 were discussed at the end 
of each relevant chapter (sections 4.7, 5.6 and 6.5). The following section details the main 
limitations of this body of research.  
7.4.1 Modest sample size 
The main limitation of the current investigations was the modest sample size, which limited 
the power to detect significant relationships within the data. More specifically, low rates of 
specific psychiatric diagnoses such as recurrent major depressive disorder (MDDR) in the 
samples may have reduced the power to detect differences/similarities between the 
samples. As a result of the modest sample size and exploratory nature of the study, multiple 
comparisons were not corrected for. However, this sample was particularly difficult to 
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recruit given that HD is a rare disorder and only families where at least two siblings were 
aware of their genetic status and were gene positive for HD were invited to take part. 
Nevertheless, within the given time frame, 102 individuals were interviewed throughout the 
UK for the familality study and a further 50 individuals were recruited and assessed for the 
study validating depression rating scales in HD. The gene negative sample was particularly 
difficult to recruit given that the gene positive siblings were typically responsible for passing 
the information on to their gene negative sibling(s), which due to the memory problems and 
apathy frequently experienced by individuals with HD meant that the gene positive siblings 
were often not contacted. Additionally, in many of the families recruited to the study, which 
comprised 3 or more siblings, the additional siblings, although not showing any symptoms of 
HD, were often unaware of their genetic status and therefore it was not possible to include 
them in the study. 
 
7.4.2 Reporting of lifetime psychiatric history 
The reporting of an individual’s psychiatric history was retrospective and therefore could 
have led to some inaccuracies in the data. However, information was gathered from 
numerous different sources including a caregiver where possible and case notes in order to 
try and minimise this and a prospective study would not have been possible in the time 
frame. Additionally, although lifetime psychiatric ratings were made, lifetime only represents 
an individual’s psychiatric history up until their age at interview for the study. Therefore, the 
data collected is not a complete representation of an individual’s lifetime psychiatric history 
as it is possible that an individual will experience first onset or further episodes of psychiatric 
illness post-interview. 
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7.4.3 Potential sample biases 
Although sibling pairs were recruited to the study solely on the basis that both siblings were 
gene positive for HD, it is possible that those individuals with a psychiatric history were 
better known to their HD Consultant and were therefore more likely to be recruited to the 
study. Similarly, for the study validating rating scales of depression, it is possible that there 
was a recruitment bias towards HD individuals with a history of depression. Conversely, 
those individuals with more severe psychiatric symptoms such as severe depression or 
psychosis were likely to be underrepresented in the study because they are less likely to 
respond to an invitation to take part in research and also, the study population was nearly all 
out-patient. It is also possible that the gene negative sample was biased towards individuals 
with psychiatric illness as they may be more interested in taking part in research/mental 
health research. 
 
7.5 Future research 
Further research into the psychiatric phenotype of HD is required in larger samples. For 
assessing the lifetime psychiatric phenotype of HD, a sample of consecutive, unrelated 
individuals gene positive for HD should be recruited. For replication of the familiality study, it 
is likely that collaboration is required to achieve the necessary larger sample sizes (for 
example with the sibling HD populations investigated at the Baltimore Huntington Disease 
Center, USA and the Huntington Disease Medical Genetics Clinic, Vancouver, Canada for the 
familiality of the age at onset of motor symptoms, Rosenblatt et al., 2001). Alternatively, 
focusing on recruiting families of probands gene positive for HD with a specific lifetime DSM-
IV diagnosis such as depressive disorders as well as families of probands with no psychiatric 
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history and then determining the frequency of depressive disorders in the first degree 
relatives, should help increase the power to detect familial influences on the depression 
phenotype in HD. 
 
Further research into the contribution of other biological and environmental factors to the 
psychiatric phenotype of HD is warranted. Longitudinal studies to identify possible 
environmental precipitants and modifiers of psychiatric illness in HD would be valuable. To 
identify possible biological risk factors, the search for genetic modifiers of the psychiatric 
phenotype in HD will likely prove an interesting area for future research. Genetic modifiers 
of HD (i.e. a gene or genes other than the HD gene that cause variation in the expression of 
HD) likely act at different stages of the disease and affect different HD phenotypes, including 
its psychiatric presentation (Gusella and MacDonald, 2009). The investigation of possible 
genetic risk variants for psychiatric disorders/symptoms in HD undoubtedly requires large 
scale collaboration. For example, genome-wide association studies (GWAS), often require 
more than 10 000 participants (Collins and Sullivan, 2013).  
 
Given the difficulties with identifying genetic risk variants of complex, psychiatric disorders 
in the non-HD population (Collins and Sullivan, 2013), it may be useful to first improve the 
phenotypic definition of specific psychiatric symptoms/disorders in HD such as depressive 
and anxiety disorders in order to define relatively homogenous subgroups. Administration of 
the semi-structured interview, the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN), which rates the presence and severity of items associated with major psychiatric 
disorders, to a large sample of individuals with for example HD and MDD or HD and panic 
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disorder, may following factor analysis, yield groupings of correlated symptoms, which 
represent symptom dimensions that result from the action of a contributory gene or group 
of genes.  
 
Additionally, research could focus on the identification of possible biological 
endophenotypes, which are an internal phenotype, not obvious to the unaided eye that 
bridge the gap between behavioural phenotype and genotype (Hasler et al., 2004). The use 
of such quantitative, biological markers may more likely reflect single gene effects than the 
clinical phenotype and therefore improve the ability to identify the role of genes other than 
the HD gene in the psychiatric presentation of HD (Hasler et al., 2004). In terms of 
depression in HD, possible biological enophenotypes could include indicators of HPA axis 
dysregulation and measures of brain structural changes such as hypometabolism in the 
orbital inferior prefrontal cortex. 
 
Qualitative studies may prove useful in gaining greater insight into the psychiatric phenotype 
of syndromes such as apathy and NOS diagnoses and may enable the development of 
measurement tools specifically for use in the HD population. This would prove useful not 
only in clinical practice but also in research settings such as end points for clinical trials. An 
improved understanding of the aetiology of psychiatric syndromes/symptoms in HD may 
also help in understanding the causes of psychiatric illness in the non-HD population. 
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7.6 Summary 
This thesis has presented the findings of an investigation into the psychiatric phenotype of 
HD using gold standard methodologies. Evidence has been found to support the suggestion 
that some HD families have a predisposition to developing psychiatric disorders and the 
results suggest that the familial influences cannot be entirely explained by the HD gene. 
Additionally, evidence was found to suggest that psychiatric disorders are more prevalent in 
individuals with HD than in the general population and that the depression phenotype may 
be different in HD than in the non-HD population. This was the first study to validate the use 
of self-report depression rating scales in HD, with the recommendation that the depression 
subscale of the HADS at a cut-off of 6/7 be used for screening purposes in the HD 
population. These findings have important implications for the clinical management and 
treatment of individuals with HD as well as for gene negative individuals. Further research in 
larger samples to determine the biological and psychosocial underpinnings of psychiatric 
syndromes/symptoms in HD is required.   
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APPENDICES 
A  Appendices for Chapter 3 
Ai Participant information sheets, reply slip, HDA website advertisement, consent 
forms, GP letter 
PARTICIPANT INFORMATION SHEET – GENE POSITIVE SIBLING 
RESEARCH INTO SIBLINGS WITH HUNTINGTON’S DISEASE 
VERSION 2: Wednesday 15th October 2008 
 INTRODUCTION 
I am a member of a research team working in the Department of Neuropsychiatry at The Barberry 
(formerly the Queen Elizabeth Psychiatric Hospital), Birmingham. We are currently conducting a 
study investigating the clinical features of siblings with Huntington’s Disease. To help you decide 
whether or not you wish to take part in this study, please read the following information carefully, 
which explains why this study is being carried out and what participation entails. Please take your 
time to decide and if you wish, discuss the study with your family, friends or General Practitioner.  
 PURPOSE OF THE RESEARCH 
It is known that people with Huntington’s Disease typically experience disordered movements, 
thinking and behaviour. However, it is less well known why these symptoms vary in presentation and 
age at onset from one person to the next. We are interested in looking at brothers or sisters with HD 
in order to try and identify which particular symptoms may have a familial (genetic and/or 
environmental) basis. This research will significantly improve our understanding of Huntington’s 
Disease and will help improve the treatment needs of people with HD. The results could also guide 
future research in terms of identifying genes that predispose someone with HD to develop particular 
symptoms and also in the development of new and better treatments.  
 HOW WILL WE DO THIS? 
We would like to interview families where at least two brothers or sisters have Huntington’s Disease 
– whether already symptomatic or not yet symptomatic but have had a positive predictive test. 
Within these families, we would also like to recruit any brothers or sisters who have had a negative 
predictive test and therefore do not have Huntington’s Disease. This will help us better understand 
which symptoms may co-occur with Huntington’s Disease and which are unrelated to having the HD 
gene. 
 WHAT DOES TAKING PART INVOLVE? 
We hope to recruit a sample of 80-100 brothers or sisters with Huntington’s Disease as well as any 
willing unaffected siblings. Participation in this study involves: 
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1. An assessment of your movements, thinking and day-to-day functional capabilities (1/2 hour). 
2. An interview asking you about any psychiatric symptoms you may have experienced (1 hour). 
3. Completing 2 questionnaires (1/4 hour). 
We will only need to see you once for this study and this visit will be arranged at a suitable time for 
you in your home or another place convenient for you.  
With your permission, we would also like to look at your medical records in strict confidence. 
We would also like to contact any of your brothers or sisters who have Huntington’s Disease 
(whether symptomatic or not) or who have had a negative predictive test. This contact would be via 
a letter, which we would ask you to send to your brother or sister, and they would be under no 
obligation themselves to take part. 
 WHAT ARE THE BENEFITS OF TAKING PART? ARE THERE ANY RISKS? 
There may be no direct benefits from taking part in the study. However, your help will be of great 
value in allowing us to learn more about Huntington’s Disease and may lead to improvements in the 
clinical management of HD patients and enable the development of more effective treatments. 
There are no specific risks arising from your participation in this study given that this is an 
observational study. 
We may check with your doctors involved in your care to ensure it would be appropriate for you to 
take part in this study. 
 DO I HAVE TO TAKE PART? 
Your participation in this research project is voluntary. It is up to you to decide whether or not to 
take part.  If you do decide to take part, you will be asked to sign a consent form. If you decide to 
take part you are free to withdraw from the study at any time without giving reason. A decision to 
withdraw at any time, or a decision not to take part in the study, will not affect your medical 
treatment or the standard of care you receive.  
 WHAT WILL HAPPEN TO THE RESULTS OF THIS STUDY? 
At the end of the study, the results will be analysed and the results will be published in Scientific 
Journals. In addition, the results will be presented at conferences and to specialists working in the 
Huntington’s Disease field. The anonymised data will be stored for five years after the end of the 
study in a locked cabinet. 
 CONFIDENTIALITY 
All information collected from you will be kept strictly confidential and stored in locked filing cabinets 
with access restricted to the investigators involved in the study. The information obtained will also 
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be entered onto a secure computer database for analysis, but evaluation and publication of the 
results will be carried out anonymously. None of your personal data will be made public. 
 
 WILL MY GENERAL PRACTITIONER (GP) KNOW THAT I AM INVOLVED IN THIS STUDY? 
Should you agree to take part in this study, it is important that your GP is kept informed of your 
participation and he/she will also be sent a copy of this information sheet. 
 WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Dr. Hugh Rickards MD FRCPsych and Jenny Keylock BSc MSc in the 
Department of Neuropsychiatry at The Barberry, Birmingham. Birmingham and Solihull Mental 
Health Foundation Trust are sponsoring the research project.  
 WHAT IF I HAVE ANY CONCERNS? 
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PARTICIPANT INFORMATION SHEET – GENE NEGATIVE SIBLING 
RESEARCH INTO SIBLINGS WITH HUNTINGTON’S DISEASE 
VERSION 2: Wednesday 15th October 2008 
 
 INTRODUCTION 
I am a member of a research team working in the Department of Neuropsychiatry at The Barberry 
(formerly the Queen Elizabeth Psychiatric Hospital), Birmingham. We are currently conducting a 
study investigating the clinical features of siblings with Huntington’s Disease. To help you decide 
whether or not you wish to take part in this study, please read the following information carefully, 
which explains why this study is being carried out and what participation entails. Please take your 
time to decide and if you wish, discuss the study with your family, friends or General Practitioner.  
 PURPOSE OF THE RESEARCH 
It is known that people with Huntington’s Disease typically experience disordered movements, 
thinking and behaviour. However, it is less well known why these symptoms vary in presentation and 
age at onset from one person to the next. We are interested in looking at brothers or sisters with HD 
in order to try and identify which particular symptoms may have a familial (genetic and/or 
environmental) basis. This research will not only help improve the treatment needs of people with 
HD but will also guide future research in terms of identifying genes that predispose someone with HD 
to develop particular symptoms and also in the development of new and better treatments.  
 HOW WILL WE DO THIS? 
We would like to interview families where at least two brothers or sisters have Huntington’s Disease 
– whether already symptomatic or not yet symptomatic but have had a positive predictive test. 
Within these families, we would also like to recruit any brothers or sisters who have had a negative 
predictive test and therefore do not have Huntington’s Disease. This will help us better understand 
which symptoms may co-occur with Huntington’s Disease and which are unrelated to having the HD 
gene. 
 WHAT DOES TAKING PART INVOLVE? 
We hope to recruit a sample of 80-100 brothers or sisters with Huntington’s Disease as well as any 
willing unaffected siblings. Participation in this study involves: 
1. An interview asking you about any psychiatric symptoms you may have experienced (1 hour). 
2. Completing 2 questionnaires (1/4 hour). 
 
We will only need to see you once for this study and this visit will be arranged at a suitable time for 
you in your home or another place convenient for you.  
With your permission, we would also like to look at your medical records in strict confidence. 
 WHAT ARE THE BENEFITS OF TAKING PART? ARE THERE ANY RISKS? 
There may be no direct benefits from taking part in the study. However, your help will be of great 
value in allowing us to learn more about Huntington’s Disease and may lead to improvements in the 
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clinical management of HD patients and enable the development of more effective treatments. 
There are no specific risks arising from your participation in this study given that this is an 
observational study. 
 DO I HAVE TO TAKE PART? 
Your participation in this research project is voluntary. It is up to you to decide whether or not to 
take part.  If you do decide to take part, you will be asked to sign a consent form. If you decide to 
take part you are free to withdraw from the study at any time without giving reason. A decision to 
withdraw at any time, or a decision not to take part in the study, will not affect your medical 
treatment or the standard of care you receive.  
 WHAT WILL HAPPEN TO THE RESULTS OF THIS STUDY? 
At the end of the study, the results will be analysed and the results will be published in Scientific 
Journals. In addition, the results will be presented at conferences and to specialists working in the 
Huntington’s Disease field. You will also be sent information regarding the outcome of the study. The 
anonymised data will be stored for five years after the end of the study in a locked cabinet. 
 CONFIDENTIALITY 
All information collected from you will be kept strictly confidential and stored in locked filing cabinets 
with access restricted to the investigators involved in the study. The information obtained will also 
be entered onto a secure computer database for analysis, but evaluation and publication of the 
results will be carried out anonymously. None of your personal data will be made public. 
 WILL MY GENERAL PRACTITIONER (GP) KNOW THAT I AM INVOLVED IN THIS STUDY? 
Should you agree to take part in this study, it is important that your GP is kept informed of your 
participation and he/she will also be sent a copy of this information sheet. 
 WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised by Dr. Hugh Rickards MD FRCPsych and Jenny Keylock BSc MSc in the 
Department of Neuropsychiatry at The Barberry, Birmingham. The research project is being 
sponsored by the Birmingham and Solihull Mental Health Foundation Trust. 
 WHAT IF I HAVE ANY CONCERNS? 
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REPLY SLIP 
RESEARCH INTO SIBLINGS WITH HUNTINGTON’S DISEASE 
Version 2: Wednesday 15th October 2008 
 
Once you have thought about the information provided in the participant information sheet, please 
would you kindly fill out your name, address and telephone number and indicate which of the three 
statements below best refers to you. Please return your response in the pre-paid envelope provided 
to Jenny Keylock. If you have misplaced the envelope, the address is also printed at the top of the 
Patient Information sheet. 
 
Name:_______________________________________________________________ 
 
Telephone number:____________________________________________________ 
 
Address:_____________________________________________________________ 
                 
                _____________________________________________________________ 
 
               _____________________________________________________________ 
 
Post code:____________________________________________________________ 
 
Please tick the appropriate box below. I have read and understood the patient information sheet 
dated Wednesday 15 October 2008, version 2 and: 
1. I am interested in taking part  
 
Best days and times to call you: ___________________________________________ 
 
2. I require more information about the study before deciding whether to take part 
 
3. I am not interested in taking part 
In the case of (1) and (2) only, you will be contacted within 2 weeks in order to clarify any queries you 
may have and if you are still interested in taking part to arrange an appointment.  
Many thanks for taking the time to read this information and for completing the reply slip.  
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HUNTINGTON’S DISEASE ASSOCIATION (HDA) WEBSITE 
RESEARCH INTO SIBLINGS WITH HUNTINGTON’S DISEASE 
Version 2: Wednesday 15th October 2008 
 
A study is currently underway in the United Kingdom investigating the clinical features of siblings 
with Huntington’s disease (HD). The purpose of the study is to better understand why the symptoms 
of HD vary in presentation and age at onset from one person to the next and if any particular 
symptoms cluster in families affected with HD. 
 
We would like to interview families where at least two brothers or sisters have HD – whether already 
symptomatic or not yet symptomatic but have had a positive predictive test. Also, if within these 
families there are any siblings who have had a negative predictive test and therefore do not have HD, 
we would be very interested in interviewing these family members too. 
 
Participation in this study involves a single clinical assessment lasting approximately 2 hours, 
arranged at a suitable time for you in your home or another place convenient for you. The 
assessment consists of: 
o An assessment of your movements, thinking and day-to-day functional capabilities. 
o An interview about any psychiatric symptoms you may have experienced. 
o Two self-report questionnaires. 
 
 
 
 
  
224 
 
CONSENT FORMS 
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Healthy sibling consent sheet 
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GP LETTER  
RESEARCH INTO SIBLINGS WITH HUNTINGTON’S DISEASE 
VERSION 1: MONDAY 12TH MAY 2008 
 
Date 
Dear Dr. 
 Re:  Patient name and Date of Birth 
         Patient address 
Your patient ……………….. has agreed to participate in a study investigating the familiality of clinical 
symptoms in Huntington’s Disease. This study involves a single clinical assessment at the 
participant’s home and is observational only. A copy of the information sheet has been enclosed. 
 
The supervisor for the trial is Dr. Hugh Rickards, Consultant Neuropsychiatrist at the address above 
and the trial has been approved by the Multi-Centre Research Ethics Committee. If you require any 
further information about the study, please contact Jenny Keylock, the Chief Investigator on the 
number at the foot of the patient information sheet.   
 
Yours sincerely, 
 
Jenny Keylock 
Research Psychologist 
 
Enc. Patient information sheet 
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Aii Demographic information 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
DEMOGRAPHIC INFORMATION 
 
 
Date of Birth:         
 
 
 
Gender: 
 1=male 
 2=female 
 
 
Ethnicity:_____________________________________ 
 
Index participant       Affected sibling            Unaffected sibling 
 
 
Years of education:_____________________________ 
 
Highest level of qualification:_____________________ 
 
Currently employed:_____________________________ 
 
Main occupation:_______________________________ 
 
 
Age at symptom onset:____________________________________ 
 
Address:           __________________________________________ 
 
               ________________________________________________ 
 
_______________________________________________________ 
 
Telephone:______________________________________________ 
 
GP details:______________________________________________ 
 
_______________________________________________________ 
 
_______________________________________________________ 
 
Place of birth:___________________________________________ 
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Any illnesses other than HD:    Yes   No   
 
Description:____________________________________________ 
 
_______________________________________________________ 
 
Currently on any medication? Yes  No   
 
Medication description and dose:___________________________ 
 
_______________________________________________________ 
 
_______________________________________________________ 
 
Currently smokes: 
 
No  Yes  Ex-smoker 
 
If ex-smoker, time of last cigarette:__________________________ 
 
Weight:___________ 
 
Height:___________ 
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Aiii Clinical Assessment of Huntington’s disease: UHDRS motor assessment, 
UHDRS cognitive assessment, Total Functional Capacity Scale  
UHDRS MOTOR ASSESSMENT (Huntington Study Group, 1996) 
Participant’s initials:_______ 
Participant’s no.:__________                                                   Date data obtained:__________________ 
UHDRS  MOTOR ASSESSMENT 
 
Total Motor score: 
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UHDRS COGNITIVE ASSESSMENT (Huntington Study Group, 1996) 
 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
UHDRS VERBAL FLUENCY TEST 
 
 
TOTAL NUMBER OF WORDS         
 
 
          
                                      0- 30 SECONDS         30-60 SECONDS 
  
                         
 
 
 
 
 
 
 
 
F   
 
 
 
 
 
 
 
 
 
SUBTOTAL                                 INTRUSIONS                               PERSEVERATIONS  
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          0-30 SECONDS         30-60 SECONDS 
 
 
 
 
 
 
 
 
 
A   
 
 
 
 
 
 
 
SUBTOTAL                                INTRUSIONS                       PERSEVERATIONS 
 
 
                                              0-30 SECONDS                                            30-60 SECONDS 
 
 
 
 
 
 
 
 
 
S   
 
 
 
 
 
 
 
 
SUBTOTAL                          INTRUSIONS        PERSEVERATIONS 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
   
235 
 
UHDRS COGNITIVE ASSESSMENT (HUNTINGTON STUDY GROUP, 1996) 
 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
                                             UHDRS SYMBOL DIGIT TEST 
 
TOTAL NUMBER OF CORRECT ANSWERS  
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UHDRS COGNITIVE ASSESSMENT (Huntington Study Group, 1996) 
STROOP TEST – COLOUR NAMING 
Participant’s initials:__________________ 
Participant’s no:_____________________  Date data obtained:_____________________ 
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UHDRS COGNITIVE ASSESSMENT (Huntington Study Group, 1996) 
STROOP TEST – WORD READING 
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UHDRS COGNITIVE ASSESSMENT (Huntington Study Group, 1996) 
STROOP TEST – INTERFERENCE 
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TOTAL FUNCTIONAL CAPACITY SCALE (Shoulson and Fahn, 1979) 
Participant’s initials:_______ 
Participant’s no.:__________                      Date data obtained:__________________ 
TOTAL FUNCTIONAL CAPACITY 
TOTAL SCORE 
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Aiv Brief screen of psychiatric history 
BRIEF SCREEN OF PSYCHIATRIC HISTORY 
Participant’s initials:_______ 
Participant’s no.:__________                                                                       Date data obtained:__________________ 
Have you ever experienced mental health problems in your life, even if very mild? 
 Y/N Sought help from GP/other 
health professional 
Received counseling Prescribed 
medication 
Seen psychiatrist/ 
hospital admission 
Current symptoms 
Anxious or panic attacks 
 
      
Feeling very low in spirits, depression or low 
mood? 
      
Feeling much too high in spirits or elated or 
very irritable without reason, manic 
depression or bipolar disorder 
      
Experiencing things that are difficult to 
explain or understand like hearing voices or 
seeing things, psychosis or schizophrenia 
      
OCD – checking things you know you have 
done, keeping things in a special order, 
repeatedly cleaning things. 
      
Eating disorders 
 
      
Other 
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Av Psychiatric consensus rating form 
Study ID _____   Initials _____    DOB____ 
Rater ____   Date _____ 
Main Diagnosis 
DSM-IV ICD- 
  
 
Other diagnosis 
DSM-IV ICD- 
  
 
DSM-IV ICD- 
  
 
DSM-IV ICD- 
  
 
DSM-IV ICD- 
  
 
BADDS Dimension Scores:  M ___  ___  ___ 
     D ___  ___  ___ 
     P ___  ___  ___ 
     I ___  ___  ___ 
 
Gas scores Lifetime worst ever episode   ___ 
  Lifetime worst in depressive episode  ___ 
  Lifetime worst in manic episode  ___ 
  Past week     ___ 
 
Section 2 features  ___  Mood Congruence  ___              Near Section 2 ___ 
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No. Episodes:  Mania  ___  Depression  ___ Anxiety  ___ 
 
 
Longest Duration: Mania  ___  Depression  ___ Anxiety  ___ 
 
 
Age of onset: any psychiatric disorder 
 
 
Symptom ___      Impairment ___      Contact ___      Admission ___ 
 
 
First Depression ____   First Mania ____   First Psychosis ____ 
 
 
First anxiety/panic/phobia ____ First obsessional illness  ____ 
 
 
First Eating disorder    ____ First alcohol or substance ____ 
 
 
Suicidal ideation ___   Rapid Cycling ___  Puerperal  ____ 
 
  
Age onset irritablilty _____  Age onset aggression _____ 
 
 
Age onset perseveration _____  Age onset apathy _____ 
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Avi OPerational CRITeria checklist (OPCRIT) 
OPCRIT: modified 63 item version 
MODIFIED OPCRIT – SYMPTOM CHECKLIST 
Study ID _______________ 
 
DEPRESSIVE SYMPTOMS 
 
LE 
 
WE 
1 Dysphoria   
2 Loss of pleasure   
3 Diurnal variation (mood worse am)   
4 Suicidal ideation   
5 Excessive self reproach   
6 Poor concentration   
7 Slowed activity   
8 Loss of energy/tiredness   
9 Poor appetite   
10 Weight loss   
11 Increased appetite   
12 Weight gain   
13 Initial insomnia   
14 Middle insomnia   
15 Early morning waking   
16 Excessive sleep   
17 Diminished libido   
18 Agitated activity   
 
 
 
 
 
MANIC SYMPTOMS 
 
LE 
 
WE 
19 Elevated mood   
20 Irritable mood   
21 Thoughts racing   
22 Pressured speech   
23 Distractibility   
24 Excessive activity   
25 Increased self-esteem   
26 Reckless activity   
27 Reduced need for sleep   
28 Increased sociability   
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PSYCHOTIC SYMPTOMS 
 
LE 
 
WE 
29 3rd person auditory hallucinations   
30 Running commentary voices   
31 Abusive/accusatory/persecutory voices   
32 Other (non-affective) hallucinations   
33 Non-affective visual hallucinations   
34 Non-affective hallucination in other modality   
35 Thought echo   
36 Thought insertion   
37 Thought broadcast   
38 Thought withdrawal   
39 Delusions of passivity   
40 Delusions of influence   
41 Primary delusional perception   
42 Persecutory delusions   
43 Bizarre delusions   
44 Other primary delusions   
45 Bizarre behaviour   
46 Catatonia   
47 Speech difficult to understand   
48 Incoherent   
49 Positive formal thought disorder   
50 Negative formal thought disorder   
51 Restricted affect   
52 Blunted affect   
53 Inappropriate affect   
54 Perplexity   
 
 
 
 
PSYCHOTIC AFFECTIVE SYMPTOMS 
 
LE 
 
WE 
55 Grandiose delusions   
56 Delusions of guilt   
57 Delusions of poverty   
58 Nihilistic delusions   
59 Mood congruent 3rd person Auditory Hallucinations   
60 Mood congruent 2nd person Auditory Hallucinations   
61 Mood congruent Visual Hallucinations   
62 Mood congruent hallucinations in other modality   
63 Other secondary delusions   
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Avii The  Bipolar Affective Disorder Dimensional Scale, version 3.0 (BADDS 3.0) 
General information 
The Bipolar Affective Disorder Dimension Scale (BADDS) has been developed in order to address 
some of the disadvantages of a purely categorical approach to diagnostic classification of Bipolar 
Spectrum Disorders.  
 
BADDS is a dimensional rating scheme that retains and builds upon current categorical classifications. 
It is intended for use in clinical samples from populations over-represented by Bipolar Spectrum 
illness. It was not developed for use in general population samples.  
 
BADDS has been under development since 1996 and has now been used by a variety of researchers 
within our group on more than 1100 cases. It has proved to be user friendly and has excellent 
reliability, even on sets of diagnostically challenging cases. 
 
BADDS comprises 4 dimensions: M: Mania; D: Depression; P: Psychosis; I: Incongruence. Each 
dimension is rated using integer scores on a 0 – 100 scale. Ratings are made after review of all 
available clinical data on a subject (eg. case records, semi-structured psychiatric interview and 
information from an informant) and can be performed as a simple addition to the conventional 
consensus lifetime psychiatric diagnostic procedures already in use by many research groups. Each 
rating reflects a mixture of severity and frequency of clinical features. Guidelines are provided that 
define anchor points in the rating scales and specify how ratings should be made. 
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BADDS: General rating guidelines 
 
1) Do not rate a dimension if there is insufficient information - just leave the dimension blank. 
 
2) Use all available information to make the best judgement for each rating. 
 
3) It is expected that when used for research BADDS will be used within the accepted framework of 
the lifetime best-estimate consensus diagnostic procedure. 
 
4) All ratings should be made using integers in the range 0 - 100. 
 
5) Ratings for M and D are a mixture of severity and frequency. Generally the severity of the most 
severe episode identifies a range in which the rating will be made and the frequency determines the 
score assigned within the range. In assigning a rating, start at the lowest score in the range and then 
add points according to any relevant psychopathology over and above that of the most severe 
episode according to the following guidelines:  
a) In general each additional episode of that level of severity will add a score of 2 in a 20 
point range and 1 in a 10 point range.  
b) Scores in the identified severity range can and should be modified according to severity 
and duration of total episodes – but with a substantial down-weighting for episodes of lower 
severity.  
c) For episodes that are one level of severity lower than the rating range, add 0.25 points for 
each episode of lower severity for a score in a 10 point range and 0.5 points for each episode 
of lower severity for a score in a 20 point range.  
d) For episodes that are more than one level of severity lower than the rating range the total 
adjustment should not normally exceed 1 or 2 points. 
 
6) For the P and I dimensions anchor points are given in these guidelines. Judgment is used to assign 
scores between anchor points. 
 
7) Under very exceptional circumstances a score can be rated outside the severity range. However, 
this should always be agreed by at least two raters and the rating should lie in the interval 0 - 100. 
Such a rating should be indicated by an asterisk (*) following the rating for that dimension. An 
example of the applicability of this rule is the rating up of an episode in which the balance of 
evidence clearly suggests a severe illness that is not adequately supported by the documented 
evidence because of poor documentation. Another example would be the rating down of an episode 
if the balance of evidence strongly suggests that the formal evidence clearly over-represents the 
clinical significance of the episode. 
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1) Mania dimension (M) 
 
The rating reflects severity and frequency.  
Use ICD10 to define symptom and duration criteria for hypomanic and manic syndromes. 
Sub-hypomanic features in the ranges 1 - 19 and 20 - 39 should be rated using judgement according 
to the balance of number and duration of symptoms.  
No impairment criterion is used for hypomania.  
The impairment criteria for mania are one or more of: 
 
Disrupts work or social life more or less completely 
Markedly inappropriate overspending that is reckless within the context of the subject’s financial position  
Fights 
Lost job 
Police involvement 
Family split up 
Received specific treatment (including dose increase of mood stabilizer) for acute mania 
Psychotic features 
 
Incapacitating mania refers to a severe manic episode that includes the presence of one or more of 
the following features: incoherence, disorientation, loss of contact with reality (which includes 
psychotic features), frenzied or bizarre psychomotor activity.  NB: Being admitted on a Section is an 
example of incapacitating mania. 
Mixed episodes are rated on the M dimension. If all manic episodes are mixed, add “m” to the rating 
(eg. 65m).  
 
Key points and ranges on the M dimension 
 
0    No manic features. 
1 - 19    Mild sub-hypomanic features. Elation/irritability and less than 3  
symptoms. 
20 - 39  Sub-hypomanic features. Elation/irritability and 3+ symptoms for at  
least 1 day. 
40 - 59  Hypomanic features. At least one hypomanic episode. 
60 - 79  Manic features. At least one manic episode. 
80 - 100 Severe manic features. At least one episode of incapacitating mania. 
 
NB: a) if * enter as .01, e.g., 65* = 65.01 
 b) if m enter as .02, e.g., 65m = 65.02 
 c) if both * and m enter as .03, e.g., 65*m = 65.03) 
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2) Depression (D) 
 
Rating reflects severity and duration.  
Use ICD10 to define depressive syndromes. This includes 10 symptoms of depression  that count for 
the purposes of diagnosis:  
 
  A Depressed mood 
Loss of interest/pleasure 
Loss of energy 
 
   B Suicidal ideation 
Pathological guilt 
Loss of confidence/self esteem 
Loss of concentration 
Slowed activity 
Change of appetite or weight 
Change in sleep pattern 
   
Depression severity: Mild - 4+ symptoms (2+ from A); moderate - 6+ symptoms (2+ from A); severe - 
8+ symptoms (3 from A). Refer to ICD10 for full definition of syndromes and symptoms. 
Duration criterion for Major Depressive Episode is 2 + weeks. If 1- 2 weeks, classify as Minor 
Depression. 
Rate depression as severe if (a) ICD10 criteria fulfilled,  or (b) criteria for major depression are 
fulfilled and there has been a serious suicide attempt,  ECT treatment or hospital admission for 
depression. 
Minor depression refers to at least 1 week of low mood accompanied by 2 or more depression items 
or to brief episodes that would otherwise meet criteria for Major Depression. 
Incapacitating depression refers to severe major depression that includes presence of one or more of 
the following features: stupor; mutism; loss of contact with reality (including psychotic features).  NB: 
Being admitted on a Section is an example of incapacitating depression. 
If psychotic features are present, a depressive episode can be rated as incapacitating if  the minimum 
criteria for major depression are satisfied (ie. 4 items).  
 
Key points and ranges on D dimension 
 
0     No features of depression during lifetime. . 
1 – 19    Sub-Minor depression. 
20 - 39   Minor depression. 
40 - 49   Mild major depression. 
50 - 59   Moderate major depression. 
60 - 79   Severe depression. 
80 - 100  Incapacitating depression 
 
NB: a) if * enter as .01, e.g., 65* = 65.01 
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3) Psychotic features (P) 
 
Psychotic features refers to delusions, hallucinations, positive formal thought disorder, catatonia or 
grossly disorganized behaviour (but see exclusions below). 
Ratings on this dimension exclude stupor or excitement during an affective episode or positive 
formal thought disorder during mania. 
Lifetime occurrence of psychotic features is rated.  
Near psychotic schizotypal features refers to the following DSMIV schizotypal items: ideas of 
reference; odd beliefs or magical thinking that influences behaviour and is inconsistent with sub-
cultural norms; unusual perceptual experiences including bodily illusions; odd thinking and speech;  
suspiciousness or paranoid ideation; behaviour or appearance that is odd eccentric or peculiar. 
Depersonalization and derealization are not classified as near psychotic features. 
The period of illness considered refers to all affective and non-affective periods of psychopathology. 
Rating should take account of both number and duration of episodes with and without psychotic 
features. If in doubt, “rate up” the psychotic features. Examples: 
If there have been two 1 week long affective psychotic episodes and a 1 year non-psychotic 
depressive episode, rate 60 (ie. approx. 2/3 of illness episodes). 
If there have been nine 1 month non-psychotic affective episodes, one 1 month psychotic 
affective episode and 4 years of chronic hallucinations outside affective episodes, rate 80 (ie. approx. 
80% of illness duration). 
The Uncertain category (P = 1) is used for situations in which insufficient information is available to 
determine if sign or symptom meets criteria for near psychotic feature. 
 
Key points and ranges on P dimension 
 
0   Absent. 
1   Uncertain. 
2 - 9    Near psychotic features: occasional at low end of range, frequent at  
high end of range. Occurrence of true psychotic symptoms should not  
be rated in this range. 
10 - 20  Brief clear-cut psychotic symptom that are not a prominent  
feature of illness. 
10 – Single. 
20 – Multiple. 
21 – 100 Psychotic symptoms that are a prominent feature in one of more  
episodes of illness. 
25 - present for 25% of illness. 
50 - present for 50% of illness. 
75 - present for 75% of illness. 
100 - prominent psychotic features present throughout illness. 
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4) Mood incongruence (I) 
 
 DSMIV definitions of congruence and incongruence are used. 
 Rate incongruence of lifetime occurrence of psychotic features. 
 For convenience, the set of psychotic symptoms recognized as having special weight in the 
diagnosis of schizophrenia and schizoaffective disorder (thought echo, insertion, withdrawal 
or broadcasting; passivity experiences; hallucinatory voices giving running commentary, 
discussing subject in third person or originating in some part of the body; bizarre delusions; 
catatonia) are denoted in the guidelines as the “S set”. 
 If Psychosis Features dimension, P < 10, leave I blank. 
 
Key points on I dimension 
 
0 -40  Psychotic symptoms occur only during affective episodes and do not include any of 
the S set. 
Rating 0 – virtually completely mood congruent. 
Rating 20 – approximate balance between mood congruent and  incongruent. 
Rating 40- virtually completely mood incongruent 
43  Psychotic symptoms occur only during affective episodes and include one or more of 
the S set which have not definitely been present for 2 weeks. 
47  Psychotic symptoms occur only during affective episodes and include one or more of 
the S set which have definitely been present for 2 weeks. 
50 - 59 Psychotic symptoms probably present for at least 2 weeks either side of an affective 
episode. 
Rating 50 – on at least one occasion. 
Ratings of 51-59 used to reflect recurrence and/or certainty. 
60 - 100 Psychotic symptoms definitely present for at least 2 weeks either side of an affective 
episode. 
Rating 60 – on at least one occasion. 
Rating 80- on many occasions. 
Rating 100 – Psychotic symptoms predominate illness and occur chronically outside 
(or in absence of) affective episodes. 
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Aviii  The Global Assessment Scale (GAS) 
 
GAS: 
Rate the subject’s level of functioning in the worst episode of depression by selecting the lowest 
range that describes his functioning on a hypothetical continuum of mental health illness. For 
example, a subject whose “behaviour is considerably influenced by delusions” (range 21-30) should 
be given a rating in that range even though he has “major impairment in several areas” (range 31-
40). Use intermediary levels when appropriate (eg. 35, 58, 63). Rate actual functioning independent 
of whether or not subject is receiving, and may be helped by, medication or some other form of 
treatment. 
100 – 91 No symptoms, superior functioning in a wide range of activities, life’s problems never 
seem to get out of hand, is sought out by others because of his warmth and integrity. 
  90 – 81 Transient symptoms may occur, but good functioning in all areas, interested and 
involved in a wide range of activities, socially effective, generally satisfied with life, 
“everyday” worries that only occasionally get out of hand. 
  80 – 71 Minimal symptoms may be present but no more that slight impairment in 
functioning, varying degrees of “everyday” worries and problems that sometimes get 
out of hand. 
  70 – 61 Some mild symptoms (eg. depressive mood and mild insomnia) OR some difficulty in 
several areas of functioning, but generally functioning pretty well, has some 
meaningful interpersonal relationships and most untrained people would not 
consider him “sick”. 
  60 – 51 Moderate symptoms OR generally functioning with some difficulty (eg few friends 
and flat affect, depressed mood and pathological self-doubt; euphoric mood and 
pressure of speech, moderately severe antisocial behaviour). 
  50 – 41 Any serious symptomatology or impairment in functioning that most clinicians would 
think obviously requires treatment or attention (eg. suicidal preoccupation or 
gesture, severe obsessional rituals, frequent anxiety attacks, serious antisocial 
behaviour, compulsive drinking). 
40 – 31 Major impairment in several areas, such as work, family relations, judgement, 
thinking or mood (eg. depressed woman avoids friends, neglects family, unable to do 
housework), OR some impairment in reality testing or communication (eg. speech is 
at times obscure, illogical or irrelevant), OR single serious suicide attempt. 
       
30 – 21 Unable to function in almost all areas (eg. stays in bed all day), OR behaviour is 
considerably influenced by either delusions or hallucinations, OR serious impairment 
in communication (eg. sometimes incoherent or unresponsive) or judgement (eg. 
acts grossly inappropriately). 
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20 – 11 Needs some supervision to prevent hurting self or others, or to maintain minimal 
personal hygiene (eg. repeated suicide attempts, frequently violent, manic 
excitement, smears faeces), OR gross impairment in communication (eg. largely 
incoherent or mute). 
 
  10 – 1 Needs constant supervision for several days to prevent hurting self or others, or 
makes no attempt to maintain minimal personal hygiene.  
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Aix Problem Behaviours Assessment for Huntington’s disease (PBA-HD)  
 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
 
SHORT BEHAVIOURAL ASSESSMENT FORM 
 
This assessment is a modified version of the Problem Behaviours Assessment Scale for Huntington’s 
disease (PBA-HD) (Craufurd et al., 2001), which will measure whether the neuropsychiatric symptoms 
of irritability, aggression, apathy and perseverative thinking have ever been experienced by the 
patient. If the symptom has been present, record the date at onset of first symptoms and then rate 
the frequency and severity of that behavior during the worst episode using the general guidelines 
below.  
 
General rating guidelines: 
 
Severity              Frequency 
0 = absent     0 = never/almost never                           
1 = slight, questionable    1 = seldom (less than once/week) 
2 = mild (present, not a problem)  2 = sometimes (up to 4 times a week) 
3 = moderate (symptom causing problem) 3 = frequently (most days/5,6 or 7 times a week) 
4 = severe (almost intolerable for carer)  4 = daily/almost daily for most (or all) of day 
 
Rate 9 if not known or not applicable 
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IRRITABILITY:                                                                      Severity          Frequency   
 
 
 
(This item is used to rate the ease at which the subject loses his/her temper, rather than the degree 
to which the self-control is lost once the subject is angry (the latter is rated in the next item). It 
should also be used to record irritable moods, which might have developed into an angry outburst if 
the carer had not acted with increased tact or discretion).  
 
Suggested prompts: 
 Have you ever found yourself feeling irritable, bad-tempered, moody or ‘cranky’? 
 Do you think you get cross more easily than you used to? 
 (if yes to above) How does this affect people around you? Do you think they treat you 
differently when you are like that? 
 
0 no more irritable than the average person 
1 questionable or trivial; within normal limits but worse than he/she used to be 
2 definitely more irritable than is reasonable but not to an extent which causes significant 
problems or distress for other household members; rate 2 if subject appeared to be in a bad 
mood, but rater considered that subject might have become angry if not treated with tact. 
3 Subject very irritable and loses temper over trivial matters; household members have to be 
careful what they say and do to avoid problems; rate 3 if subject’s appearance and behaviour 
are suggestive of angry mood, such that outbursts would almost certainly have occurred if 
care had not been taken to placate subject or keep out of his/her way. 
4 Subject very irritable and looses temper without any obvious reason at all; living with 
him/her is like walking on eggshells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  If present, date of 
onset     
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ANGRY OR AGGRESSIVE BEHAVIOUR:                                              Severity            Frequency   
 
 
 
Suggested prompts: 
o Have you found yourself having any emotional or angry outbursts? 
o Have you had times when you have lost control of your temper? 
o Have you hit, shoved or thrown things or expressed your temper in a physical way? 
o Have you used threats or hostile words? 
 
0 normal 
1 questionable 
2 verbal outbursts which are outside socially acceptable limits but do not cause significant 
problems or distress for other household members; for example, rate 2 if subject 
becomes angry with self or inanimate objects when confronted with frustrating 
situations due to disability, such as failure when attempting to rewire a plug. 
3 Temper tantrums are severe enough to cause distress for other household members 
and/or practical difficulties caring for subject; rate 3 when verbal hostility or anger is 
directed towards another person (e.g. shouting, sarcastic name-calling, use of foul or 
abusive language). Also, rate 3 if there are explicit verbal threats of violence to another 
person, or behaviour causing a justifiable fear of personal violence (e.g. subject 
approaches too close, raises fist, mild pushing). Also, rate 3 for violence towards 
property. 
4 Subject has temper tantrums so severe that relationship with carers is compromised, 
creating risk that subject will be rejected; rate 4 if there has been any kind of actual 
physical assault (includes pushing, shoving, hitting, biting, scratching, kicking) or 
threatening behaviour involving weapons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   If present, date at 
onset 
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LACK OF INITIATIVE (APATHY):                                             Severity       Frequency   
 
 
 
Suggested prompts: 
o Have you found that you have lost interest in things that used to be important to you? Are 
you just as interested as always in trying new things, starting new projects? 
o Do you have to be pushed to get started on chores that need doing? Do you leave it to 
friends to take the initiative for organising social activities? Do you sit around a lot doing 
nothing? 
 
0 symptom absent 
1 questionable 
2 subject no longer tries new things; may need gentle prompting to initiate hobbies or 
pastimes which he/she usually enjoys; make less effort to keep up with friends and relatives; 
tends to put off household tasks which were previously part of normal daily routine and may 
need gentle prompting to do these things. 
3 Needs quite overt prompting to take part in hobbies or pastimes which he/she used to enjoy, 
or to carry out routine daily household tasks; makes little or no effort to keep in touch with 
friends and leaves it to other to initiate any social contacts; able to take part in (and 
apparently enjoy) conversation, but tends to follow and is less likely to initiate a change of 
subject. 
4 No longer performs any household chores, even if prompted repeatedly; never initiates 
activities, and displays no interest in hobbies or pastimes; markedly impoverished speech, 
rarely initiates new topics of conversation except in relation to own needs; active choices 
limited to selecting TV programmes to watch, and perhaps switching on or changing channel 
to do this. 
8 unable to assess because condition too advanced (e.g. mute and immobile) 
 
(This item will usually be rated 9 (data missing) in the absence of a reliable informant) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   If present, date at 
onset 
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PERSEVERATIVE THINKING OR BEHAVIOUR:                                        Severity          Frequency   
 
 
 
Suggested prompts: 
 Have you found yourself getting stuck on certain ideas or actions? 
 Have your family or friends complained that you are getting obsessed about something or 
going on about it more than you should, or doing something over and over again? 
 
0 symptom absent 
1 questionable 
2 mild perseverative behaviours or abnormal preoccupations are present but do not interfere 
with everyday life or cause significant distress for subjects or carers; rate 2 if carer reports 
that subject tends to come out with comments, which refer to an earlier topic of 
conversation, or when rater observes perseverative phenomena during examination (e.g. 
continues tandem walking after test is completed). 
3 Abnormal preoccupations or repetitive behaviours occupy a significant proportion of 
subject’s attention and cause distress for subject or practical problems for carers; for 
example, rate 3 if carers report that subject will not let matter drop after an argument, and 
keeps returning to the same contentious issue all day, or has repetitive behaviours (see 
below) which cause some interference with everyday care. 
4 Abnormal preocuupations occupy most of subject’s attention for several days at a time, 
causing major problems or distress for subjects and carers, or subject cannot be diverted 
from repetitive behaviours (pacing, smoking, repeatedly visiting the toilet), which interfere 
significantly with everyday care. 
8 unable to assess because condition too advanced (e.g. mute and immobile) 
 
(This item will usually be rated 9 (data missing) in the absence of a reliable informant) 
  
 
  
   If present, date at 
onset 
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B Appendices for Chapter 6 
Bi Participant information sheet, reply slip, consent form, GP letter 
PARTICIPANT INFORMATION SHEET  
VALIDITY OF DEPRESSION RATING SCALES IN HUNTINGTON’S DISEASE 
VERSION 2: Friday 7th July 2006 
Patient Information Sheet 
 
Validity of Depression Rating Scales in Huntington’s Disease 
 
 Invitation to take part in a research study 
You are invited to take part in a research study investigating the validity of self-report rating scales in 
measuring depression severity in persons with Huntington’s Disease. To help you decide whether or 
not you wish to take part in this study, please read the following information carefully, which 
explains why this study is being carried out and what participation entails. Please take your time to 
decide and if you wish, discuss the study with your family, friends or General Practitioner.  
 
 Purpose of the study 
The purpose of this study is to assess the validity of three simple self-report measures of depression 
severity in a sample of individuals with Huntington’s Disease. An accurate diagnosis of depression can 
be especially difficult to make in the setting of Huntington’s Disease because many symptoms of 
depression such as fatigue, loss of appetite, weight loss and sleep disturbance may also be seen in 
non-depressed Huntington’s Disease patients. Therefore, this study aims to determine the most 
sensitive self-rating scale that will provide a quick, cost-effective means for clinicians to more 
accurately diagnose and therefore treat depression and to monitor any changes in depression 
severity. 
 
 Why have I been chosen? 
Participants in this study will all have a clinical diagnosis of Huntington’s Disease, which has been 
confirmed by a genetic test. It is not necessary for you to have depression in order to participate in 
this study. Fifty to eighty participants are needed to take part in this study so that we can reliably 
determine which rating scale is most accurate in diagnosing depression severity. You have been 
invited to take part in this study because you have Huntington’s Disease and you are registered with 
the HD service based at the Queen Elizabeth Psychiatric Hospital. 
 
 Do I have to take part? 
No. Your participation in this research project is voluntary.  Before deciding whether or not to take 
part you should read this leaflet very carefully and ask if there is anything you do not understand or if 
you want further information. If you do decide to take part, you will be asked to sign a consent form 
indicating that you understand what the study involves. You will then be given a copy of this 
information sheet and a signed consent form to keep. You are also free to withdraw from the study 
at any time and without giving reason. This potential withdrawal does not affect your current 
clinical care and treatment. If you decide not to take part, again you do not have to give any reason 
for your decision and it will not affect your continuing clinical treatment.  
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 What does participation involve? 
Participation in the study entails a single clinical assessment, which depending on your preference 
will either take place at your home at a time convenient to you or in the out-patient clinic at the 
QEPH, Birmingham. The assessment will first involve measuring your movements, thinking, and 
functional capabilities similar to the consultations which you already undergo in the Huntington’s 
disease clinic. This will be followed by an assessment of your mood including a semi-structured 
interview and three simple self-report depression rating scales. The total assessment will take 
approximately an hour and a half to complete.  
 
 Are there any risks attached to this study? 
There are no specific risks arising from your participation in this study given that it is an observational 
study. 
 
 What are the possible benefits of taking part? 
There may be no direct benefits from taking part in the study. However, it is hoped that results from 
this study will have important implications for the management of Huntington’s Disease through 
improvements in diagnosing severity of depression. 
 
 What will happen to the results of this study? 
At the end of the study, the results will be analysed and a report will be written for a medical journal. 
You will also be sent information regarding the outcome of the study. The anonymised data will be 
stored for five years after the end of the study in a locked cabinet. 
 
 Confidentiality 
All information collected from you will be kept strictly confidential and stored in locked filing cabinets 
with access restricted to the investigators involved in the study. The information will also be entered 
onto a secure computer database for analysis, but you will not be identified when the results are 
reported.  
 
 Will my General Practitioner (GP) know that I am involved in this study? 
Should you agree to take part in this study, it is important that your GP is kept informed of your 
participation and he/she will also be sent a copy of this information sheet. 
 
 Who is organising and funding the research? 
The study is being organised by Dr. Hugh Rickards MD MRCPsych and Jenny Keylock BSc MSc in the 
department of neuropsychiatry at the Queen Elizabeth Psychiatric Hospital, Birmingham. The 
research project is being sponsored by the Birmingham and Solihull Mental Health Trust. 
 
 For further information please contact 
 What if I have any concerns? 
If you have any concerns or questions about this study or the way it has been conducted, you should 
contact the supervisor Dr. Rickards, or you may contact the Queen Elizabeth Psychiatric Hospital or 
Birmingham and Solihull Mental Health Trust complaints department.  
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REPLY SLIP 
VALIDITY OF DEPRESSION RATING SCALES IN HUNTINGTON’S DISEASE 
VERSION 2: FRIDAY 7TH JULY 2006 
 
Please would you kindly indicate which of the statements below refers to you and return your 
response in the pre-paid envelope provided to Jenny Keylock. If you have misplaced the envelope, 
the address is also printed at the top of the Patient Information sheet. 
 
Name:___________________________________ 
 
Telephone number:________________________ 
 
Address:_________________________________ 
                 
                _________________________________ 
 
               __________________________________ 
 
Post code:_________________________________ 
 
 
I have read and understood the patient information sheet dated Friday, July 7th 2006, version 2 and: 
 
1. I am interested in taking part 
 
2. I require more information about the study before deciding 
 
3. I am not interested in taking part 
 
 
In the case of (1) and (2) only, you will be contacted within 3 weeks in order to clarify any queries you 
may have and to arrange an appointment. 
 
Many thanks for taking the time to read this information and for completing the reply slip. 
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PATIENT CONSENT SHEET 
 
VALIDITY OF DEPRESSION RATING SCALES IN HUNTINGTON’S DISEASE 
VERSION 2: FRIDAY 7TH JULY 2006 
 
Chief Investigator 
Dr. Hugh Rickards MB ChB MD MRCPsych M Med Sci   
 
Research Assistant 
Jenny Keylock BSc MSc       
 
1. I have read and understood the patient information sheet ‘Validity of Depression Rating 
Scales in Huntington’s Disease, version 2 07/07/2006’. I have had the opportunity to ask 
questions and have had sufficient time to decide whether to participate in the study.  
 
2. I understand that participation is voluntary and that I am free to withdraw from the study at 
any time without giving reason and without affecting my continuing medical treatment. 
 
3. I agree to the publication of any findings that arise from this study so long as my anonymity is 
preserved. 
 
4. I understand that my GP will be informed that I am taking part in this study. 
 
 
 
Patient’s signature______________________________ 
 
Patient’s name_________________________________      Date___________________ 
 
Researcher’s signature___________________________ 
 
Researcher’s name______________________________     Date___________________ 
  
 
 
 
Please 
initial boxes 
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GP LETTER  
VALIDITY OF DEPRESSION RATING SCALES IN HUNTINGTON’S DISEASE 
VERSION 1: MONDAY 15TH MAY 2006 
 
Date 
Dear Dr. 
 Re:  Patient name and Date of Birth 
         Patient address 
Your patient . . . . . . .has agreed to participate in a study to validate self-report severity measures of 
depression in Huntington’s disease patients. This study, based at the Queen Elizabeth Psychiatric 
Hospital, Birmingham involves a single clinical assessment and is observational only. A copy of the 
information sheet has been enclosed. 
 
The supervisor for the trial is Dr. Hugh Rickards, Consultant Neuropsychiatrist at the address above 
and the trial has been approved by the local Research Ethics Committee. If you require any further 
information about the study, please contact Jenny Keylock, trial administrator on the number at the 
foot of the patient information sheet.   
 
Yours sincerely, 
 
Jenny Keylock 
Research Psychologist 
 
Enc. Patient information sheet 
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Bii Demographic Information 
 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
DEMOGRAPHIC INFORMATION 
 
 
Date of Birth:         
 
 
 
Gender: 
 1=male 
 2=female 
 
 
Ethnicity:_____________________________________ 
 
 
Years of education:_____________________________ 
 
 
Age at symptom onset:__________________________ 
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Biii Beck Depression Inventory-II 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
BECK DEPRESSION INVENTORY-II 
 
This questionnaire consists of 21 groups of statements. Please read each group of statements 
carefully, and then pick out one statement in each group that best describes the way you have 
been feeling during the past two weeks, including today. Circle the number beside the statement 
you have picked. If several statements in the group seem to apply equally well, circle the highest 
number for that group. Be sure that you do not choose more than one statement for any group, 
including item 16 (Changes in Sleep Pattern) or Item 18 (Changes in Appetite).  
 
Total score:                                                                                                                     
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________  
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
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Biv The Hospital Anxiety and Depression Scale (HADS) 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) 
Please read each item carefully and tick the box next to the response, which best represents how 
you have been feeling in the past week. Please select only one answer for each group and try not 
to take too long over your replies. 
 
1. I feel tense or wound up:  
 Most of the time  
 A lot of the time  
 From time to time, occasionally  
 Not at all  
 
 
2. I still enjoy the things I used to enjoy:  
 Definitely as much  
 Not quite so much  
 Only a little  
 Hardly at all  
 
 
3. I get a sort of frightened feeling as if something awful is about to happen:  
 Very definitely and quite badly  
 Yes, but not too badly  
 A little, but it doesn’t worry me  
 Not at all  
 
 
4. I can laugh and see the funny side of things:  
 As much as I always could  
 Not quite so much now  
 Definitely not so much now  
 Not at all  
 
 
5. Worrying thoughts go through my mind:  
 A great deal of the time  
 A lot of the time  
 From time to time, but not too often  
 Only occasionally  
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
 
6. I feel cheerful:  
 Not at all  
 Not often  
 Sometimes  
 Most of the time  
 
 
7. I can sit at ease and feel relaxed:  
 Definitely  
 Usually  
 Not often  
 Not at all  
 
 
8. I feel as if I am slowed down:  
 Nearly all the time  
 Very often  
 Sometimes  
 Not at all  
 
 
9. I get a sort of frightened feeling like ‘butterflies’ in the stomach:  
 Not at all  
 Occasionally  
 Quite often  
 Very often  
 
 
10. I have lost interest in my appearance:  
 Definitely  
 I don’t take as much care as I should  
 I may not take quite as much care  
 I take just as much care as ever  
 
 
11. I feel restless as if I have to be on the move:  
 Very much indeed  
 Quite a lot  
 Not very much  
 Not at all  
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Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
 
12. I look forward with enjoyment to things:  
 As much as I ever did  
 Rather less than I used to  
 Definitely less than I used to  
 Hardly at all  
 
 
13. I get sudden feelings of panic:  
 Very often indeed  
 Quite often  
 Not very often  
 Not at all  
 
 
14. I can enjoy a good book or radio or TV program  
 Often  
 Sometimes  
 Not often  
 Very seldom  
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Bv The Depression Intensity Scale Cirlces (DISCs) 
Participant’s initials:_______ 
 
Participant’s no.:__________                      Date data obtained:__________________ 
 
DEPRESSION INTENSITY SCALE CIRCLES (DISCs) 
This is a scale for measuring sadness or depression. The grey circles show how sad or depressed you 
feel. The bottom circle shows no sadness or depression. The top circle shows sadness or depression 
as bad as it can be. As you go from the bottom to the top circle you can see that sadness or 
depression is becoming more and more severe. Which of these circles shows best how sad or 
depressed you feel today? 
        Participant’s score: 
  
  
 
 
 
 
 
 
 
Most severe 
depression 
No Depression 
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